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ABSTRACT 
Kathleen M. McClain: Polyunsaturated Fatty Acids and the Barrett’s Esophagus-
Esophageal Adenocarcinoma Continuum 
(Under the direction of Marilie D. Gammon) 
 
 
Barrett’s esophagus (BE) is a precursor lesion for esophageal 
adenocarcinoma/gastric cardia adenocarcinoma (EA/GCA), which are cancers with 
increasing incidences in the United States (US) and very poor prognoses. In 
experimental studies, the impact of polyunsaturated fatty acids (PUFAs) on 
carcinogenesis varies, with ω-3 PUFAs (primarily found in fish) and ω-6 PUFAs (often 
found in oils and other foods) displaying anti- and pro-carcinogenic effects, respectively. 
My hypotheses were that the risk of developing BE/EA/GCA and/or dying from EA/GCA 
would be inversely associated with non-fried fish intake and other measures of ω-3 
PUFAs, but positively associated with ω-6 PUFAs. In my dissertation, I pooled two 
case-control studies of BE and two case-control studies of EA/GCA with case follow-up 
for mortality. The total sample size included 471 BE cases with 490 controls, 1027 
EA/GCA cases with 2027 controls, and 884 EA/GCA deaths. Using study-specific food 
frequency questionnaires, I harmonized and pooled dietary information to estimate 
PUFA measures including intake of fish (with consideration given to cooking methods), 
ω-3, ω-6, and ω-6:ω-3 ratio. Using logistic, polytomous logistic, and Cox proportional 
hazards regression models, I estimated odds ratios and hazards ratios, respectively, 
with 95% confidence intervals. Higher intake of baked/broiled fish was associated with 
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approximately 30% decreased risk for development of BE (particularly the more severe 
long-segment BE), EA, and GCA. ω-6 intake was also associated with an increased risk 
of EA and GCA; however, so was ω-3. Finally higher ω-6:ω-3 was associated with 
lower EA mortality, but not GCA mortality. There was no evidence of modification by 
inflammation-related factors for any of the outcomes assessed. My findings of inverse 
associations for baked/broiled fish intake with BE/EA/GCA development and positive 
associations for ω-6 with EA/GCA development are consistent with my hypotheses. But 
the positive association between ω-3 intake and EA/GCA development, and the inverse 
association between ω-6:ω-3 and EA mortality, are not. If findings are confirmed, 
increasing intake of baked/broiled fish may be a plausible risk reduction strategy for BE 
(especially long-segment BE), EA, and GCA, and could reduce the disease burden of 
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CHAPTER I: BACKGROUND 
 
Introduction 
Barrett’s esophagus (BE) is hypothesized to be a complication of long-term 
gastric reflux [1], and a precursor to esophageal adenocarcinoma (EA). EA and gastric 
cardia adenocarcinoma (GCA) are cancers often considered as one clinical entity, due 
to anatomical proximity, shared risk factors and treatments, and similar very poor 
prognoses [2-7]. The Barrett’s esophagus-esophageal adenocarcinoma (BE-EA) 
continuum (Figure 1.1) presents a schematic to help determine plausible windows of 
susceptibility along the cancer continuum that could be targeted for interventions. The 
BE-EA continuum represents two possible routes of histological changes: normal 
esophageal tissue  BE  EA/GCA  mortality following EA/GCA, and normal 
esophageal tissue  EA/GCA  mortality following EA/GCA. Figure 1.2 shows the 
histological changes of the esophageal lining throughout the BE-EA continuum.  
The goals of this dissertation were to assess the associations between the BE-
EA continuum and polyunsaturated fatty acids (PUFAs), which are found in the human 
diet and may act as anti-carcinogenesis and/or carcinogenesis promoting agents [8]. 
The study’s hypotheses were that PUFAs will be differentially associated with the risk of 
the three outcomes along the BE-EA continuum (development of BE, risk of developing 
EA/GCA, and mortality following a diagnosis of EA/GCA), and the direction of the 
associations will be based on the PUFA measure considered.  
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The rationale for this study was built upon population research, in particular time 
trends and geographical trends. The incidences of BE and EA/GCA have been 
increasing in the western world over the last 50 years [4,7,9-21]. A major dietary shift in 
the intake of PUFAs in western countries has occurred in the last century as well, 
mainly due to the increase in production and consumption of vegetable oils [22,23]. The 
ratio of the intake of ω-6:ω-3 (the detrimental PUFAs:the beneficial PUFAs) has 
increased substantially over this time period, particularly among westernized countries 
[24,25]. Additionally, the prevalence of BE [9,13-15,26-28] and the incidence EA/GCA 
[10-12,29-36] are notably lower in Asian populations than in the western world. These 
countries with lower rates of BE and EA/GCA, typically have a much different diet when 
compared to western countries. The diets in Eastern countries, such as Japan, have a 
much higher intake of ω-3 fatty acids and consequently a lower ratio of ω-6:ω-3 intake 
[37]. 
 The hypotheses for this dissertation were driven by laboratory research and 
epidemiological research. In the laboratory, ω-3 PUFAs have been shown to reduce 
inflammation [38], inhibit cell growth [39-41], and enhance apoptosis [42,43], and in 
epidemiologic studies are associated with reduced risk of breast [44] and prostate [45] 
cancer, as well as colorectal adenomas [46]. In contrast, ω-6 PUFAs have been shown 
to promote cancer cell proliferation in animal models [47,48], and to be adversely 
associated with risk in the same diseases in human populations [46,49,50].  
 A more detailed discussion of the scientific background, biologic foundation, and 
the study’s significance and innovation is presented below. I first summarize the 
descriptive epidemiology of BE along with the established and suspected risk factors for 
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BE, followed by corresponding sections on EA/GCA incidence and survival. I then 
provide more detail on previous laboratory and epidemiologic studies focused on PUFA 
intake in association with the BE-EA/GCA continuum.  
 
Barrett’s Esophagus 
BE is defined as the transformation of the esophageal mucosa from normal 
squamous epithelium into metaplastic columnar epithelium [51,52]. BE is the only 
known precursor lesion to EA. GCA is often considered one clinical entity along with EA, 
and these two tumors are highly fatal with increasing incidence in the western world 
[4,10,17-20,53].  
 
Descriptive Epidemiology of BE 
The true prevalence of BE is not known because many individuals with BE can 
be asymptomatic (estimates as high as 65% of BE cases do not exhibit symptoms [54]) 
and often do not seek medical care for this condition, resulting in only an estimated 5% 
of patients with BE receiving a diagnosis [55]. Estimates suggest that between 1.5 
million and 2 million individuals in the United States (US) are affected by BE [51]. As for 
high-risk groups, it is suggested that 5-15% of those with gastroesophageal reflux 
disease (GERD) symptoms have BE [56], and around 15% or more of the US 
population suffers from GERD [57].  
 Multiple studies consistently report that the prevalence of BE is increasing 
worldwide [4,9,58,59], independent of the number of endoscopies performed [58]. Using 
a database from the Netherlands with over 500,000 patient records, diagnoses of BE 
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increased from 16.6/1000 upper endoscopies in 1996 to 37.1/1000 upper endoscopies 
in 2003 [58]. This study also showed that the prevalence of BE had increased more 
than 60% between 1997 and 2002 [58]. Comparing data from the Rochester 
Epidemiology Project in the US, the diagnoses of BE had increased 28-fold from 1965-
1969 to 1995-1997 [60]. However, the authors concluded that this drastic of an increase 
in prevalence was due to the increase in endoscopies over that period. The Northern 
Ireland Barrett’s Oesophagus Register (NBOR) found evidence of a 159% increase in 
BE comparing the 2002-2005 data with the 1993-1997 data [59]. This study also found 
that two demographic groups had the greatest increase, individuals under the age of 60 
and particularly males under the age of 40.  
 There are geographic differences in the prevalence of BE. Studies in Asia have 
shown a much lower prevalence of BE. In Eastern China, a study of almost 140,000 
participants undergoing gastroscopy found a prevalence of 0.17% [26]. This difference 
in prevalence extends to high-risk populations in these geographic areas. A study of 
individuals undergoing endoscopy for upper gastrointestinal symptoms in China 
observed a BE prevalence of 1.0% [27]. A Korean study of patients receiving upper 
gastrointestinal endoscopy with clinical symptoms had similar results, with a BE 
prevalence of 1.0% [28].  
BE prevalence decreases with the severity of disease. The prevalence of BE 
differs by segment length: short-segment BE (SSBE), typically defined as less than 3 
cm in length, is estimated to be three times more frequent than long-segment BE 
(LSBE; ≥3 cm) [61-63]. BE is also classified by the presence and degree of dysplasia, 
and can be graded as negative, indefinite for dysplasia, low-grade dysplasia (LGD), and 
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high-grade dysplasia (HGD) [64]. The presence of dysplasia differs by segment length 
of BE [61,62]: for SSBE about 8% of patients have specialized intestinal metaplasia 
(SIM), and for LSBE estimates range between 15% and 25%.  
Summary of BE Descriptive Epidemiology 
Although the true prevalence of BE is unknown [55], researchers acknowledge 
that the prevalence has been increasing worldwide [4,9,58,59]. This increase is 
particularly noteworthy among individuals under the age of 60, and males under the age 
of 40 [59]. BE is distributed differentially in geographic regions: it is highly prevalent in 
the developed western world [13,14,58,59] and much less frequently diagnosed in Asian 
countries [26-28]. BE severity, measured by segment length or presence of dysplasia, 
affects prevalence with less severe disease more prevalent than LSBE or HGD [61-63].  
 
BE Risk Factors 
Medical Conditions and BE 
GERD: The most well established risk factor for BE is GERD. GERD is a chronic 
digestive disease that develops when the reflux of gastric contents into the esophagus 
irritates the lining [65]. A meta-analysis of 26 studies by Taylor et al. examining the 
association between GERD and BE found an overall odds ratio (OR)=2.90 
(95%CI=1.86-4.54) [66]. However there was a significant amount of heterogeneity 
among these studies. When restricting to studies of “highest quality” and studies that 
collected information on BE segment length, the association with SSBE was null 
(OR=1.15, 95%CI=0.76-1.73) but the estimate for LSBE was much more pronounced 
(OR=4.92, 95%CI=2.01-12.0) [66]. When examining GERD characteristics such as age 
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of onset, frequency of symptoms, and severity of GERD, Thrift et al. found that the risk 
of BE increased with frequency of symptoms, severity of symptoms, and earlier age at 
onset [67]. 
Esophagitis: Inflammation and ulceration of the esophagus, or esophagitis, is a 
complication of GERD [68]. Two studies, one from Sweden [69] and one from China 
[27], have demonstrated that esophagitis may be a risk factor for BE (controlling for 
GERD) with effect estimates of 5.2 (risk ratio (RR), 95%CI=1.2-22.9) and 4.4 (OR, 
95%CI=1.2-1.6), respectively.  
Hiatal hernia (HH): HH, a condition where the stomach protrudes into the chest 
cavity by way of a hole in the diaphragm [70]. HH has been of interest in regards to the 
development of BE because HH may promote gastric reflux by increasing intra-
abdominal pressure, or when acid trapped in the HH sac enters the esophagus when 
the lower esophageal sphincter (LES) relaxes [71]. HH is more prevalent in those with 
BE, particularly high-grade dysplasia, than in those with GERD [70] or esophagitis [71], 
and more prevalent in BE patients than in controls scoped without reflux [71]. Similar to 
what is seen with GERD, HH appears to be more strongly associated with LSBE 
(OR=12.67, 95%CI=8.33-19.25) than with SSBE (OR=2.87, 95%CI=1.75-4.70) from a 
meta-analysis of nine studies [72]. 
Helicobacter pylori (Hp): Hp infection has been hypothesized to suppress gastric 
acid secretion and lead to gastric atrophy [73,74]. Hp is associated with decreased risk 
of EA [75,76] and BE [77]. A recent meta-analysis of 49 studies found a pooled 
OR=0.73 (95%CI=0.60-0.88) for Hp infection on BE [77]. The inverse association was 
more pronounced when: restricting to studies with appropriate measurement of Hp and 
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without selection bias (OR=0.46, 95%CI=0.35-0.60), when restricting to studies 
performed in the US (OR=0.46, 95%CI=0.40-0.53), or limiting to cytotoxin-associated 
gene A (CagA) positive Hp strains (OR=0.38, 95%CI=0.19-0.78) [77]. 
Lifestyle Factors and BE 
Obesity: Obesity is a well-established risk factor for BE. A meta-analysis of nine 
studies showed a 35% increase in risk for BE when comparing those with an obese 
body mass index (BMI; ≥30 kg/m2) to those who were not obese (BMI <30 kg/m2) [78]. 
Additionally, there was a 49% increase in risk for BE when comparing those with an 
overweight or obese BMI (≥25 kg/m2) to those who were not overweight (BMI <25 
kg/m2). Other measures of abdominal obesity have also been shown to be associated 
with BE, including increases in waist circumference (WC) [79,80], waist-hip ratio (WHR) 
[79], sagittal abdominal diameter (SAD) [79], waist-height ratio (WHtR) [79], visceral 
adipose tissue (VAT) [81], and subcutaneous adipose tissue (SAT) [81]. Using these 
measures may be preferential to BMI because investigators have suggested that 
centralized obesity may be more important to the development of BE through 
mechanisms such as intragastric pressure, metabolically active tissue, and inflammation 
[1,82].  
Physical Activity (PA): To date there has only been one study assessing the 
association between PA and development of BE [83]. The Texas-based case-control 
study conducted by Hilal et al. examined PA in the week prior to interview and found no 
associations between BE and the highest level of PA (ORHigh-Low=1.19, 95%CI=0.82-
1.73) or total amount of PA (ORHigh-None=1.28, 95%CI=0.93-1.75) [83]. Although the 
estimate for high amounts of PA (compared to none) suggests there may be a positive 
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relationship, more studies are necessary to determine associations between PA and 
BE. The potential mechanism of action between PA and BE is unclear, although it has 
been suggested it may act through reducing obesity [83] or other pathways [83] such as 
reducing chronic inflammation [84]. 
Cigarette Smoking: There is no consensus regarding the relationship between 
BE and cigarette smoking [85-87]. However there is evidence that cigarette smoking 
may increase risk of BE by relaxing the LES and increasing the likelihood of gastric acid 
reflux [88,89]. A meta-analysis of 13 studies of BE cases compared with non-GERD 
controls found that for those who had ever smoked the OR=1.44 (95%CI=1.20-1.74) 
[90]. There also appear to be a trend of increasing risk with increase in pack-years 
smoked. Using ten of the studies from the meta-analysis by Andrici et al., when 
comparing the lowest number of pack-years smoked to the never smokers risk of BE 
increased (OR=1.41, 95%CI=1.22-1.63) with a slightly more pronounced estimate for 
the highest number of pack-years (OR=1.53, 95%CI=1.27-1.84). A pooled analysis 
using the International Barrett’s and Esophageal Adenocarcinoma Consortium 
(BEACON) data has similar results: when compared to never smokers for <15 pack-
years OR=1.59 (95%CI=1.02-2.47), and for ≥45 pack-years OR=1.92 (95%CI=1.05-
3.51) [85]. 
Alcohol Use: Alcohol use has been of great interest as a risk factor for BE, but 
results have been inconclusive. Two recent meta-analyses, both from 2015, have come 
to different conclusions [91,92]. The first using 15 studies with 42,925 participants and 
3,775 BE cases found a null association comparing highest and lowest intake 
(RR=0.98, 95%CI=0.62-1.34), additionally there was no evidence suggesting a dose 
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response relationship [91]. However a reduced risk was found when restricting to 
women (RR=0.51, 95%CI=1.11-1.56), and increased risk was found when examining 
Asian studies only (RR=1.34, 95%CI=1.11-1.56). The second meta-analyses included 
20 studies, 45,181 participants, and 4,432 BE cases [92]. There was a suggestive 
positive association when comparing any versus no alcohol consumption (RR=1.10, 
95%CI=0.96-1.27), and increased risks found in men (RR=1.35, 95%CI=1.13-1.61) and 
in Asian populations (RR=1.60, 95%CI=1.03-2.49). When assessing alcohol type, liquor 
was found to increase risk of BE (RR=1.16, 95%CI=1.02-1.32). Another study pooled 
data from five BEACON-affiliated studies, and found a borderline inverse association 
(OR=0.77, 95%CI=0.60-1.00) comparing any intake versus no intake; and when 
examining alcohol type, the authors also reported a modest inverse association with 
wine intake (OR=0.71, 95%CI=0.51-0.98) [93]. These conflicting results may be 
explained by the different biological mechanisms alcohol can affect BE through. Alcohol 
can increase gastric reflux [94] increasing the risk for BE, but may confer benefits by 
decreasing insulin resistance and wine contains potentially beneficial antioxidants [95]. 
Nonsteroidal Anti-inflammatory Drug (NSAID) Use: NSAIDs, in particular aspirin, 
may reduce the risk of BE through inhibition of cyclooxygenase enzyme (COX)-2 
[96,97]. BE patients have been shown to overexpress COX-2 [98-100], and COX-2 
inhibitors have been shown to slow cell proliferation in BE cell lines [101]. An Irish case-
control study showed a reduction in risk of BE for both aspirin use (OR=0.53, 
95%CI=0.31-0.90) and non-aspirin NSAID use (OR=0.40, 95%CI=0.19-0.81) [102]. A 
California study found a reduction in risk for aspirin only, and when examining duration 
of use a significant trend of decreasing risk with increasing duration was seen 
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(ptrend=0.003) [103]. A study performed in Australia found that non-aspirin NSAIDs were 
associated with a decreased risk of BE but only in nondysplastic cases (OR=0.69, 
95%CI=0.49-0.97) [104]. 
Dietary Intake: Recently, a variety of dietary components have been examined 
for relationships with the development of BE. But with the exception of fruits and 
vegetables, vitamin C, vitamin E, and β-carotene, there are few studies on other dietary 
factors to compile the evidence. A case-control study in Washington state found a 
reduced risk for BE for vegetable intake (ORT3-T1=0.33, 95%CI=0.17-0.63) and 
combined fruit and vegetable intake (ORT3-T1=0.39, 95%CI=0.21-0.75) [105]. A 
California study found a similar reduction in risk for BE with combined fruit and 
vegetable intake (ORQ4-Q1=0.27, 95%CI=0.15-0.50), in addition to vitamin C (ORQ4-
Q1=0.48, 95%CI=0.26-0.90), β-carotene (ORQ4-Q1=0.56, 95%CI=0.32-0.99), and vitamin 
E (ORQ4-Q1=0.25, 95%CI=0.11-0.59) [106]. In a separate study from the same California 
population, fiber from fruits and vegetables was found to reduce the risk of BE with an 
ORQ3-Q1=0.47 (95%CI=0.25-0.88) [107]. The Factors Influencing the 
Barrett’s/Adenocarcinoma Relationship (FINBAR) study conducted in Ireland, found a 
null relationship between antioxidants and BE [108], but did observe an inverse 
association with dietary fiber intake (ORT3-T1=0.44, 95%CI=0.25-0.80) [109]. Fruits and 
vegetables may have risk reduction properties because of substances within them that 
have the potential to decrease inflammation and oxidative stress [110,111].  
Demographic Characteristics and BE 
Age: BE is most prevalent in the 6th and 7th decades of life but may present at an 
earlier age (very rarely before the age of 40) [9,58,112,113]. There is also evidence 
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that, on average, males present with BE much earlier than females [58,112]. Increasing 
age allows for the accumulation of damage to the esophageal mucosa, and is 
associated with other risk factors such as obesity [114] and GERD [115]. 
Sex: Males are the predominant sex affected by BE. Estimates of the 
male:female sex ratio for BE have been estimated to be between 2:1 and 3:1 
[112,116,117]. A meta-analysis of 32 studies by Cook et al. showed a pooled 
male:female sex ratio of 1.96:1 [118]. Males are more likely to suffer from abdominal 
obesity than females [119], which can increase intragastric pressure, metabolically 
active tissue, and inflammation [1,82] affecting BE risk.  
Race and Ethnicity: BE is also most common among Caucasians [9]. In a study 
by Abrams et al. the prevalence among whites was 6.1% compared to 1.7% among 
Hispanics and 1.6% among African Americans [117]; and in another study by Ford et al. 
the prevalence was 2.8% among Caucasians and 0.3% among South Asians [116]. It 
has been hypothesized this could be due to unknown genetic factors [120], or may be 
due to racial differences in obesity distribution [114] and Hp infection [121]. 
Socioeconomic Status (SES): In regards to socioeconomic status (SES), those 
with higher education and higher annual household income have a decreased risk of BE 
with ORs of 0.47 (95%CI=0.27-0.82) for college education and beyond vs. high school 
or less and 0.68 (95%CI=0.42-1.11) for annual income of ≥$75,000 vs. <$50,000 [122]. 
Education and income are associated with health-seeking behaviors, which may explain 




Summary of BE Risk Factors 
A variety of medical, lifestyle, and demographic factors have been identified as 
factors associated with development of BE. Older age [9,58,112,113], white race 
[9,116,117], male sex [112,116,117], GERD [66], esophagitis [27,69], HH [70,71], 
obesity [78-81], and cigarette smoking [85] have been positively associated with the risk 
of BE. The risk reduction factors that have been identified are: higher education level 
[122], higher annual income [122], Hp infection [77], NSAID use [102,103], and fruit and 
vegetable intake [105-107]. Each of these factors will be considered as potential 
confounders by including them in the directed acyclic graphs (DAGs) representing the 
relationship between PUFAs and the development of BE. 
 
Esophageal Adenocarcinoma and Gastric Cardia Adenocarcinoma  
EA is one of the two main histological types of esophageal cancer, the other 
being esophageal squamous cell carcinoma (ESCC). EA is typically found in the lower 
third of the esophagus, close to the gastroesophageal junction (GEJ) [10]. GCA is a 
tumor rising from the cardiac epithelium or metaplastic junctional epithelium, in the 
portion of the stomach closest to the GEJ [7]. Although these two cancers may be 
distinct diseases, EA and GCA are often considered one clinical entity due to their 
anatomically adjacent position, mutual risk factors, similar histological features, shared 





Descriptive Epidemiology of EA/GCA Incidence 
In 2012, there were over 455,000 incident esophageal cancer cases worldwide, 
making it the eighth most frequently diagnosed cancer [33]. However this includes both 
EA and ESCC histological subtypes. In the US in 2016 an estimated 16,910 esophageal 
cancers will be newly diagnosed, and more than half of these will be EA cases [33,120]. 
In 2009 incidence of EA was estimated at 2.58 per 100,000, and for GCA was about 2.0 
per 100,000 in 2008 [7,20].  
 EA/GCA incidence in the US has rapidly increased over the last few decades 
[4,7,16-21], and this increase has been greater than any other cancer over the same 
time period [125]. Using the Surveillance, Epidemiology, and End Results (SEER) data, 
the incidence of EA in the US has been estimated to have increased from 3.6 per million 
in 1973 to 25.6 per million in 2006, resulting in a seven-fold increase in incidence [126]. 
GCA rates have also been estimated from the SEER registry, and have increased from 
1.2 per 100,000 to just under 2.0 per 100,000 from 1970 through 2008 [7]. Global data 
from other North American and European countries, as well as Australia, show similar 
incidence trends for EA and GCA as seen in the US [12,127-134]. Comparing the two 
cancer sites, the increase in EA is sharper than the increase in GCA, and EA rates have 
continued to rise where GCA rates appear to have begun to level off [7,130]. 
 There are major variations in incidence rates in EA/GCA by geographic location 
[10-12,29-32]. In the highest-risk areas for esophageal cancer (often referred to as the 
“esophageal cancer belt”, which extends from the Middle East through China), 
approximately 90% of all esophageal cancer cases are ESCC [33,34]. This is in stark 
contrast to westernized countries, where in the US for example only 26% of all cases 
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are ESCC and this proportion is decreasing (thought to be due to the decline in 
cigarette smoking) [33,34]. Between 1970 and 1990, it was estimated that the 
proportion of EA cases among esophageal cancers was between 1% and 4% in east 
Asian countries [35]. Consequently, it has been shown that the ratio of EA:ESCC 
patients is well over 1.0 in whites and is much less than 1.0 for Asians [35]. Cumulative 
rates of EA in Asian countries have been estimated as low as 0.01% and the highest 
being 0.15% (for males in Hong Kong) [35,36]. The highest rates in Asian countries are 
in the lower end of the rates in western countries with majority whites, for example 
0.19% in Canada and 0.28% in the Netherlands for males [36].  
Summary of Descriptive Epidemiology of EA/GCA Incidence 
EA and GCA are rare tumors, with incidences between 2 and 2.5 per 100,000 
[7,20]. But their incidences have been increasing over the last forty to fifty years [4,7,17-
21], outpacing the increase in all other non-skin cancers in the US (notably breast and 
prostate cancer) [125]. And this increase is expected to continue in the coming decades 
[2,53,135]. When examining EA and GCA individually, the trends observed for EA are 
more drastic when compared to GCA [7,130]. Incidence rates vary widely dependent 
upon geographic location, with much higher rates in western countries when compared 
to developed Asian countries [10-12,29-32].  
 
EA and GCA Risk Factors 
Medical Conditions and EA/GCA Incidence  
BE: Barrett’s esophagus, as the precursor lesion, is the strongest risk factor for 
EA/GCA [136-139]. A study using data from the Danish Pathology Registry and the 
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Danish Cancer Registry found that when compared to the general population those with 
BE were at a much higher risk of EA (standardized incidence ratio (SIR)=11.3, 
95%CI=8.8-14.4) [136]. When dysplasia was considered, the risk of EA was higher for 
those with diagnosed low-grade dysplasia than for those with BE without dysplasia 
(SIR=4.8, 95%CI=2.6-8.8). A United Kingdom study found a much higher increase in 
risk of EA for those diagnosed with BE, with a SIR=29.8 (95%CI=9.6-106) [137]. 
Analysis on the United Kingdom NBOR data showed that segment length of BE was 
also related to the risk of EA [138]. Compared to those with <3 cm of BE, those with >9 
cm of BE had an IRR=2.051 (95%CI=0.614-6.847), and while this estimate was non-
significant, the small sample size limited these analyses. A study out of Northern Ireland 
that combined the EA, GCA, and HGD into one outcome, showed that presence of SIM 
(hazard ratio (HR)=3.54, 95%CI=2.09-6.00), long segment length (HR=2.31, 
95%CI=0.89-6.01), and low-grade dysplasia (HR=5.67, 95%CI=3.77-8.53) increase risk 
[139]. 
Esophagitis: Esophagitis is a well-established risk factor for BE, but the evidence 
for EA/GCA is scarce. One study using the General Practice Research Database from 
the United Kingdom, found that the risk of EA in a cohort of individuals with reflux 
esophagitis, when compared to a reference cohort, was increased with a SIR=4.5 
(95%CI=1.04-19.6) [137]. A Danish study showed that patients with esophagitis, when 
compared to the general Danish population, were at an increased risk of EA (SIR=2.2, 
95%CI=1.6-3.0) [140]. Combining EA and GCA into a single outcome, an analysis from 
the Southern California Kaiser Foundation Health Plan found that 
esophagitis/esophageal ulcers increased risk (OR=5.0, 95%CI=1.5-16.4) [141]. 
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However, the Los Angeles County (LAC) Multiethnic Study found null associations with 
both EA and GCA [142]. This could be due to small numbers of those with esophagitis 
diagnosed by a physician. 
GERD: GERD, independent of BE, has been of interest as a risk factor for 
EA/GCA. GERD may predispose individuals to cancer development through the 
damaging of the mucosa of the esophagus and gastric cardia by gastric acid reflux 
[141,143]. A pooled analysis of 12 BEACON studies with 1,197 EA cases examined the 
association between EA cases and reflux symptoms [143]. For those with recurrent 
heartburn or regurgitation, the ORs for EA were 4.64 (95%CI=3.28-6.57) and 4.57 
(95%CI=3.43-6.08), respectively. When examining frequency of heartburn and 
regurgitation, the associations grew stronger as symptoms were more frequent; those 
experience daily symptoms compared to those never experiencing them had an 
OR=7.96 (95%CI=4.51-14.04). The risk increased as duration of these symptoms 
increased, for those experiencing heartburn and regurgitation for ≥30 years the 
OR=6.08 (95%CI=3.26-11.34). When examining reports of esophageal reflux, a study 
using data from Southern California found that the risk of EA/GCA was increased 
(OR=2.1, 95%CI=1.2-3.6) and risk was more pronounced when these symptoms were 
first reported >5 years prior (OR=2.7, 95%CI=1.5-4.9) [141].  
HH: HH could be risk factor for EA/GCA through the same mechanisms as for 
BE, through increasing intra-abdominal pressure and promoting gastric reflux [71]. A 
positive association was seen between the presence of HH and EA and GCA in the 
LAC Multiethnic Study [142]. The association with HH was stronger for EA (OR=4.85, 
95%CI=3.21-7.33) than for GCA (OR=2.26, 95%CI=1.47-3.45). Data from the Southern 
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California Kaiser Foundation Health Plan also found an increased risk of EA/GCA with 
the presence of HH (OR=3.8, 95%CI=1.9-7.6) [141]. Another study by Avidan et al. 
found that large HH was associated with an increased risk of HGD/EA as a combined 
outcome (OR=2.48, 95%CI=2.13-2.89) [70]. And a smaller study out of Berlin found a 
similar but more pronounced association between HH and increased risk of HGD/EA 
(OR=7.68, 95%CI=3.54-16.65) [144].  
Hp: Recently, Hp has received a lot of attention as a risk reduction factor for 
EA/GCA. The proposed biological mechanism is the same as for BE, through 
suppression of gastric acid [120]. A meta-analysis by Islami and Kamangar estimated 
the association between Hp and EA using 13 studies with 840 cases [76]. A significant 
decreased risk was seen for Hp positivity, with an OR=0.56 (95%CI=0.46-0.68). When 
restricting to the CagA positive Hp strains, the inverse association was more 
pronounced (OR=0.40, 95%CI=0.28-0.56). A smaller, more recent German study found 
a suggested inverse association between Hp and HGD/EA (OR=0.50, 95%CI=0.23-
1.09) [144]. When examining Hp relationship with GCA, a study using the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention data estimated a reduced risk with an 
OR=0.31 (95%CI=0.11-0.89) [145]. They also assessed this association by CagA 
status, where the authors found a reduced risk only for CagA negative Hp strains 
(OR=0.21, 95%CI=0.06-0.81), although this study may be limited by small sample sizes.  
Family History: Family history has been hypothesized to be a risk factor for 
EA/GCA, mainly due to observed familial clustering and the knowledge that those who 
are male and Caucasian tend to be at highest risk of EA/GCA [146-149]. However, 
there is no consensus across previous studies that address this issue. A study 
 18 
performed in the US, showed that patients with EA did not have an association with a 
positive family history of digestive cancers, subsite specific or as a whole [150]. For 
GCA, there was no association with any subsite family history but there was evidence of 
a possible increased risk when examining family history of any digestive cancer. A 
Swedish study found similar results: null associations for EA, and a suggested 
increased risk with family history of stomach cancer (including the cardia; OR=1.6, 
95%CI=1.0-2.6) [151]. A separate Swedish study using the Swedish Family-Cancer 
Database, found an increased risk for EA when a parent was diagnosed with ESCC 
(SIR=4.05, 95%CI=1.05-10.46) or any esophageal cancer (SIR=3.52, 95%CI=1.11-
8.28) [152].  
Lifestyle Factors and EA/GCA Incidence 
Obesity: The increasing obesity epidemic has paralleled the increasing rates of 
EA and GCA. Obesity may increase risk of EA/GCA through the same mechanisms as 
for BE [1,82], and by promoting the transition of normal esophageal tissue to BE. A 
meta-analysis from 2003 with 2,488 EA and 2,509 GCA cases found positive 
associations with overweight/obesity and EA and GCA [153]. The associations were 
stronger with EA for overweight (OR=1.9, 95%CI=1.5-2.4) and obesity (OR=2.4, 
95%CI=2.0-2.8) than for GCA (OR=1.2, 95%CI=1.0-1.5 and OR=1.5, 95%CI=1.2-1.9, 
for overweight and obesity, respectively). A pooled analysis from BEACON investigated 
associations between BMI and EA among 1,997 EA cases, 1,900 GCA cases, and 
11,159 controls [154]. Compared to those of normal/underweight BMI (<25 kg/m2), there 
was increase in risk for overweight BMI (25.0-29.9 kg/m2; OR=1.54, 95%CI=1.26-1.88), 
and the risk increased with each category through those with BMI ≥40 kg/m2 (OR=4.76, 
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95%CI=2.96-7.66). A study by Abnet et al. using the National Institutes of Health-AARP 
Diet and Health (NIH-AARP) Study found that those with a baseline BMI ≥30 had an 
increased risk of GCA (BMI 30-34.9: OR=1.70, 95%CI=1.22-2.36; BMI ≥35: OR=2.46, 
95%CI=1.60-3.80) compared to normal BMI (18.5-24.9 kg/m2) [155].  
PA: PA may modify EA/GCA risk by reducing obesity [83] or through cancer-
reducing mechanisms [83] including reducing inflammation and improving insulin 
sensitivity [84]. A pooled study using five prospective studies with 899 EA cases, and 
six studies with 790 GCA cases examined leisure-time PA and incident cancer [156]. 
When comparing those with high leisure-time PA (90th percentile) with low leisure-time 
PA (10th percentile) and adjusting for BMI, risk was reduced for EA (HR=0.62, 
95%CI=0.40-0.97), and a suggested risk reduction for GCA (HR=0.85, 95%CI=0.69-
1.04). A 2014 meta-analysis based on seven studies of EA and seven studies of GCA, 
showed an inverse association between PA and EA and GCA [157]. A high level of PA 
reduced the risk of EA (RR=0.79, 95%CI=0.66-0.94) and GCA (RR=0.83, 95%CI=0.69-
0.99) when compared to low levels of PA. Another meta-analysis undertaken in 2014 by 
Singh et al., used four studies and saw a 32% (95%CI=0.55-0.85) decrease in risk of 
EA in individuals engaging in the most PA when compared to those who engaged in the 
least amount [158]. 
Tobacco Use: Cigarette smoking is one of the most well-studied risk factors for 
EA/GCA. Cigarette smoke contains a variety of carcinogenic compounds that damage 
deoxyribonucleic acid (DNA), and smoking has been hypothesized to increase cellular 
division and the proliferation of columnar epithelial cells (which would speed up the 
changes from BE to EA) [159]. Tramacere et al. performed a 33-study meta-analysis 
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assessing the relationship between tobacco use and EA/GCA [160]. Comparing to 
never smokers, the pooled RR=1.76 (95%CI=1.54-2.01) for ever smokers. There was a 
more pronounced association for current smokers (RR=2.32, 95%CI=1.96-2.75), and a 
slightly attenuated estimate for former smokers (RR=1.62, 95%CI=1.40-1.87). A dose-
response relationship was seen when examining both dose (cigarettes/day) and 
duration (years) of cigarette smoking. Using the BEACON data, Cook et al. showed that 
the longer the amount of time since smoking cessation the risk of EA/GCA decreases 
(OR≥10-0=0.71, 95%CI=0.56-0.89) [161].  
Alcohol Use: The relationship between alcohol use and EA/GCA has not been 
clearly established. But has been continued to be studied because of its clear 
relationship with ESCC, and because alcohol can increase gastroesophageal reflux by 
relaxing the LES [94]. Conversely, alcohol can have positive effects on insulin 
resistance and some types (wine, specific types of beer) may contain beneficial 
antioxidants [95]. A meta-analysis of 24 studies including 5,500 cases showed a null 
association when comparing drinkers to non-drinkers (RR=0.96, 95%CI=0.85-1.09) [94]. 
However, there was evidence of a decreased risk of EA/GCA when comparing light 
drinkers (≤1 drink/day) with non-drinkers (RR=0.86, 95%CI=0.75-0.99). But no 
association was seen with moderate or heavy drinkers and EA/GCA. Similar results 
were seen in a pooled analysis of BEACON data, where there was a suggested 
association with moderate alcohol intake (0.5-<1 drinks/day) and EA (OR=0.63, 
95%CI=0.41-0.99) and GCA (OR=0.78, 95%CI=0.62-0.99) but no other associations 
were seen [95]. Beer consumption showed evidence of a decreased risk for both EA 
(OR1-<3-None=0.72, 95%CI=0.51-1.04) and GCA (OR1-<3-None=0.64, 95%CI=0.46-0.90), 
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similar results were seen for wine (EA: OR1-<3-None=0.71, 95%CI=0.49-1.03; GCA: OR1-
<3-None=0.72, 95%CI=0.52-1.02).  
NSAID Use: The mechanism by which NSAIDs and aspirin may reduce the risk 
of EA/GCA is through a COX-2 pathway [96], similar to the one for BE. A meta-analysis 
of 11 studies (9 case-control and 2 cohort studies) found a RR=0.64 (95%CI=0.52-0.78) 
for regular aspirin use and the risk of EA/GCA [162]. A separate meta-analysis 
observed that use of non-aspirin NSAIDs was associated with reduced risk of EA 
(OR=0.65, 95%CI=0.50-0.85) and GCA (OR=0.80, 95%CI=0.67-0.95) [163]. A study of 
BE patients found that the risk of developing EA for current users of NSAIDs at baseline 
was lower than for never users (HR=0.32, 95%CI=0.14-0.76) [164].  
Dietary Intake: Many recent epidemiologic studies have examined the 
association between diet and EA/GCA, but the most consistent results come from 
assessing fruits and vegetables and their nutrient components. Fruits and vegetables 
contain components that have the potential to decrease inflammation, oxidative stress, 
and cellular proliferation, as well as increase apoptosis [110,111]. A meta-analysis by Li 
et al. investigated the role of fruits and vegetables in the risk of EA using 12 studies with 
1572 EA cases [165]. Fruits (RRHigh-Low=0.73, 95%CI=0.55-0.98) and vegetables 
(RRHigh-Low=0.76, 95%CI=0.59-0.96) were shown to decrease risk of EA, but the 
greatest decrease was observed when combining fruits and vegetable intake (RRHigh-
Low=0.68, 95%CI=0.49-0.93). The authors also observed significant dose-response 
relationships for all three of these measures when examining 100 g/day increments in 
intake. When examining carotenoid intake, another meta-analysis of four studies with 
638 cases saw a reduction in risk for β-carotene intake (OR=0.46, 95%CI=0.36-0.58) 
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[166]. Antioxidants have also been shown to reduce risk; a meta-analysis of seven 
studies showed inverse associations with EA/GCA for vitamin C (ORQ54-Q1=0.65, 
95%CI=0.54-0.78), vitamin E (ORQ54-Q1=0.64, 95%CI=0.41-0.78), and β-
carotene/vitamin A (ORQ54-Q1=0.57, 95%CI=0.47-0.68) [167].  
Demographic Characteristics and EA/GCA Incidence 
Similar to what is seen for BE, specific demographic groups have been found to 
be at higher risk for EA/GCA.  
Age: As is the case for the majority of other cancers, the incidence of EA and 
GCA increases with age. Increasing age allows for the accumulation of damage, and is 
associated with other risk factors such as obesity [114], GERD [115], and BE 
[9,58,112,113]. Rates rise with age until about 80 or 85 and begin to decline in these 
much older age groups. Using SEER data and data from the Danish Cancer Registry, it 
was seen that rates for EA and GCA are highest in the age range of 75-84 years 
[168,169]. 
Race: Whites are much more affected by EA and GCA than are other race 
groups [169,170]. A study by El-Serag et al. using SEER data found that age-adjusted 
incidence rates for EA were 3-4 times higher in whites than in African Americans, and 
for GCA were 1.5-2 times higher [169]. A later study also using SEER data saw that 
incidence rates for EA at all age groups and for both sexes were higher among whites 
than African Americans, with Hispanics incidence rates in the middle [170]. Similar to 
the proposed mechanisms for BE, these racial differences could be due to genetics 
[120], or may be due to racial differences in obesity [114], Hp infection [121], or BE 
[9,116,117]. 
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Sex: Male sex is one of the major risk factors for EA and GCA [168-170]. This 
may be due to the sex disparity observed in BE [171] or due to the fact that males are 
more predisposed to abdominal obesity than females [119]. There are other hypotheses 
that estrogen may be acting as an inhibitor of carcinogenesis, which has been seen in 
vivo with EA [171]. A Danish study found that the age-adjusted male:female ratio was 
5.91 (95%CI=4.4-7.9) for EA and 4.26 (95%CI=2.94-6.17) for GCA [168]. Studies using 
SEER data found that the sex disparity was wider for EA, estimated as RR ranging from 
7.0 in African Americans to 20.5 in Hispanics with white in the middle at 10.8 [170], but 
similar for GCA with men being affected 3-5 times more than women [169].  
SES: Low SES, using income and education, has been identified as a risk factor 
for both EA and GCA [172,173]. A Swedish study by Lagergren et al, assessed the 
relationship between income, education, and incident EA and GCA [172]. The highest 
level of income was associated with decreased risk of EA (incidence rate ratio (IRR)Q5-
Q1=0.83, 95%CI=0.71-0.97) and GCA (IRRQ5-Q1=0.75, 95%CI=0.65-0.86) for men, but 
null associations were seen among women. Increasing level of education was 
associated with decreased risk of EA and GCA for both men and women. In men having 
completed a higher tertiary education, the risk of EA and GCA were decreased by 33% 
(95%CI=0.56-0.79) and 26% (95%CI=0.63-0.87) respectively. The decreased risk was 
similar in women: for EA the IRR=0.74 (95%CI=0.49-1.11), and for GCA the IRR=0.79 
(95%CI=0.58-1.09). The US Multicenter Study found that both higher income and higher 
education levels were associated with decreased risk of EA and GCA [173]. Compared 
to those whose annual income <$15,000, those who made >$75,000 per year had an 
OR=0.5 (95%CI=0.3-1.0) for EA, and an OR=0.8 (95%CI=0.4-1.6) for GCA. When 
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looking at education, those who had graduate level education have a decreased risk of 
EA (OR=0.7, 95%CI=0.3-1.3) and GCA (OR=0.8, 95%CI=0.4-1.6) compared to those 
with <12 years of education. Another Swedish study showed that compared to 
professional workers, those who are unskilled/semiskilled manual workers have a 
higher risk of EA (OR=2.0, 95%CI=0.9-4.5) [174]. SES could impact the risk of EA/GCA 
through its association with health-seeking behaviors or by modifying the risk of BE 
[122].  
Marital Status: Studies have previously suggested that married adults are overall 
healthier than those who are unmarried [175], and this may be more pronounced for 
men than for women [176]. Using data from the Swedish Cancer Registry, when 
compared to those who have been married 15 or more years and never divorced, men 
who have been divorced five or more years have a higher risk of EA (IRR=1.26, 1.11, 
1.43) and perhaps GCA (IRR=1.11, 95%CI=0.99-1.26) [172]. Men who have been 
widowed five or more years, and men who have been never married had similar results 
where there was an increased risk of EA and a suggested increased risk of GCA. 
Women showed a similar pattern of results, divorced women had higher risk of EA and 
GCA although not statistically significant while never married women had higher risks of 
EA (IRR=1.51, 95%CI=1.09-2.08) and GCA (IRR=1.42, 95%CI=1.10-1.82). A separate 
Swedish study by Jansson et al. found that those who lived with a partner for <1 year 
were at higher risk of EA (OR=2.3, 95%CI=1.2-4.5) when compared to those living with 




Summary of Risk Factors for EA/GCA Incidence 
The primary risk factors that have been identified to increase risk for EA/GCA 
are: BE [136-139], esophagitis [137,140,141], GERD [141,143], HH [70,141,142,144], 
obesity [153-155], cigarette smoking [160,161], increasing age [168,169], white race 
[169,170], male sex [168-170], and low SES [172,173]. Several risk reduction factors 
have also been identified, including Hp [76,144], PA [156-158], NSAIDs [162-164], 
having a long-term spouse-like partner [172,174], and dietary factors [165-167]. These 
characteristics will be important to consider as potential confounders when designing 
DAGS and models for the relationships between PUFAs and incident EA/GCA.  
 
Esophageal Adenocarcinoma and Gastric Cardia Adenocarcinoma Survival 
EA/GCA is not usually detected until after symptoms present and the cancer is at 
an advanced stage [2,3]. Despite advances in screening, diagnostics, treatment, and 
improving survival of EA/GCA [19], the prognosis is still very poor [2-7].  
 
Descriptive Epidemiology of Survival after EA and GCA 
Similar to the statistics for the incidence of EA/GCA, there are no significant 
differences between EA and GCA survival [123,177] and it has been shown that the 
mortality from these cancers has been increasing over the past few decades [20,178]. 
The mortality rates increased rapidly from the 1970s to the late 1990s where this 
increase gradually slowed down [20,178]. Estimates of the increases in mortality over 
the last 30 years have ranged from 2 per 100,000 to 15 per 100,000 for EA/GCA [178], 
or from 4 per million to 23 per million for EA alone [20]. Between 1973 and 2008, 
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survival for EA/GCA has increased for all stages of disease [7,179]; GCA five-year 
survival has increased from less than 10% to 20% [7], and EA median survival times 
have increased from 11, 10, and 4 months to 35, 15, and 6 months for local, regional, 
and distant disease [179]. It has been observed that the gradual leveling of the mortality 
curve appears to coincide with the improvement in survival for localized disease [20]. 
Over the same 30 year period, the five-year survival of localized EA went from 2% to 
over 50% [20]. Unfortunately, the majority of EA/GCA cancers are diagnosed at the 
regional or distant stage because the early stage tumors are often asymptomatic [7,20]. 
Although the survival times for the later stage tumors have increased from about 1975-
2005 [20], the corresponding five-year survival rates for EA are 20% and 3% for 
regional and distant stage, respectively [20], and for GCA are 12% and 2%.[7]. The 
local staged tumors only make up about 25% of all cases, where the distant staged 
account for around 40% [20,123,179]. Because of this, the 5-year survival rate for 
patients diagnosed with any stage of disease remains low, reported at less than 20% 
[2,4-7].  
Summary of the Descriptive Epidemiology of Survival after EA/GCA 
As the incidence of EA/GCA has been increasing [4,7,16-21], so too has the 
number of deaths from these cancers [20,178]. And although improvements have been 
made in diagnosing and treating these cancers [19], the prognosis is still very poor [2-7]. 
EA/GCA is not usually detected until after symptoms present and the cancer is at an 
advanced stage [2,3]; most patients with EA/GCA present with regional or distant 
disease [7,20,180]. While survival for these tumors has increased over time [20], 
because of these issues the overall survival rates for these tumors remain low [2,4-7]. 
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Prognostic Factors for Survival after EA and GCA 
Tumor Characteristics & Treatment and Survival after EA/GCA 
Stage: In the US Multicenter Study when compared to distant cancers, localized 
cancers had a much lower risk of mortality for EA (HR=0.22, 95%CI=0.15-0.31) and 
GCA (HR=0.18, 95%CI=0.11-0.31) [181]. Distant staged cancers indicate more 
advanced disease and worse prognoses.  
Grade: Tumor grade did not appear to be an important prognostic factor. In the 
same study using US Multicenter Study data, well- and moderately-differentiated tumors 
had a suggested decreased risk of mortality for both EA and GCA (HR=0.85, 
95%CI=0.65-1.11 and HR=0.83, 95%CI=0.62-1.10, respectively) [181]. 
Tumor Location: Prognoses for EA tumors are better than for GCA tumors [182]. 
Surveillance and earlier presentation are thought to be driving these differences. There 
is no current surveillance for the gastric cardia, and tumors in the esophagus are likely 
to present earlier with dysphagia [182]. 
Lymphovascular Involvement: It has been suggested that mortality is lower for 
those patients with tumors without lymphovascular invasion [183,184]. A small study 
with 99 EA cases with T1 cancer (the cancer has not yet grown into the muscularis 
propria) who also underwent esophagectomy saw that lymphovascular involvement had 
an decreased in five-year overall survival (36%) when compared to those without 
lymphovascular involvement (85%) [183]. A more recent study out of the Mayo Clinic on 
269 patients with T1 EA showed that those with involvement of the vascular or 
lymphatic system had a HR=1.95 (95%CI=1.18-3.22) [184]. Analogous to what is seen 
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for stage, lymphovascular involvement indicates more spread disease and would be 
associated with a higher risk for mortality.  
Treatment: Treatment regimen has been identified as a prognostic factor 
[185,186]. A study using SEER data, showed that three-year survival has been 
improved in the group of patients receiving an esophagectomy (54%) compared to 
those cases who did not undergo this surgery (16%) [185]. This improvement was seen 
for all stages of EA and for both overall survival and cancer-specific survival time. 
Another study using SEER data saw that in EA patients, regardless of receipt of 
surgery, chemotherapy decreased mortality (HR=0.6, 95%CI=0.4-1.1) [186]. However, 
this improvement was not seen in GCA patients (HR=1.1, 95%CI=0.7-1.2). Surgery as a 
treatment option may indicate earlier stage tumors, leading to an observed survival 
benefit. 
Medical Conditions and Survival after EA/GCA 
BE: In a small study of 70 EA patients treated at one center during an eight-year 
period, it was shown that 46% of these patients were diagnosed with BE before their 
cancer diagnosis [187]. The EA tumors arising from BE were larger and less likely 
completely respond to chemoradiation, but had better differentiation than those tumors 
arising in patients without BE. When examining survival, those tumors arising from BE 
had better one-year and five-year survival (81% and 64%, respectively) than the tumors 
that did not arise from BE (70% and 32%, respectively). Although the mechanism is not 
well understood, this reduction in mortality may be due to more frequent interaction with 
the medical system and potentially more endoscopic screening leading to earlier 
diagnosis. 
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GERD: The presence of GERD symptoms may confer a survival benefit in both 
EA and GCA [181]. A 20% reduction (95%CI=0.63-1.03) in risk of mortality was seen for 
EA patients, and a 26% reduction (95%CI=0.56-0.98) in risk for GCA. Similar to the 
mechanism between BE and improved EA/GCA survival, these higher risk patients may 
be diagnosed earlier because of existing GERD.  
Dysphagia: Dysphagia is a condition where swallowing is difficult or 
uncomfortable due to disease. Patients who present with dysphagia at diagnosis have a 
worse prognosis, and this is most likely due to more advanced disease than those 
without dysphagia [182].  
Lifestyle Factors and Survival after EA/GCA 
Obesity: A meta-analysis by Fahey et al. based on three studies, found a 
decreased risk of mortality in overweight/obese (≥25 kg/m2) individuals using pre-
diagnosis BMI with a HR=0.80 (95%CI=0.68-0.95), a suggested inverse association 
was seen when examining only obesity individuals (≥30 kg/m2; HR=0.85, 95%CI=0.68-
1.06) [188].  
Weight Loss: Patients who experience weight loss before start of treatment have 
worse prognoses than patients who do not [182]. This may be explained by weight loss 
prior to treatment being an indication of advanced disease. Additionally, this may 
explain why obesity appears to have a mortality reducing effect since higher body mass 
would allow the wasting nature of this disease to go on for longer at the same rate. 
 Other lifestyle factors such as cigarette use, alcohol use, NSAID use, and PA 
have not been shown to have an impact on EA/GCA survival according to results from 
the previously mentioned meta-analysis [188].  
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Demographic Characteristics and Survival after EA/GCA 
Age [181,189], sex [181,190], education level [181,191] have not been shown to 
be associated with survival among EA/GCA patients. Racial/ethnic differences in 
mortality among EA/GCA patients are of interest, but there are typically so few non-
white EA/GCA cases it makes these analyses difficult.  
SES: Income has been shown to be associated with EA/GCA survival; the US 
Multicenter Study showed that an annual household income ≥$15,000 had a reduced 
risk of death for both EA (HR=0.64, 95%CI=0.48-0.87) and GCA (HR=0.62, 
95%CI=0.43-0.88) [181]. Income may be a proxy for SES and represent access to 
quality health care and access to preferred treatments [181], or represents other health-
seeking behaviors [122]. 
 
Summary of Prognostic Factors for Survival after EA/GCA 
Several prognostic factors for EA/GCA have been identified, and include: stage, 
tumor location, lymphovascular involvement, treatment, dysphagia, BE, GERD, obesity, 
weight loss, and income. Advanced stage [181], tumors located in the gastric cardia 
[182], lymphovascular invasion [183,184], presence of dysphagia [182], weight loss 
before treatment [182], and lower income [181] are all considered risk factors for 
mortality following an EA/GCA diagnosis. While surgery and chemotherapy [185,186], 
BE [187] and GERD [181] previous to cancer diagnosis, and obesity [188] are 
prognostic factors associated with improved mortality following EA/GCA diagnosis. 
These EA/GCA mortality modifiers will be considered when creating DAGs and 
statistical models for the association between PUFAs and EA/GCA survival.  
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Barrett’s Esophagus-Esophageal Adenocarcinoma Continuum  
Biology and Natural History 
The neoplastic transformation from normal esophageal lining into BE is a 
stepwise process of cellular changes. Figure 1.2 displays the histopathologic features 
of this transformation, which follows from normal esophageal tissue, non-dysplastic BE, 
LGD, HGD, and finally to invasive EA [1,192]. Although many patients do not detect 
each of these stages and very few BE patients will develop EA, with risk of about 0.5% 
per patient-year [193-195].  
One hypothesis suggests that the normal squamous lining of the esophagus can 
be damaged by chronic GERD [192,196], which involves heartburn and regurgitation of 
gastric contents (stomach acid, bile, duodenal secretions etc.) into the esophagus 
[65,197]. GERD can be further complicated by esophagitis, which is inflammation and 
ulceration of the esophagus [68]. The most important step is intestinal metaplasia, or 
the transformation of the esophageal mucosa to goblet cells, which are typically found in 
the intestines [198]. The damage created by GERD and esophagitis could pave the way 
for the reepithelialization of the esophagus by these goblet cells, and indicates the 
incidence of SIM [192,198]. The SIM that now present in the esophagus can progress to 
LGD and HGD, where dysplasia is defined as neoplastic epithelium within the basement 
membrane, but is contained there unlike in invasive cancer [199,200]. Finally, this 
dysplasia of the esophagus can develop into a neoplasm, indicating incident EA.  
A similar process is hypothesized for GCA, where the cardia region of the 
stomach, adjacent to the GEJ, develops intestinal metaplasia (CIM) [197,201-204], but 
the scientific community has not come to a consensus [196,197].   
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Summary of BE/EA/GCA-continuum Biology 
BE is diagnosed after the lining of the esophagus under neoplastic changes from 
normal tissue to intestinal metaplasia [198]. This change is thought to occur after 
chronic damage, potentially from reflux of gastric acid, duodenal secretions, and bile 
[65,196,197]. BE can then progress from non-dysplastic to LGD and then finally HGD 
before invasive EA [1], although very few cases of BE will progress to cancer [193-195]. 
There is evidence to support a similar histological path from normal gastric cardia, to 
CIM, and finally GCA [197,201-204]. 
 
Epidemiology of Polyunsaturated Fatty Acids 
One candidate for a modifiable dietary risk factor is PUFAs. PUFAs may be both 
anticarcinogenic and carcinogenesis promoting compounds [8]. The ω-3 PUFAs, which 
are not commonly consumed in the US [24], are considered the beneficial fatty acids [8]. 
And the ω-6 PUFAs, which are very commonly consumed in the US [24], are 
considered the deleterious fatty acids [8]. The ω-3 and ω-6 PUFAs are named after the 
position of the final double bond where the methyl group is located [8]. The primary 
subtypes of ω-3 PUFAs are: alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), 
docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA). And the primary 
subtypes of ω-6 PUFAs are: linoleic acid (LA) and arachidonic acid (AA). These fatty 
acids are essential, but the human body cannot make these compounds so they need to 
be consumed through the diet [8]. Table 1.1 shows major sources of the two types of 
PUFAs in a typical western diet; ω-3 are most often consumed in fish/shellfish and 
nuts/seeds, while ω-6 come from margarine, meat products, and mayonnaise [205].  
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The availability and intake of PUFAs in the US and the western world has 
changed over time. It is thought that humans evolved eating a ω-6:ω-3 ratios of 1:1, but 
over time diets have evolved to include more ω-6 PUFAs [22,23]. This change has 
largely taken place over the last 100-150 years, due to the production of oils high in ω-6 
such as corn oil, safflower oil, and soybean oil [22,23]. The ratio of ω-6:ω-3 fatty acids 
has steadily increased over the last century, with an estimated total increase from 20-
40% [24,25].  
PUFA dietary intake varies widely dependent upon geography. The intake of ω-6 
fatty acids in a typical western diet greatly outweighs the amount of ω-3 fatty acids, with 
a ω-6:ω-3 ranging between 15:1 and 20:1 [37]. LA, the most abundant ω-6 subtype, 
comprises at least 85% of total PUFA intake, while ALA, the most abundant ω-3 
subtype comprises only 10% [24]. While in countries such as India and Japan, the ratios 
are much lower and are estimated to be 6:1 and 4:1, respectively [37]. 
Increasing ω-3 fatty acid intake and/or decreasing ω-6 fatty acid intake may have 
the potential to decrease the burden associated with this disease progression from 
normal tissue to BE to invasive cancer. 
Summary of PUFA Epidemiology  
PUFAs are essential fats need to be ingested in the human diet, and come in two 
families: ω-3, the beneficial, and ω-6, the deleterious, fatty acids [8]. The intake of 
PUFAs has drastically changed over time, mainly a drastic increase in ω-6 consumption 
[24,25], which is assumed to be due to the increase in production and consumption of 
vegetable oils [22,23]. Intake varies geographically as well; Asian countries consume a 
much lower ratio of ω-6:ω-3 compared to countries that consume a typical western diet 
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[37]. Interventions on PUFA intake may be a potential risk reduction strategy for the BE-
EA continuum, and identification of the appropriate windows for implementation along 
the cancer continuum could further refine these strategies.  
 
PUFAs and the BE-EA Continuum: Biological Mechanisms 
The two families of PUFAs, ω-3 and ω-6, have different biochemical roles, are 
necessary fats, and cannot be converted into one another [23]. However through other 
processes, such as subsequent desaturation (removal of hydrogen and addition of 
double bond) and elongation (extension of the chain by two carbon molecules) 
reactions, the ω-3 and ω-6 subtypes can be synthesized from one another in vivo 
[206,207]. Figure 1.3 displays the methods by which LA and ALA (the essential fatty 
acids) are synthesized into the other longer ω-6 and ω-3 fatty acids, respectively [206-
209].  
PUFAs are incorporated into the cellular membrane and are then available for 
metabolism [209,210]. Both families of PUFAs use the same metabolic pathways and 
are competitively inhibited by one another, by vying for binding sites on the same 
enzymes [23,210,211]. The metabolism occurs through three pathways, COX and 
lipoxygenase (LOX) [23,209,210,212], and finally cytochrome P450 (CYP) [213-215]. 
The metabolism of AA and EPA results in the formation of eicosanoids, which are 
intermediate molecules that are very biologically active and may affect inflammatory and 
immune response, cellular growth and differentiation, and platelet aggregation [23,212]. 
The enzymes act as catalysts for the formation of these eicosanoid metabolites [208], 
along with the mediators in the metabolic process [23,210,213]. The eicosanoids can be 
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AA-derived or EPA-derived, and this is dependent upon the concentration of the two 
families of PUFAs in the cell membranes [212]. When comparing ω-3 and ω-6 
metabolism, the resulting metabolites of these pathways have competing biological 
functions [23].  
The first pathway for PUFA metabolism is COX. The COX pathway has three 
major metabolic enzymes: COX-1, COX-2, and COX-3 [213]. This pathway generates 
prostaglandins (PGs) and thromboxanes (TXAs) [23,208,212]. In addition to the function 
of the metabolites produced through the pathway, overexpression of COX-2 has been 
implicated in most human cancers and in some cancer precursors, and has been 
associated with poor prognosis [23,207,216].  
The LOX pathway is another pathway for PUFA metabolism. The enzymes 
involved in the LOX pathway are 5-LOX, 8-LOX, 12-LOX, and 15-LOX [213]. These 
enzymes synthesize the eicosanoids generated in the LOX pathway: leukotrienes (LTs), 
along with hydroxyeicosatetraenoic (HETEs) acids [23,208,212]. 
The final PUFA metabolic pathway is the CYP pathway, which has two separate 
families of enzymes involved: the ω-hydroxylase and epoxygenase enzymes [213]. ω-
hydroxylase and epoxygenase convert AA into HETEs and epoxyeicosatrienoic acids 
(EETs), respectively [213,214]. The research on this pathway has focused on 
inflammation, angiogenesis, and cardiovascular disease [213], the interest its role in 
cancer development and progression has only recently peaked.   
The preponderance of AA-derived eicosanoids has been associated with factors 
that would increase cancer risk. PGE2, the primary metabolite in the COX path, has 
been linked to promotion of cell survival, apoptosis (by both reducing pro-apoptotic 
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proteins and inducing anti-apoptotic proteins), increased invasiveness of malignant cells 
[210,212]. It has also been found in higher concentrations in cancer cells when 
compared to normal cells [212]. LTB4, from LOX metabolic path, boosts the generation 
of reactive oxygen species, which can affect DNA and lead to cancer initiation [212]. 
TXA2 has been found to enhance metastasis [216]. 20-HETE, the principal eicosanoid 
of ω-hydroxylase CYP pathway, stimulates the production of inflammatory cytokines 
and has been linked to increased tumor mass [213]. 11,12-EET has been suggested to 
induce angiogenesis, make tumors more active, and increase proliferation [214]. While 
the majority of AA-derived molecules have cancer-promoting properties, PGI2 has been 
found to decrease cellular proliferation and inflammation, increase apoptosis, and inhibit 
metastasis [212,216]. Overall AA-derived eicosanoids are pro-inflammatory, pro-
angiogenic, decrease apoptosis, promote cell survival and progression, and enhance 
proliferation [213].  
Figure 1.4 shows a schematic of AA metabolism including the pathways, 
enzymes, mediators, and metabolites.  
Summary of PUFA Biology 
The carcinogenesis promoting effect of ω-6 fatty acids increases AA-derived 
eicosanoids, while the anti-carcinogenic effect of ω-3 fatty acids have been shown to 
suppress AA-derived eicosanoid biosynthesis [8,212]. And because ω-3 and ω-6 are 
competing for the same binding sites on enzymes [23,210,211], higher intake of ω-3 
fatty acids leads to increased presence of EPA and decreased presence of AA in the 
cell membrane [8,23,209]. Increased presence of ω-3 fatty acids decreases the 
production of AA-derived eicosanoids, which are highly biologically active, and produces 
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the EPA-derived molecules which are much less active molecules [207,212]. 
Additionally increased presence of EPA and DHA can lower the expression of COX-2 
[207,210], which has been implicated in a variety of human cancers [23,216]. 
Furthermore COX-2 inhibitors have been shown to suppress tumor growth, 
angiogenesis, and metastasis [23,207]. 
A streamlined version of the biological mechanisms from which the proposed 
study derives its hypotheses about the associations between PUFAs and the BE-EA 
continuum is shown in Figure 1.5. 
 
Epidemiology of PUFAs and the BE-EA Continuum  
Details of and results from the previous epidemiologic studies examining the 
associations between PUFAs and the BE-EA continuum are summarized in Figure 1.6 
and Table 1.2. 
PUFAs and BE 
As the literature stands today, only three studies have examined some measure 
of PUFAs with the development of BE [107,217,218] and meta-analysis of two of these 
studies [219].  
Two of these studies used fish intake as a measure, an Irish study by O’Doherty 
et al. [218] and a Dutch study by Keszei et al. [217]. Using the FINBAR case-control 
study data, the Irish study with 220 BE cases found no association with fish intake and 
the effect estimate suggest a possible increased risk of BE (ORQ4-Q1=1.39, 95%CI=0.62-
3.11) [218]. The Dutch study was a prospective cohort study with 447 BE cases, and 
these analyses were stratified by sex. There was a null association between fish intake 
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and BE in both men and women with ORsT3-T1=1.01 (95%CI=0.70-1.47) and 1.13 
(95%CI=0.87-1.96), respectively [217].  
O’Doherty et al. explored total PUFA intake in the FINBAR study [218], and Kubo 
et al. also examined total PUFAs in a California study population with 296 BE cases 
[107]. The FINBAR study showed no association with total PUFAs (ORQ4-Q1=0.94, 
95%CI=0.40-2.17) [218]. Kubo et al. also did not find significant association, but the 
effect estimate suggested a possible inverse association (ORQ4-Q1=0.47, 95%CI=0.17-
1.27) [107]. A meta-analysis by Zhao et al. combined the results from these studies and 
found no association between BE and PUFAs (ORHighestvs.Lowest=0.67, 95%CI=0.35, 
1.26) [219].  
Kubo et al. was the only study to examine ω-3 fatty acids and found a decreased 
risk of BE with higher intake of ω-3 (ORQ4-Q1=0.36, 95%CI=0.14-0.90) [107]. 
In a fourth study, the California study population used an alternative method, 
dietary patterns, that provided evidence supporting fish intake as a possible risk 
reduction factor. In a separate study by Kubo et al., a “health conscious” dietary pattern 
was created where non-fried fish was a large contributor along with fruits and 
vegetables [220]. A high adherence to this “health conscious” diet was associated with 
decreased risk of BE (ORQ4-Q1=0.35, 95%CI=0.20-0.64), and this trend of decreasing 
risk held as adherence increased (ptrend=0.001).  
PUFAS and EA/GCA Incidence 
Ten previous epidemiologic studies [218,221-229] and three meta-analyses [230-
232] have assessed the associations between PUFAs and EA or GCA. 
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The association between fish intake and EA/GCA were examined in seven of 
these studies. Six of these, with a total of 1,610 case participants from five case-control 
and one cohort, were included in a meta-analysis for fish intake and EA by Han et al. 
[230]. Individually, two of these studies showed risk reduction for EA [221,225], two had 
non-significant suggestive increased risks [218,223], and two were null [222,224]. The 
meta-analysis had a summary RR of 0.86 (95%CI=0.61-1.22) [230]. Three of these 
studies were included in another meta-analysis by Jiang et al. which also showed a null 
association between fish intake and EA (summary RR=0.64, 95%CI=0.26-1.60) [231]. 
One final study examining fish intake and EA, by Navarro Silvera et al., found a non-
significant but positive association between increasing intake of fish by one serving and 
risk of EA (OR=1.39, 95%CI=0.61-3.19) [227]. Three of these studies also examined the 
relationship between fish intake and GCA [222,225,227]. The LAC Multiethnic Study 
saw a slightly increased risk of GCA with higher levels of fish intake (ORQ4-Q1=1.16, 
95%CI=0.8-1.8) [222]. In a study by Navarro Silvera et al. using data from the US 
Multicenter Study, the risk of GCA increased with each one serving increase of fish per 
day (OR=1.79, 95%CI=0.85-3.80) [227]. In a prospective study using the NIH-AARP 
Study, there was a null association between fish intake and GCA (HRQ5-Q1=0.98, 
95%CI=0.71-1.35) [225].  
Five studies and a meta-analysis assessed total PUFAs and the risk of EA/GCA 
[218,222,226]. In the FINBAR study, increasing intake of PUFAs was associated with an 
increase in the risk of EA (ORQ3-Q1=2.68, 95%CI=1.23-5.85) [218]. There was no 
association between EA and total PUFAs (ORQ5-Q1=0.91, 95%CI=0.70-1.19), and no 
association between GCA and total PUFAs (ORQ5-Q1=0.95, 95%CI=0.69-1.30) with the 
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NIH-AARP Study data [226]. Similarly, there were no associations between PUFAS and 
EA (ORQ4-Q1=1.07, 95%CI=0.7-1.7) or GCA (ORQ4-Q1=1.24, 95%CI=0.8-1.9) in the LAC 
Multiethnic Study [222]. Results from the US Multicenter Study found no associations 
between PUFAs and EA (OR75th%vs25th%=0.86, 95%CI=0.59-1-24) or GCA 
OR75th%vs25th%=0.86, 95%CI=0.60-1-22) [228]. Finally, a Greek study by Tzonou et al. 
showed a suggestive increased risk for EA with PUFAs (OR=1.35, 95%CI=0.94-1.94), 
but only included 56 EA cases [229]. The meta-analysis by Du He et al. included five 
studies and found a null association between PUFAs and EA (summary RR=1.04, 95% 
CI=0.86, 1.27) [232]. 
The NIH-AARP Study also examined ω-3 fatty acids: there was no association 
for EA (ORQ5-Q1=0.98, 95%CI=0.75-1.29) and no association for GCA (ORQ5-Q1=1.08, 
95%CI=0.79-1.43) with ω-3 [226]. 
Two studies have used dietary patterns to examine possible relationships 
between fish and EA/GCA. A Swedish study created a “healthy” diet, of which fish was 
a primary component, and those who had the highest “healthy” diet scores had 
suggestive decreased risks of both EA (ORHigh-Low=0.8, 95%CI=0.5-1.3) and GCA 
(ORHigh-Low=0.7, 95%CI=0.5-1.1) [233]. In another study using the US Multicenter Study 
data, high adherence to a dietary pattern of “fish/vitamin C”, where fish intake was an 
extremely high contributor to this pattern, was associated with a very slight increase in 
risk of GCA (ORQ4-Q1=1.11, 95%CI=0.70-1.74) but no association with EA [224].  
PUFAs and Survival After EA/GCA  
To date, there have been no investigations into the associations between PUFAs 
and survival following a diagnosis of EA/GCA.  
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Summary of PUFAs and the BE-EA Continuum 
Fish intake and BE/EA/GCA associations have been studied previously, but the 
research has been limited. Only one of these studies, a meta-analysis, has shown a 
possible risk reduction effect of fish intake [230], while a few of these have suggested a 
positive association with BE/EA/GCA [218,222]. These inconsistent results may be 
because none of these studies have considered type of fish eaten, which can have 
varying nutritional content [24], or the cooking method, which can also affect nutritional 
values [234].  
 The evidence for PUFAs and BE/EA/GCA has been inconsistent. One of the two 
studies for BE suggested a possible inverse association [107], while two of the studies 
for EA/GCA showed a positive association with EA [218,229]. The varied results may be 
due to the fact that overall PUFA measures do not take into account the distinctions 
between the beneficial and deleterious PUFAs. Using the relative balance represents 
how ω-3 and ω-6 are competitively inhibited by each other, and may differentially affect 
the carcinogenic process [8,49,212,216,235-237].  
 The associations between ω-3 fatty acids and BE/EA/GCA have been studied 
very rarely. An inverse association was found with the development of BE [107], but no 
association was seen with either EA or GCA [226]. These studies may be limited 
because the interplay between ω-3 and ω-6 fatty acids could be more biologically 
relevant [8,49,212,216,235-237], and better reflect how individuals are exposed to these 
potential risk modifiers. 
 No studies have been conducted examining ω-6, the relative balance between 
ω-3 and ω-6, or the subtypes of ω-3 and ω-6 fatty acids and BE/EA/GCA, and there are 
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Aim 1: PUFAs and BE 
Determined if PUFA intake (fish intake, ω-3, ω-6, ω-3*ω-6 interaction,  
ω-6:ω-3 ratio, and ω-3 and ω-6 subtypes) was associated with the development of BE. 
 
Aim 2: PUFAs and Risk of Developing EA/GCA 
Determined if PUFA intake (fish intake, ω-3, ω-6, ω-3*ω-6 interaction,  
ω-6:ω-3 ratio, and ω-3 and ω-6 subtypes) was associated with the risk of developing 
EA/GCA. 
 
Aim 3: PUFAs and Mortality after Diagnosis of EA/GCA 
Determined if PUFA intake (fish intake, ω-3, ω-6, ω-3*ω-6 interaction,  
ω-6:ω-3 ratio, and ω-3 and ω-6 subtypes) was associated with mortality among patients 
diagnosed with EA/GCA. 
 
Hypotheses 
Higher intake of fish and ω-3 fatty acids would be associated with reduced risk of 
BE-EA continuum outcomes, while the relative balance of ω-6 and ω-3 fatty acids 
(which will be dominated by ω-6 intake) would be associated with increased risk of 
these outcomes. 
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Background Summary  
The incidence of EA/GCA is increasing [4,7,16-21], this increase is expected to 
continue with time [2,53,135], and the prognosis remains poor [2-7]. The incidence of 
the only known precursor lesion, BE, is also increasing [4,9,58,59]. The major risk 
factors for BE/EA/GCA development include: older age [9,58,112,113,168,169], white 
race [9,116,117,169,170], male sex [112,116-118,168-170], GERD [66,67,141,143], 
obesity [78-81,153-155], and cigarette smoking [85,160,161]. The first three risk factors 
are non-modifiable. GERD is a chronic disease that requires treatment and 
maintenance therapy, but even with treatment 30-60% of patients experience relapse 
[238]. Of the other mentioned risk factors, obesity and cigarette smoking are the only 
potentially modifiable factors. Unfortunately, weight loss [239] and smoking cessation 
[240] are difficult to achieve and, especially for obesity [241-243], difficult to maintain. A 
few risk reduction factors have also been identified, including, Hp [76,77,144], NSAIDs 
[102-104,162-164] (but are difficult to utilize long-term because of well-known gastric 
side effects [244]), PA [83,156-158], and, perhaps, fruits and vegetables [105,106,165]. 
Dietary factors appear to be amenable to intervention [245-249], and thus provide 
opportunities for risk reduction. Research suggests that dietary modifications may be an 
effective method to reduce chronic disease risk [250,251], particularly among individuals 
already at increased risk for these diseases [252].  
The etiology for outcomes along the BE-EA continuum is complex and multiple 
risk reduction strategies are likely needed. PUFAs have the potential to reduce disease 
burden of these outcomes; increasing the beneficial ω-3 fatty acid consumption, while 
simultaneously decreasing the deleterious ω-6 PUFAs, is a plausible risk reduction 
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strategy [8,24]. This dissertation examined the associations between PUFAs and the 
three BE-EA continuum outcomes: development of BE, risk of developing EA/GCA, and 
mortality following a diagnosis of EA/GCA. If associations are found this could lead to 
continuum-specific strategies to reduce the risk of developing these esophageal/gastric 
diseases, or to improve the prognoses of these deadly cancers. 
 
 
























Subtype Examples of foods rich in PUFAs 
ω-3 
α-linolenic acid (ALA) Flaxseed, walnuts 
Eicosapentaenoic acid (EPA) Fish roe, herring, oysters 
Docosahexaenoic acid (DHA) Swordfish, salmon, mussels 
Docosapentaenoic acid (DPA) Salmon, mackerel, trout 
ω-6 
Linoleic acid (LA) Margarine, canola oil, mayonnaise 
Arachidonic acid (AA) Pork, lard, egg 
 
Source: [205]  
 










Figure 1.4. Metabolism of arachidonic acid including the pathways (green), enzymes (blue), mediators (red), and 


































































EA and GCA 







vs. 25th percentle 
PUFA: 
EA – OR=0.86 (0.59, 1.24) 
GCA – OR=0.86 (0.60, 1.22) 















Fish (Q4 vs. Q1): 
EA – OR=0.14 (0.04, 0.48) 
Bahmanyar 











“Healthy diet” – high in fruits, 
vegetables, fish, poultry (high 
vs. low) 
EA – OR=0.8 (0.5, 1.3) 








EA and GCA 








Fish/shellfish (Q4 vs. Q1): 
EA – OR=0.85 (0.5, 1.4) 
GCA – OR=0.86 (0.6, 1.3) 
PUFA (Q4 vs. Q1): 
EA – OR=1.07 (0.7, 1.7) 
GCA – OR=1.24 (0.8, 1.9) 















“Health-conscious diet” – high 
in fruits, vegetable, non-fried 
fish (Q4 vs. Q1): 






























EA and GCA 








Fish (increase intake by 1 
serving/day): 
EA – OR=1.39 (0.61, 3.19) 
GCA – OR=1.79 (0.85, 3.80) 
















PUFA (Q4 vs. Q1): 
BE – OR=0.49 (0.22, 1.11) 
ω-3 (Q4 vs. Q1): 






Cohort EA and GCA 
492,186 
participants 




Fish (Q5 vs. Q1): 
EA – OR=0.78 (0.59, 1.03) 
GCA – OR=0.98 (0.71, 1.35) 
Mulholland 














0, 0-1, ≥1 
portions/week 
 
Oily fish (≥1 portions/week vs. 
0 portions/week): 










EA and GCA 






“Fish and vitamin C pattern” – 
high in fish and dietary 
vitamin C (Q4 vs. Q1): 
EA – OR=0.94 (0.59, 1.48) 






















Adjusted OR/HR (95% CI) 
O’Doherty 









BE and EA 
224 BE cases 






Fish (Q4 vs. Q1): 
BE – OR=1.39 (0.62, 3.11) 
EA – OR=1.49 (0.72, 3.10) 
PUFA (Q4 vs. Q1): 
BE – OR=0.94 (0.40, 2.17) 
EA – OR=1.60 (0.73, 3.49) 
O’Doherty 















PUFA (Q5 vs. Q1): 
EA – HR=0.91 (0.70, 1.19) 
GCA –HR=0.95 (0.69, 1.30) 
ω-3 (Q5 vs. Q1): 
EA – HR=0.98 (0.75, 1.29) 
GCA – HR=1.08 (0.79, 1.47) 

















Fish (highest intake vs. 
lowest) 

















Fish (T3 vs. T1): 
Male BE –  
HR=0.99 (0.70, 1.41) 
Female BE –  
HR=1.13 (0.76, 1.69) 












EA – RR=0.64 (0.26, 1.60) 



















CHAPTER II: METHODS 
 
Overview 
The aims of this dissertation were to examine the associations between 
polyunsaturated fatty acid (PUFA) intake and outcomes along the Barrett’s esophagus-
esophageal adenocarcinoma (BE-EA) continuum. To examine these associations, I 
drew upon resources from four existing epidemiologic studies conducted in the United 
States (US). For my dissertation, I proposed to use both case-control and follow-up 
study designs to address these aims in three steps.  
Step 1: Estimated PUFA dietary intake for the study participants, using the PUFA 
dietary intake responses assessed as part the four parent studies and which have 
already been harmonized. 
Step 2: Pooled the PUFA dietary intake estimates across the four studies. 
Step 3: Estimated odds ratios (ORs)/hazard ratios (HRs) for the associations of 
PUFAs and three outcomes along the BE-EA continuum: Barrett’s esophagus (BE) 
development, risk of developing esophageal adenocarcinoma (EA)/gastric cardia 
adenocarcinoma (GCA) incidence, and mortality following an EA/GCA diagnosis.  
The case-control study design was used to examine the associations between 
PUFAs with the development of BE (Aim 1) and risk of developing EA/GCA (Aim 2). 
Using the cases from the two EA/GCA studies, a follow-up approach examined the 
associations between PUFAs and mortality following a diagnosis of invasive cancer 
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(Aim 3). I proposed to pool harmonized data from two BE case-control studies and two 
EA/GCA case-controls studies to address these aims. 
BE and EA/GCA are rare diseases, and thus the most efficient study designs 
were the case-control and case-only follow-up designs that I employed. Alternative 
study designs to address these aims were two prospective cohort studies. First, a 
cohort study of gastroesophageal reflux disease (GERD) patients to examine 
associations between PUFAs and incident BE. Second, an additional cohort study of BE 
patients to examine associations between PUFAs and incident EA/GCA. Although BE is 
hypothesized to be a complication of GERD, it is estimated only 10-15% of GERD 
patients develop BE [196]. Similarly, even though BE patients are more likely to develop 
EA/GCA, the likelihood of a BE patient being diagnosed with EA/GCA annually is 0.1-
3.5% [136,253-255]. Using the prospective cohort method to examine associations with 
the risk of developing BE and EA/GCA or with mortality after EA/GCA, would require a 
very large sample size, due to the rarity of these outcomes [15,19], and a long follow-
up, due to lengthy induction periods [256,257], to accrue the necessary number of 
cases, resulting in an extremely time-intensive and expensive study method. Therefore 
the proposed study design of pooling existing case-control studies was a practical and 
time- and cost-effective method, and resulted in a sufficient sample size to examine the 
associations between PUFAs and the BE-EA continuum. Similarly, the follow-up design, 
which focused on determining vital status among the case respondents only, was an 
efficient approach to examining associations with mortality after diagnosis with EA/GCA. 
The four studies I proposed to use for my dissertation were conducted by 
members of the International Barrett’s and Esophageal Adenocarcinoma Consortium 
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(BEACON), an international group of investigators with an open forum for epidemiologic 
research focusing on these two diseases and the sharing and pooling of data. The 
studies within BEACON are similar in regards to: study designs, participant selection 
methods, interview methods, and food frequency questionnaire (FFQ) structure.  
 
Specific Aims 
The specific aims of this dissertation were as follows.  
Aim 1: Determined if PUFA intake (fish intake, ω-3, ω-6, ω-3*ω-6 interaction, ω-
6:ω-3 ratio, and ω-3 and ω-6 subtypes) was associated with the development of BE. 
Aim 2: Determined if PUFA intake (fish intake, ω-3, ω-6, ω-3*ω-6 interaction, ω-
6:ω-3 ratio, and ω-3 and ω-6 subtypes) was associated with the risk of developing 
EA/GCA. 
Aim 3: Determined if PUFA intake (fish intake, ω-3, ω-6, ω-3*ω-6 interaction, ω-
6:ω-3 ratio, and ω-3 and ω-6 subtypes) was associated with mortality among patients 
diagnosed with EA/GCA.  
 
Hypotheses 
I hypothesized that: (1) higher intake of fish and ω-3 fatty acids would be 
associated with reduced risk of BE/EA continuum outcomes; and (2) higher intake of the 
ω-6 fatty acids and the relative balance (the interaction or ratio of ω-3 and ω-6, which in 
the US will be dominated by ω-6 intake [25,258]) would be associated with an increased 
risk of BE-EA continuum outcomes. The biological mechanisms supporting these 
hypotheses were discussed in chapter 1 (see Figure 1.5).  
58 
Study Populations and Design 
To address the study aims, I pooled the harmonized data from two parent case-
control studies of BE (Study of Reflux Disease [259] and Epidemiology and Incidence of 
BE Study [80]) and two parent case-control studies of EA/GCA (US Multicenter Study 
[173] and Los Angeles County (LAC) Multiethnic Study [260]). Descriptions of each of 
the four parent study populations are presented below and are summarized in Table 
2.1. 
 
Study of Reflux Disease 
The Study of Reflux Disease [259] was a case-control study of BE conducted in 
western Washington (WA) state from 1997-2000. 
Potential cases were selected from residents 20-80 years of age who underwent 
an upper endoscopy for GERD symptoms at four community gastroenterology clinics 
between October 1, 1997 and September 30, 2000, and were newly diagnosed with BE. 
During the endoscopy procedure the consenting participants had 4-quadrant biopsy 
specimens taken from the esophagus. Cases were defined as those with the presence 
of specialized metaplastic epithelium (SIM) on at least one of the four specimens. 
Physicians also noted the presence of visible columnar epithelium, and its length, during 
the endoscopy.  
Controls were residents of western WA, community-based, and selected using a 
modified Waksberg random digit dialing (RDD) [261,262]. This RDD technique identifies 
controls residing in the same geographic area by using the first five digits of each case’s 
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residential telephone number as the primary sampling unit [263,264]. Controls were 
community-based, and individually matched to cases on age (+/- 3 years) and sex.  
 
Epidemiology and Incidence of BE Study 
The Epidemiology and Incidence of BE Study [80] was a case-control study of 
BE within the Kaiser Permanente of Northern California (KPNC) health care system 
conducted between 2002 and 2005.  
 Cases were KPNC members aged 18-79 with an incident diagnosis of BE 
between October 2002 and September 2005. The newly diagnosed patients were 
identified using the International Classification of Disease, Ninth Revision (ICD-9) code 
530.2.  
Controls were KPNC members aged 18-79 without a BE diagnosis before the 
case selection period, and were selected using risk set sampling [265]. The controls 
were community-based and frequency matched to the cases on sex, age (5-year 
groups), and geographic region.  
All participants had to be continuously enrolled in KPNC for at least two years 
before the index date (index date for cases: date of BE diagnosis, and for controls: 
midpoint of each two- to three-month selection interval for the cases), and had to be 






US Multicenter Study 
The US Multicenter Study [173] was a case-control study of EA/GCA conducted 
from 1993-1995 in Connecticut (CT), a 15-county area of New Jersey (NJ), and a three-
county area of western WA. 
 Eligible cases were English-speaking residents aged 30-79 who were diagnosed 
with a first primary EA/GCA and were identified by state tumor registries through an 
established rapid-reporting system. Cases had to be diagnosed within specific time 
periods: from February 1, 1993 through January 31, 1995 in CT; from April 1, 1993 
through November 30, 1994 in NJ; and from March 1, 1993 through February 28, 1995 
in Washington. Pathology materials were obtained for all potential cases, and final 
determination of eligibility was based on review by study pathologists using 
standardized criteria.  
 Controls were sampled using different methods according to age. Controls who 
were 30-64 years were identified using Waksberg RDD [261], and controls 65-79 were 
identified by random sample of Health Care Financing Administration (HCFA) rosters. 
The controls were population-based and frequency matched on age (5-year groups) 
and sex, and in NJ matched on race as well. 
 
LAC Multiethnic Study 
The LAC Multiethnic Study [260] was a case-control study of EA/GCA conducted 
in LAC from 1992-1997.  
 Cases were eligible if they were 30-74 years old when newly diagnosed with 
EA/GCA and identified by the LAC Cancer Surveillance Program (CSP) between 1992-
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1997. All pathology reports were reviewed to consistently confirm cancer subsite; the 
cancers included were defined by International Classification of Diseases for Oncology 
(ICD-O) codes for EA (C15.0-15.9) and GCA (C16.0).  
 Controls were individually matched on gender, race, and age (+/- 5 years), and 
must not have had a previous diagnosis of esophageal or gastric cancer. These 
neighborhood controls were identified through a systematic algorithm based on the 
address of the matched case patient. 
 
Data Collection 
Each of the four parent studies received approval from the Institutional Review 
Board (IRB) of the organizations involved, and informed consent was obtained for all 
study participants before interview.  
 
Study of Reflux Disease 
Of the eligible case and control subjects, 92.8% and 68.7% of these were 
successfully interviewed. Trained staff conducted structured interviews of study 
participants in their home or another requested location. The questionnaire took about 
45 minutes to complete, and assessed demographics, medical history, medication use, 
smoking habits, and alcohol consumption. The interviewers also took anthropometric 
measures (height, weight, waist circumference, hip circumference, and thigh 
circumference) [266]. Dietary information was collected using the validated, 131 food 
item Fred Hutchinson Cancer Research Center (FHCRC) FFQ [267]. This diet history 
assessed the one-year period before the interview date.  
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Epidemiology and Incidence of BE Study 
Interviews were conducted in-person for all study participants by trained 
interviewers, most frequently at the participant’s home. The response rate for the 
eligible cases and controls were 47% and 37%, respectively. The interview collected 
information on demographics, GERD symptoms, medical history, medication use, 
tobacco use, and alcohol consumption in the year prior to the index date. 
Anthropometric measures (height, weight, abdominal circumference, and mid-thigh 
circumference) were taken by the interviewers using standardized equipment. Diet 
history corresponding to the one-year before the index date was assessed using the 
Block 1998, a validated 110 food item FFQ [268,269].  
 
US Multicenter Study 
Interviews were performed in-person for a majority of case (80.6%) and control 
(73.7%) subjects. Interviews were conducted with the closest next-of-kin (NOK) proxy 
(typically the spouse) for 29.6% of cases and 3.4% of controls. The mean length of time 
between cancer diagnosis and interview was 3.7 months for non-proxy interviews, and 
8.5 months for proxy interviews. Trained interviewers administered a structured 
questionnaire, which took about 130 minutes to complete. The questionnaire collected 
information on demographic characteristics, tobacco use, alcohol consumption, medical 
history, use of medications, and occupational history. The reference date for this study 
was defined as the date of diagnosis for the cases and date of identification for the 
controls. Dietary information was collected using a validated and modified FHCRC FFQ 
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[270], which included 104 food items. This FFQ assessed the period three to five years 
prior to diagnosis or interview for cases and controls, respectively.  
 
LAC Multiethnic Study 
Interviews were completed with 75% of approached cases, and NOK interviews 
were used for 30% of the case subjects. The questionnaire was completed during an in-
person interview completed by the study subject or NOK. The structure questionnaire 
used was specifically designed for this study. It assessed demographic information, 
lifestyle behaviors (tobacco and alcohol use in particular), anthropometric measures, 
personal medical history and medication use, family history, and occupational history. A 
reference date was established for the cases and controls: one year before the date of 
EA/GCA diagnosis for cases, and the same reference date was used for each case’s 
matched controls. Similarly, diet history corresponding to the one year prior to the 





BE cases were defined as those with SIM identified during endoscopy [259] or 
those who received a new diagnosis with an ICD-9 code of BE in medical records [80]. 
Board-certified gastroenterologists or pathologists reviewed the endoscopy and 
pathology records in order to identify eligible BE cases [80,259].  
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BE Segment Length 
BE cases were also described using the segment length observed on 
endoscopy. The two degrees of BE segment length were defined as short-segment BE 
(SSBE; <3 cm) and long-segment BE (LSBE; ≥3 cm on endoscopy), which are often 
used as clinical definitions of the severity of disease [80,272,273]. 
 
EA and GCA 
EA/GCA cases were defined as those with an incident diagnosis of EA/GCA 
identified by local tumor or cancer registries during the time periods previously specified 
[173,260]. ICD-O codes were used to classify tumors: EA cases were identified by 
C150.0-150.9 [173] and C15.0-15.9 [260] and GCA by C151.0 [173] and C16.0 [260]. 
Final determination of case status, the anatomical location of the tumor, and other 




The follow-up studies were conducted to determine vital status among the 
EA/GCA cases. The mortality outcome was assessed and date of death were 
determined by linking participants with the National Death Index (NDI) [181]. An event 
was defined as death due to any cause during the period of follow-up, and participants 
alive at the end of follow-up were censored. After 7.5 years the US Multicenter Study 
reported 476 deaths [181], and the LAC Multiethnic Study reported 426 deaths after 
10.7 years of follow-up. Overall survival time was calculated in months from the date of 
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diagnosis until date of death or censoring. Due to the aggressive nature and short 
survival time (average of less than a year) of these cancers [2,4-6,181], all-cause 
mortality was used as an approximation of EA/GCA-specific mortality.  
 
Data Management and Quality Control 
The four parent case-control studies collected covariate information during a 
structured paper-based interview conducted by trained interviewers [80,173,259,260]. 
Dietary information was either collected by interviewers [106,222,228] or self-
administered [105]. Each of the parent studies conducted quality control of the data, and 
discrepancies were resolved by referencing the original interview documents 
[105,106,222,228].  
 
Dietary Intake Exposure Assessment 
Each of the four parent studies collected dietary information using a validated 
FFQ, and these dietary measurement tools are summarized in Table 2.1. The FFQs 
that were used were validated using diet records [268,270,274,275] or multiple 24-hour 
recalls [276,277]. 
The FFQs used assessed both frequency and portion size [105,106,222] except 
for the modified FHCRC FFQ (US Multicenter Study), which assumed average portion 





Data Harmonization of Dietary Intake Responses 
To harmonize the dietary intake responses, I used each of the four parent 
studies’ FFQs and linked with a nutrient database to estimate with ounces/grams per 
day of PUFA values.  
 In each of the four FFQs participants were asked how frequently each of the line 
items was consumed. In the Study of Reflux Disease, nine choices encompassing 
never/less than once a month up to two or more time per day were given to the study 
participants. For the Epidemiology and Incidence of BE Study, participants were given 
around nine choices ranging from never and a few times per year to twice per week and 
every day. In the US Multicenter Study FFQ, participants wrote in the number of times 
the line item was consumed and then circled if this corresponded to times per day, 
week, month, or year. Options of never eaten, and unsure of how often were also 
available. Finally for the LAC Multiethnic Study, participants provided the number of 
times each line item was consumed then chose per day, week, month or year. And if 
this food was never consumed there was a separate choice.  
 In three of the FFQs portion size was explicitly assessed. For the Study of Reflux 
Disease, participants were given a definition of medium serving size for each line item. 
Then they were given three options to choose from: small serving size (≤1/2 of the 
medium serving), the medium serving previously defined, and large serving size (≥1 ½ 
of the medium serving). In the Epidemiology and Incidence of BE Study, four options for 
serving size specific to the individual line items were provided to choose from. In the 
LAC Multiethnic Study, participants were asked the usual serving size and the number 
of servings each time this item was consumed. Participants were given multiple options 
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for serving sizes for each of the line items. In the US Multicenter Study, medium serving 
sizes were assumed for the line items. 
Nutrient intake was estimated using the University of Minnesota Nutrition 
Coordinating Center (NCC) database [278], which was primarily based on the USDA 
nutrient database [205]. However, the NCC database contained more food items, and 
had a minimal amount of missing nutrient values. If certain values were not available in 
the USDA database, the NCC included values from other nutrient databases and 
appropriate information contained in scientific journals. When necessary, values were 
imputed using one of the following methods: used a value from a similar food; 
calculated value for another form of the same food; calculated values from components 
in the same food; or calculated values from recipes or food product formulations [278].  
When identifying the specific food items from the NCC database to correspond to 
the food items on the parent study FFQs, I selected the most similar line items 
available. For example, a food item from the Kaiser Permanente FFQ is “real 100% 
orange juice, including fresh, frozen, or bottle”. The corresponding food item chosen 
from the NCC is “purchased ready-to-go orange juice”. For an item with more open 
interpretation such as “refried beans”, the item chosen from the NCC is “regular, canned 
refried beans”.  
Because some of the FFQ line items represented multiple food items, the 
individual foods were weighted according to the estimates of US consumption [279]. 
The weights used by the original nutrition data processing for the Study of Reflux 
Disease and the LAC Multiethnic Study were provided. For the Epidemiology and 
Incidence of BE Study, the original weights were unobtainable and the weighting 
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scheme used was determined from the FFQs of the other participating studies. In 
instances where weights were not available for a line item, the weights were evenly split 
by the number of foods in that particular line item [280]. In the case of the US 
Multicenter Study, the original weights were unavailable, but a previous verification of 
the weights was performed using a similar FFQ’s weighting scheme [281]. This newer 
weighting scheme was similar to the original (correlation coefficient=0.97), and was 
used here. An example of calculating the PUFA intake value for one participant using a 
weighting scheme is shown in Table 2.2.  
 
Data Pooling of Harmonized Dietary Intake Responses 
To pool the harmonized dietary intake data I employed two standard approaches. 
First, using the harmonized dietary data, I generated study-specific quantiles of intake, 
and then merged the PUFA intake responses within control-based quantiles for each of 
the two BE and for each of the two EA/GCA studies [282,283]. Second, I pooled the 
harmonized data using absolute values, with the cut-points determined using responses 
from the controls only, with the BE studies considered separately from the and EA/GCA 
studies [282,283]. Absolute value-based quantiles required the inclusion of a covariate 
for the number of PUFA-containing food items in each of the FFQs. With study-specific 
quantiles, true differences in population intakes were not considered, potentially 
resulting in exposure misclassification. When using identical absolute intake cut-points 
across studies, misclassification was also possible, because intake may increase with 
the number of relevant items on each FFQ, which varied across study instruments. 
Thus, study-specific variations in foods that contain PUFAs may have been due to 
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variations in FFQ design and/or in true intakes. In Smith-Warner’s pooled study [283], 
the diet-cancer risk associations were similar for both approaches. 
 
PUFA Intake Variable Definitions 
The proposed study only included participants who completed an FFQ with 
plausible energy intake values (e.g., from 500-5000 kilocalories per day), and I began 
with exclusion criterion for those participants greater than ±3 standard deviations on the 
log-scale [105,106,222,228]. Data were available for: 88% BE cases/86% controls for 
the BE Study of Reflux Disease [105]; 93% BE cases/97% controls for the Epidemiology 
and Incidence of BE Study [106]; 96% EA cases/98% GCA cases/99% controls for the 
US Multicenter Study [228]; and 93% EA cases/93% GCA cases/96% controls for the 
LAC Multiethnic Study [222]. The final available sample size for my proposed study 
was: 466 BE cases with 491 controls, and 488 EA/512 GCA cases with 1,995 controls 
(distribution shown in Table 2.3). 
Multiple measures of PUFA intake were used to better capture the potential 
PUFA BE-EA continuum associations. The measures that were used are: fish intake, ω-
3, ω-6, ω-3 subtypes (α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA), docosapentaenoic acid (DPA)), ω-6 subtypes (linoleic 
acid (LA) and arachidonic acid (AA)), the ω-6:ω-3 ratio, and the interaction of ω-3 and 
ω-6, (which allows for more flexible modeling then the ratio). 
Fish intake was measured in ounces of intake per day, estimated from the FFQ 
responses. In each of the four FFQs, fish intake was also examined by cooking method: 
fried (e.g., fried fish, fish sandwich) and other non-frying cooking methods such as 
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broiled/baked. Cooking method was taken into consideration since a cooking method 
such as frying would introduce ω-6 PUFAs and may mask potential associations [234]. I 
would have also liked to differentiate between the intake of white fish and oily/dark fish, 
due to the higher ω-3 of oily/dark fish [24], however it was not possible due to the 
specific questions regarding fish intake in each of the four different FFQs.  
The PUFA nutrient measures were estimated in grams per day using the 
responses regarding frequency and portion size from the FFQs and the nutrient content 
of food items from the NCC database. The ω-3 and ω-6 subtype content were output in 
the databases, and the total ω-3, and total ω-6 content were calculated from the 
subtype values. The composite PUFA measures, ω-6:ω-3 ratio and the ω-3 and ω-6 
interaction, were unitless and were calculated from the PUFA nutrient measures. An 
example calculation of the nutrient PUFA measures and the ratio measure for a 
participant reporting eating 100 grams of wild Atlantic salmon is shown in Table 2.4. 
Trend analyses were also performed examining associations between the BE-EA 
continuum outcomes and increasing consumption of PUFAs using continuous variables. 
 
Covariate Assessment 
Covariate information was collected by questionnaire of each parent study as 
previously described [80,173,259,260], except for dietary covariate information, which 
was collected by each parent study’s validated FFQ [105,106,222,228]. Known and 
suspected risk factors assessed included: demographic information; body size; medical 
history including GERD symptoms; medication use including use of over-the-counter 
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drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs); smoking history; and 
alcohol use.  
 
Harmonization and Pooling of Other Exposure Variables 
Non-dietary BEACON data, including most demographic, lifestyle, known, and 
suspected risk factors, were previously harmonized and pooled by BEACON 
investigators [95,143,154,161,284]. 
 
Covariate Variable Definitions 
Covariates of interest in my proposed study that may potentially confound the 
PUFA BE-EA continuum association included: age (years), sex (male/female), race 
(white/other), education (highest level attained), income (annual household income in 
US$), marital status (currently married), body mass index (BMI; kg/m2), waist 
circumference (WC; cm), physical activity (PA; frequency and/or duration), smoking 
status (never/former/current), alcohol intake (drinks/week), total energy intake (kcal per 
day), fruit intake (servings per day), vegetable intake (servings per day), ω-3/ω-6 intake 
(grams per day), dietary supplement use (ever/never), NSAID use (ever/never), GERD 
symptoms (frequency), Helicobacter pylori infection (Hp; positive/negative), hiatal hernia 
(HH; yes/no), proxy status (non-proxy/proxy), BE (diagnosis and segment length), tumor 
stage (I-IV), tumor location (esophagus/gastric cardia), dysphagia (absent/present), 
lymphovascular involvement (yes/no) cancer treatment (chemotherapy, radiation, 
surgery, etc.), and study site. 
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BMI was calculated using either self-reported height and weight for a specified 
point in time prior to disease for the EA/GCA parent studies, due to the wasting nature 
of these diseases [173,260], or measurements taken by professional interviewers using 
standardized equipment on the interview date for the BE parent studies [80,259].  
Although there were a variety of methods to adjust for total energy intake, the 
method that I employed here is the standard method. The standard method included 
terms in the model for both the dietary exposure of interest and caloric intake [285]. The 
resulting effect estimate could be interpreted as the effect of an increase in the dietary 
factor when energy intake is held constant. Another method that may have been of 
interest was the nutrient density adjustment method. The energy density method 
included a variable for the dietary exposure as proportion of energy intake and a term 
for energy intake [285]. The effect estimate interpretation would be the effect of 
increasing the proportion of intake from the dietary exposure when energy intake is held 
constant. However, for this particular project the nutrient density method was not the 
best choice. PUFAs typically do not constitute a large portion of the caloric intake of 
diets [286], particularly in the US and when examining subtypes of PUFAs. The 
interpretation of the standard method allowed for easier interpretation, where the 
messaging was increasing/decreasing absolute amounts of intake of PUFAs. Compared 
to the interpretation of the nutrient density method, where the message would be to 
modify the distribution of macronutrients. Which would be particularly difficult for 
nutrients that do not comprise large portions of the American diet.  
GERD may be on the causal pathway of the BE-EA continuum due to the 
hypothesized relationship between GERD and BE. However, there is evidence in some 
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cases that the squamous epithelium is replaced by the intestinal-type columnar 
epithelium without existing damage from GERD [287]. And as previously stated, the 
majority of BE patients do not exhibit reflux symptoms [54]. Therefore I considered 
GERD as a potential confounder for the relationship between PUFAs and the BE-EA 
continuum outcomes.  
 
Statistical Analysis 
The first aim of the proposed dissertation was to determine if PUFA intake was 
associated with development of BE. The second aim of the study was to determine if 
PUFA intake was associated with incidence of EA/GCA. The third aim was to determine 
if PUFA intake was associated with mortality following a diagnosis of EA/GCA. Multiple 
measures of PUFA intake were used to assess these associations, including fish intake, 
ω-3, and ω-6.  
After the data were validated, I linked the dietary data with nutrient databases to 
estimate nutrient and total energy intake. To facilitate pooling of these data, covariate 
and dietary data were harmonized across the four studies. As part of my dissertation, I 
pooled the harmonized dietary intake data in order to estimate PUFA intake and energy 
intake.  
The overall distributions of the exposure, outcomes, and covariates were 





Aim 1: PUFAs and BE 
To examine the association between PUFAs and BE, unconditional logistic 
regression [288] was used to estimate ORs and 95% confidence intervals (CIs).  
 A secondary analysis was conducted using segment length of BE (SSBE and 
LSBE) as a nominal polytomous outcome. In order to test if there were differences 
between SSBE and LSBE, I used the ratio of the ORs (RORs) and the Wald test with a 
significance level of 0.10.  
 
Aim 2: PUFAs and EA/GCA Incidence 
To examine the association between PUFAs and EA/GCA, nominal polytomous 
logistic regression [288] was used to estimate ORs and 95% CIs, with EA and GCA as 
distinct outcomes. To determine if there were differences between the associations with 
EA and GCA, the Wald test was used with a significance level of 0.10. 
Since the outcomes for Aims 1 and 2 were dichotomous and the relationship 
between the outcomes and predictors were non-linear, logistic regression was an 
appropriate statistical method to use. The outcomes were statistically independent 
because there were no repeated events, and I could assume that the residuals were 
binomially distributed because this assumption is rarely violated.  
 
Aim 3: PUFAS and Survival after EA/GCA 
To examine the association between PUFAs and survival among EA/GCA cases, 
Cox proportional hazards models [289] were used to estimate HRs and 95% CIs, with 
EA and GCA as discrete outcomes. The proportional hazards (PH) assumption was 
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examined by using Kaplan-Meier curves and an interaction between exposure and 
follow-up time [289]; if the PH assumption was violated time-specific effects were used 
and the exposure and follow-up time interaction term was added to the model.   
For Aims 2 and 3, EA and GCA were treated as discrete outcomes in order to 
examine the possibility of heterogeneity of the ORs. If the effect estimates treating EA 
and GCA as discrete outcomes were consistent (the ratio of the ORs/HRs close to 1.0) 
the two outcomes were combined in order to increase power. 
 
Model Construction 
All analyses were performed using SAS software, version 9.3 (SAS Institute, 
Cary, NC), and Stata software, version 15.0 (StataCorp LP, College Station, TX). When 
modeling continuous or ordinal variables I first checked if they had a linear relationship 
with the logit form of the outcome, if this assumption for any of the variables was 
violated I modeled those particular variables using indicator terms [290].  
 All models included the study matching factors, including age, race, sex, and 
study indicator.  
Confounders for the proposed dissertation were chosen a priori by creating 
directed acyclic graphs (DAGS; Figures 2.1-2.3) for each of the three BE-EA/GCA 
continuum outcomes [291]. These DAGS were created from knowledge of the 
relationships between the exposure, outcome, and potential covariates. Minimally 
sufficient adjustment sets were created using the confounders identified in the DAGs.  
I explored EMM between total ω-3 and ω-6 intake, and by BMI and WC, as well 
as NSAID use, smoking status, and GERD symptom frequency. BMI was categorized 
76 
into overweight and obese BMI (≥25.0 kg/m2) and ideal BMI (<25.0 kg/m2) [292]. WC 
was assessed in the Study of Reflux Disease [259] and the Epidemiology and Incidence 
of BE Study [80], therefore I examined EMM by WC among the BE studies only. WC 
was categorized into two groups based on sex: the increased risk group and the ideal 
WC group [293]. The increased risk group (based upon metabolic complication and 
diabetes risk) was those with a WC >94 cm for males and >80 cm for females. The ideal 
group was those males with a WC ≤94 cm and females with a WC ≤80 cm. NSAID use 
was categorized into ever and never regular users, as defined in each of the four parent 
studies. Smoking status was categorized into never smokers and ever smokers. And 
GERD frequency was dichotomized into those who experience reflux less than weekly, 
and those who experience it once per week or more. EMM was assessed using 
multiplicative interaction comparing models with and without interaction terms using the 
likelihood ratio test with a significance level of 0.10 [290]. Additive interaction was 
assessed using interaction contrast ratios (ICRs; also known as relative excess risk due 
to interaction or RERI) [265]. ICRs that were significantly different from 0 using a 
significance level of 0.10, suggested the presence of additive interaction. Calculating 
the ICR allowed me to examine the joint effects of the interactions between the 
exposure and modifier, and thus was easier to interpret.  
The first sensitivity analyses performed were including additional confounders to 
the DAG-identified adjustment sets. The additional confounders under consideration 
were some of the primary risk factors for the BE-EA continuum outcomes: BMI, reflux 
frequency, and cigarette smoking status.  
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Sensitivity analyses were performed to examine if there were differences 
between the associations by proxy status. Because EA/GCA are diseases with poor 
prognoses and short survival time [2,4-6], 153 proxies were used in the US Multicenter 
Study [173] and 140 were used in the LAC Multiethnic study [260]. No proxies were 
used in either of the BE case-control parent studies. Although it has been seen that 
proxy and self-report are similar [294], I conducted a sensitivity analysis due to the 
possibility of misclassification of proxy responses. I performed two separate analyses 
for the second and third aim, one with non-proxies only and one with proxies only. If the 
ORs/HRs were consistent (the ratio of the ORs/HRs close to 1.0), the data collected by 
use of proxies were included in the final analyses. If the estimates were not consistent, I 
considered how to deal with the data obtained from proxy interviews and perhaps 
exclude these data. 
Another sensitivity analysis was adjusting the exclusion criterion based on daily 
caloric intake. As stated beforehand, the starting exclusions were for those participants 
greater than ±3 standard deviations on the log-scale. I examined if the associations 
between PUFAs and the BE-EA continuum outcomes were stable when relaxing the 
exclusions to those participants at the highest and lowest 2.5% of daily caloric intake.  
As mentioned previously, it was ideal to differentiate fish intake by type of fish 
consumed. And I would have liked to do this by distinguishing between consumption of 
white fish (e.g., tilapia or cod) and consumption of dark and oily fish (e.g., salmon or 
tuna). However, only one of the four FFQs from the parent studies allowed for 
examination of the associations by type of fish. The Study of Reflux Disease FFQ 
assessed “white fish (broiled or baked)” and “dark fish (broiled or baked)” individually. I 
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conducted a sensitivity analysis using on the Study of Reflux Disease data to examine 
the associations between white fish and dark/oily fish with the development of BE.  
Another consideration for a sensitivity analysis was the potential for 
heterogeneity by center, even though the four parents studies were chosen as members 
of BEACON due to their high quality and similarities in design. To determine if study 
heterogeneity was present, an interaction term between the study and the exposure 
variable was included in the model. Study-specific estimates were reported when 
necessary. This term was omitted from the model if it was found to be not statistically 
significant with a significance level of 0.10.  
Final sensitivity analyses were conducted using a meta-analytic approach to 
observe the robustness of the pooled results. Summary ORs/HRs were calculated using 
random-effects meta-analytic models. The random-effects model was the chosen 
method for this set of analyses because this model allowed for the true effect size to 
differ from study to study, whereas in the fixed-effects model it would be assumed that 
there is one true effect size underlying the included studies to be estimated [265]. The 
random-effects meta-analysis accomplished this by including a term for the unexplained 
sources of heterogeneity between studies [265]. First, study-specific ORs/HRs were 
estimated for the associations between PUFAs and the BE-EA continuum outcomes. 
Then summary ORs/HRs were generated using the random-effects meta-analytic 






Power calculations were based on the number of study participants with a 
completed FFQ and plausible energy intake values previously cited, and established 
using effect estimates observed in previous research. The total sample sizes for the 
study were: 466 BE cases with 491 controls; and 488 EA cases and 512 GCA cases 
with 1,995 controls. For Aims 2 and 3, power was calculated for the overall sample size 
and the non-proxy sample size. The non-proxy sample size was 707 EA/GCA cases 
with 1995 controls. For Aim 3, power was estimated based on 87% of cases who were 
no longer alive after maximum follow-up (7.5 years for the Multicenter Study, and 10.7 
years for the LAC Multiethnic Study) among the 488 EA patients and the 512 GCA 
patients. 
Multiple measures of PUFAs were used to address the study aims, and each of 
these measures were categorized using quantiles (quintile, quartile, tertile, and median 
value cut points) of the control distribution for BE and EA/GCA outcomes and of the 
case distribution for the mortality outcome. The effect estimates (ORs/HRs) used to 
calculate power for the effect of PUFAs ranged from 0.60-0.80 (for fish intake and ω-3) 
[107,226,230] and 1.25-1.67 (for ω-6 and the ω-6:ω-3) [218,227]. Power was estimated 







Aim 1: PUFAs and BE 
As is shown in Table 2.5, the study power for the association between PUFAs 
and BE is acceptable (>70%) when the minimal detectable OR was ≤0.70 (or 
conversely ≥1.43) and the exposure was categorized into tertiles or cut at the median. 
 
Aim 2: PUFAs and EA/GCA Incidence 
Power calculations for Aim 2, estimating the association between PUFAs and 
EA/GCA, are shown in Table 2.6 and Table 2.7. Table 2.6 displays the power 
estimates when EA and GCA were treated as discrete outcomes. The estimates 
presented were based on the number of EA cases; the exact estimates based on GCA 
cases were similar but slightly higher due to the slightly larger number of GCA cases. 
The study power when treating EA and GCA as discrete outcomes was good (> 80%) 
when the minimal detectable OR was ≤0.70 (or conversely ≥1.43) and the exposure 
was categorized into quartiles, tertiles, or cut at the median. If the ORs for the 
association between PUFAs and EA and GCA were consistent, the estimates of power 
for the association with EA/GCA as a combined outcome were great (>90%) when the 
minimal detectable OR was ≤0.70 (or conversely ≥1.43) as shown in Table 2.7. 
 The power estimates excluding participants who used proxies for EA/GCA as 
discrete outcomes and as one outcome are shown in Table 2.8 and Table 2.9, 
respectively. The power using non-proxies only was similar but slightly attenuated than 




Aim 3: PUFAs and Survival after EA/GCA 
Table 2.10 and Table 2.11 display the power estimates for the EA/GCA survival 
aim. The power when treating EA and GCA as discrete outcomes is shown in Table 
2.10. The estimates shown were based on the number of EA cases; again, the 
estimates based on GCA cases were similar and slightly higher. The power treating EA 
and GCA as discrete outcomes was acceptable (>70%) when the minimal detectable 
HR was ≤0.70 (or conversely ≥1.43), and the exposure was categorized into quartiles, 
tertiles, or cut at the median. If the HRs for these two cancers were consistent and then 
combined into one outcome, the power estimates, as shown in Table 2.11, were great 
(>90%) when the minimal detectable HR was ≤0.70 (or conversely ≥1.43). 
 The power estimates excluding participants who used proxies for EA/GCA as 
discrete outcomes and as one outcome are shown in Table 2.12 and Table 2.13 
respectively. Again, the power using non-proxies only was similar but slightly lower than 
for all participants. 
 
Limitations and Strengths 
Issues to consider when interpreting my dissertation results included the 
following limitations and strengths of the proposed study.  
One major limitation was that the study populations were primarily white and 
male, which limited generalizability. However, BE and EA/GCA primarily affect white 
males and the rates of these diseases are highest among this demographic group 
[1,2,123,124,149,256], which allowed for my results to be generalizable to this group of 
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high-risk individuals. Additionally, this study drew upon data from four studies that were 
population- or community-based, which enhanced external validity. 
Another major consideration was that FFQs were the dietary assessment method 
in each of the four parent studies. The FFQs used captured dietary intake one to five 
years prior to diagnosis/interview; and due to the nature of these diseases, patients may 
change their diet following the onset of clinical symptoms. However, as in most 
epidemiologic studies of dietary intake, I assumed that participants did not change their 
diet during the latent period of the diseases. There was also the possibility of recall error 
due to the time period the dietary assessment was directed towards, but previous 
research has reported a correlation of assessment of current dietary intake and then 
assessed again three to ten years later between 0.5 and 0.7 [295-298]. Because of this, 
I assumed that the dietary intake captured by the parent studies was a reliable estimate 
of the participants’ regular diet before disease. And each of the FFQs were validated 
using diet records [268,270,274,275] or multiple 24-hour recalls [276,277]. 
As with all pooled studies, there may have been differences in data collection, 
variable definitions, and data management between the parent studies. These 
discrepancies could introduce misclassifications of outcomes, exposures, or covariates. 
However, the four US population- and community-based BEACON studies were 
selected because of their high quality and similar data collection procedures. Also, 
several covariates (BMI, smoking, alcohol, nonsteroidal anti-inflammatory drugs 
(NSAIDs), and GERD) have already been harmonized and pooled for BEACON 
[95,143,154,161,284]; this successful pooling showed promise for my proposed 
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dissertation. Additionally, this concern may have been alleviated by the study-exposure 
interactions and meta-analytic approach I have proposed as a sensitivity analysis. 
In the EA/GCA cancer parent studies proxy interviews were conducted with next 
of kin (spouse, adult offspring, close friend, in that order) for subjects who were 
deceased or ill. Proxy interviews were conducted for 188 subjects (164 EA/GCA cases 
and 24 controls) in the US Multicenter Study [173], and 151 (all EA/GCA cases) in the 
LAC Multiethnic study [260]. There were no proxy interviews conducted in either of the 
two BE parent studies. Although it has been seen that proxy and self-report are similar 
[294], the use of proxies may increase the probability of exposure and covariate 
misclassification. However, validation studies have found that self-reported and proxy-
reported information have good concordance for smoking habits [299,300], 
anthropometric measures [299], and dietary factors [294,301]. Previous EA/GCA 
studies from BEACON, excluding proxy responses did not materially change the effect 
estimates [173,227,228,302,303]. 
The issue of multiple comparisons was considered. For all analyses, the multiple 
measures of PUFAs were used individually to determine associations between PUFAs 
and BE-EA continuum outcomes. Since I used six main measures of PUFAs and three 
BE-EA continuum outcomes, the total number of comparisons was 18. In addition, 
secondary aims examined the subtypes of ω-3 and ω-6 as exposures and segment 
length of BE as an outcome. There was a likelihood of observing statistically significant 
results due to chance because of the number of comparisons in the proposed study. I 
did not adjust for the multiple comparisons for each single association examined 
because it could have undeservedly reduced power. I assessed each of the 
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associations individually based on biologic plausibility, consistency with current 
research, and consistency across the cancer continuum [295,304,305].  
Other limitations regard data interpretation issues. Because diet is a complex 
exposure, I considered other elements that could be driving any associations that may 
have been seen in this study. When interpreting the results for the associations between 
PUFAs and the BE-EA continuum, I determined what specific food items were the most 
frequent contributors to the specific PUFA measures. Identifying the particular food 
items that were the most consumed sources of PUFAs allowed me to consider if there 
were other dietary components (e.g., saturated fat, glucose) in these food sources that 
may have been contributing to the associations observed.  
A major strength was my proposed pooling of existing case-control studies. First, 
this study was time- and cost-efficient. My pooled sample size was larger than all 
previous case-control studies [107,217,218,221-224,226], with increased power to 
detect associations with PUFA subtypes and provide more precise estimates. I had 
ample statistical power to evaluate associations between PUFAs and BE-EA/GCA 
continuum outcomes, including examination of subtypes of ω-3 and ω-6 fatty acids. 
Previous studies on PUFAS in relation to BE/EA/GCA focused on one outcome 
along the continuum [107,217,221-223,226], and none considered mortality. My 
dissertation was the first study to examine all three outcomes. By examining all three 
outcomes along the disease continuum, I was able to identify time points best to 
intervene before disease progression, which is of high priority given the high EA/GCA 
fatality [2,4-6]. My study was also the first to examine PUFAs in association with 
mortality following EA/GCA diagnosis. PUFAs have the potential to hasten or delay 
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mortality through effects on inflammatory pathways. Taking advantage of the richness of 
the BEACON parent studies, I was able to ascertain any association between PUFAs 
and risk along the entire spectrum of disease development in EA/GCA. This was 
especially important in this disease entity, because carcinogenesis may occur over 
many years, allowing for successful intervention if the appropriate time-points in disease 
development were identified.  
The multiple measures I proposed to use would allow me to better capture the 
complexity of this dietary exposure, and improve upon the inconsistency in existing 
research. Most examined fish intake (a major source of long-chain ω-3 fatty acids) as 
the only PUFA measure [217,221-223,225-227,233], without examining cooking 
methods, which can mask potential associations (such as with frying, which adds ω-6 
fatty acids). A few considered overall PUFAs [107,218,226], which overlook important 
distinctions between beneficial ω-3 and deleterious ω-6, or examined ω-3 PUFAs only 
[107,226]. No studies explored ω-6 PUFAs nor, importantly, have they considered the 
relative ω-3 and ω-6 balance (either the interaction or ratio of ω-6:ω-3). Relative 
balance is particularly important, because ω-3 and ω-6 are competitively inhibited by 
each other, are commonly found in the same foods, and may promote or suppress 
pathogenesis [8,49,212,216]. Studies of other cancer sites have used this approach 
successfully [235-237], substantiating the importance of relative PUFA balance as a risk 
modifier. 
Additionally, all four parent studies were conducted in US coastal regions with 
increased opportunity for fish intake (LAC, WA, CT, and NJ); this maximized 
heterogeneity in intake and enhanced my ability to detect differences, which was an 
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The incidence of EA/GCA is among the most rapidly increasing of any cancer 
type in the US and other western countries [4,17-20], and this increase is suspected to 
continue [2,53]. The incidence of Barrett’s esophagus (BE), the only known potential 
precursor lesion of these cancers, is also increasing [4,58]. One candidate for a 
modifiable risk factor for these diseases is PUFAs, which are a group of essential fats. 
ω-3 PUFAs have been reported to suppress mutations, reduce inflammation, inhibit cell 
growth, and enhance apoptosis, resulting in decreasing cancer risk [8,44-46]. While ω-6 
PUFAs have been shown to promote cancer cell proliferation, and to be associated with 
increased cancer risk [8,46,49,50]. I proposed to pool harmonized data from two BE 
case-control studies and two EA/GCA case-control studies to estimate the association 
between PUFA intake and BE-EA.GCA continuum outcomes using adjusted regression 
models. Multiple PUFA intake measures were considered, and were based on 
interviewer-administered, validated FFQ responses. This dissertation was the first to 
consider the relative balance of ω-3 and ω-6 PUFA intake in relation to BE/EA/GCA, 
which was important because ω-3 and ω-6 fatty acids are competitively inhibited by 
each other, are often found in the same food products, and may promote or suppress 
pathogenesis [8,49,212,216]. My proposed pooling approach was time-efficient and 
cost-efficient; the sample size and study power was increased, permitting detection of 
relatively modest associations. My dissertation was the first study to examine all three 
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outcomes along the BE-EA-GCA continuum and to use multiple measures of PUFAs, 
which may have made associations more clear. The proposed study had high public 
health impact because it may identify a modifiable risk factor for a highly fatal cancer 
[2,4-6], and because it examined the disease continuum the results could identify an 
appropriate time point to implement this strategy before disease progression. 
88 
Table 2.1. Characteristics of the case-control studies included in proposed study 
 
Study Study of Reflux 
Disease 
Epidemiology and 







Period 1997-2000 2002-2005 1993-1995 1992-1997 
















79 years newly 




with first primary 
EA/GCA identified 
















matched on age  















Waksberg RDD for 
those 30-64 years, 
and by HCFA 




on age (5-year 
groups) and sex. 
Neighborhood 
controls 









sex, race, and 
age (5-year 
groups). 
FFQ FHCRC Block 1998 Modified FHCRC University of 
Hawaii 
# of FFQ 
items 




1 year before 
interview 
1 year before 
diagnosis/midpoint 
of selection interval 
3-5 years before 
diagnosis/interview 




*15-county area of NJ and 3-county area of WA; WA-Washington; CA-California; CT-
Connecticut; NJ-New Jersey; LA-Los Angeles; KPNC-Kaiser Permanente Northern 
California; RDD-Random digit dialing; HCFA-Health Care Financing Administration; 
FHCRC-Fred Hutchinson Cancer Research Center 
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Table 2.2. Example of linoleic acid (LA) calculation using frequency, portion size, 
weights, and nutrients for the line item “Bacon, including Canadian bacon”  
 
Food Item Bacon Canadian Bacon 
Frequency  1 serving/day 
Portion size 2 slices/strips 
LA content per 100 g 5.327 g 0.690 g 
Serving size 8.1 g 13.8 g 
Line item weight 0.80 0.20 
LA intake per line item =[(8.1*5.327/100*0.80) + (13.8*0.690/100*0.20)]*1*2 





Table 2.3. Sample sizes of the four parent studies 
 
 Cases  
Study BE EA GCA Controls 
Study of Reflux Disease 170 – – 182 
Epidemiology and Incidence of BE Study 296 – – 309 
US Multicenter Study – 282 255 687 





Table 2.4. Example PUFA nutrient calculation 
 
 Wild Atlantic salmon (100 g) 
ω-3* = 0.378+0.411+1.429+0.368 =2.586 
   ALA* 0.378 
   EPA* 0.411 
   DHA* 1.429 
   DPA* 0.368 
ω-6* = 0.220 + 0.342 = 0.562 
   LA* 0.220 
   AA* 0.342 
ω-6: ω-3 = 0.562:2.586 = 0.217:1 
*Measured in grams   
 
 


























Power for 4 proportions of exposed 
controls 
 OR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 27% 30% 36% 41% 
0.70 55% 62% 71% 78% 
0.60 83% 89% 94% 98% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 30% 34% 38% 41% 
1.43 64% 70% 76% 79% 
1.67 93% 95% 97% 98% 




Table 2.6. Power estimates for the association between PUFAs and risk of developing 




Power for 4 proportions of exposed 
controls 
 OR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 38% 44% 52% 60% 
0.70 75% 82% 89% 94% 
0.60 96% 98% >99% >99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 46% 51% 57% 60% 
1.43 85% 90% 93% 94% 
1.67 >99% >99% >99% >99% 









Power for 4 proportions of exposed 
controls 
 OR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 60% 67% 75% 82% 
0.70 93% 97% 99% >99% 
0.60 >99% >99% >99% >99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 67% 73% 79% 82% 
1.43 97% 99% >99% >99% 
1.67 >99% >99% >99% >99% 
n=1000 EA/GCA cases; n=1995 controls 
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Table 2.8. Power estimates for the association between PUFAs and risk of developing 




Power for 4 proportions of exposed 
controls 
 OR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 29% 34% 40% 47% 
0.70 61% 69% 78% 86% 
0.60 89% 94% 97% 99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 37% 41% 45% 47% 
1.43 74% 80% 84% 86% 
1.67 96% 98% 99% 99% 
n=340 EA cases; n=367 GCA cases; n=1995 controls 
 
 
Table 2.9. Power estimates for the association between PUFAs and risk of developing 




Power for 4 proportions of exposed 
controls 
 OR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 49% 56% 65% 72% 
0.70 86% 92% 96% 98% 
0.60 99% >99% >99% >99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 57% 63% 69% 72% 
1.43 93% 96% 98% 98% 
1.67 >99% >99% >99% >99% 
n=707 EA/GCA cases; n=1995 controls 
 
 
Table 2.10. Power estimates for the association between PUFAs and mortality following 




Power for 4 proportions of exposed 
EA/GCA cases 
 HR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 30% 36% 46% 63% 
0.70 62% 72% 83% 95% 
0.60 89% 95% 98% >99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 32% 39% 49% 66% 
1.43 67% 76% 87% 97% 
1.67 93% 97% >99% >99% 
n=488 EA cases; n=512 GCA cases; assuming 13% of cases survived after a maximum 
follow-up of 7.5 years and 10.7 years 
 95 





Power for 4 proportions of exposed 
EA/GCA cases 
 HR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 54% 64% 76% 90% 
0.70 90% 95% 99% >99% 
0.60 >99% >99% >99% >99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 57% 67% 79% 92% 
1.43 93% 97% >99% >99% 
1.67 >99% >99% >99% >99% 
n=1000 EA/GCA cases; assuming 13% of cases survived after a maximum follow-up of 
7.5 years and 10.7 years 
 
 
Table 2.12. Power estimates for the association between PUFAs and mortality following 




Power for 4 proportions of exposed 
EA/GCA cases 
 HR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 23% 27% 34% 48% 
0.70 47% 56% 68% 85% 
0.60 76% 84% 93% 99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 24% 29% 36% 50% 
1.43 52% 61% 73% 89% 
1.67 81% 89% 96% 99% 
n=340 EA cases; n=367 GCA cases; assuming 13% of cases survived after a maximum 





Table 2.13. Power estimates for the association between PUFAs and mortality following 




Power for 4 proportions of exposed 
EA/GCA cases 
 HR 0.20 0.25 0.33 0.50 
Fish intake, or ω-3 0.80 41% 49% 61% 78% 
0.70 78% 86% 94% 99% 
0.60 97% 99% >99% >99% 
ω-6, or ω-6/ω-3 relative 
balance 
1.25 43% 52% 64% 81% 
1.43 82% 90% 96% >99% 
1.67 98% >99% >99% >99% 
n=707 EA/GCA cases; assuming 13% of cases survived after a maximum follow-up of 









CHAPTER III: ASSOCIATION OF FISH AND OTHER MEASURES OF 
POLYUNSATURATED FATTY ACIDS WITH BARRETT’S ESOPHAGUS 
 
Introduction 
Barrett’s esophagus (BE) is the transformation of esophageal mucosa from 
normal squamous epithelium into metaplastic columnar epithelium [51]. BE is the only 
known precursor lesion to esophageal adenocarcinoma (EA), a fatal cancer with 
increasing incidence in the United States (US) [4,53]. The prevalence of BE may affect 
approximately 2% of adults in westernized countries [13,307], and is increasing 
worldwide [59]. But prevalence estimates are uncertain, because many individuals are 
asymptomatic, and most are never diagnosed [54]. Severity of BE is often classified by 
segment length; short-segment BE (SSBE) is typically defined as <3 cm, whereas long-
segment BE (LSBE) is defined as ≥3 cm on endoscopy [272]. The latter is more strongly 
associated with the risk of EA, most likely due to greater diseased surface area [272]. 
Most risk factors for BE are non-modifiable, such as male sex [117] and white 
race [117], or not easily modifiable, including reflux [143] and obesity [78] where relapse 
[238] and recidivism [239,242] rates are high. Dietary factors appear to be amenable to 
intervention [245,246,248] and have therefore been of interest as risk reduction factors 
for BE [165]. Polyunsaturated fatty acids (PUFAs) may be one such risk reduction 
factor. In experimental studies, the impact of PUFAs on carcinogenesis varies by PUFA 
type; ω-3 PUFAs (of which fish, in particular oily fish, are a primary source [22]) and ω-6 
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PUFAs (often found in vegetable oils [22]) display anti- and pro-carcinogenic effects [8], 
respectively. Additionally, intake of PUFAs in Westernized diets has changed over time 
[25] where ω-6 intake has increased over the last century, similar to the increase in BE 
the last few decades [58,59]. Further, geographic variation of PUFA intake corresponds 
to the variation of BE/EA prevalence/incidence worldwide [15,26,28,34-36]. However, 
associations of ω-3 PUFAs and ω-6 PUFAs with BE risk have infrequently been 
examined in epidemiologic studies [107,217-219]. BE risk reduction may be possible by 
increasing intake of ω-3 PUFAs [8], while perhaps simultaneously reducing intake of ω-
6 PUFAs.  
To examine associations epidemiologically between PUFA intake and 
development of BE, we harmonized and pooled food frequency questionnaires (FFQs) 
from two US community-based case-control studies [80,259]. We hypothesized that 
higher intake of ω-3 fatty acids and non-fried fish (the primary dietary source of long-
chain ω-3) would be associated with reduced risk of BE, while a higher ω-6 to ω-3 ratio 
of intake (ω-6:ω-3) would be associated with increased risk. We also hypothesized 
these associations would be stronger for LSBE as compared to SSBE. We examined 
whether there is a potential interaction between ω-3 and ω-6, because ω-3 and ω-6 are 
competitively inhibited by each other and may suppress or promote pathogenesis [8]. 
Further, because inflammation is the most biologically plausible mechanism linking 
PUFAs to BE development [23,212], we hypothesized that inflammation-related 
exposures (such as body mass index (BMI), waist circumference (WC), use of non-
steroidal inflammation drugs (NSAIDs), cigarette smoking and reflux symptoms) could 
modify PUFA-BE associations.  
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Methods 
We used resources from two studies of the International Barrett’s and 
Esophageal Adenocarcinoma Consortium (BEACON): the Study of Reflux Disease and 
the Epidemiology and Incidence of BE Study. Institutional Review Board approval was 
obtained from all participating institutions. Details of these case-control studies have 
been published previously [80,259] and are summarized below.  
 
Study Population 
The Study of Reflux Disease was conducted in western Washington from 1997-
2000 [259]. Cases were newly diagnosed with BE, 20-80 years old, and underwent 
endoscopy for gastroesophageal reflux disease (GERD) symptoms. Controls were 
community-based, residents of western Washington, selected by a modified Waksberg 
telephone random digit dialing [261], and were matched to cases on age (+/- 3 years) 
and sex. Study participants included 193 cases and 211 controls. 
The Epidemiology and Incidence of BE study was conducted within the Kaiser 
Permanente Northern California health care system from 2002-2005 [80]. All 
participants had to be continuously enrolled in the Kaiser Permanente health plan for 
two years prior to study inclusion. Cases were newly diagnosed with BE (using medical 
records, endoscopic findings, and biopsy results) and aged 18-79. Controls were 
community-based Kaiser Permanente members and frequency matched to cases on 
age (5-year age groups), sex, and geographic region. Study participants included 320 
cases and 317 controls. 
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We excluded respondents without dietary intake assessment and those with 
reported energy intake greater than ±3 standard deviations on the log scale from the 




Informed consent was obtained before interview. Trained interviewers conducted 
in-person interviews that assessed demographics, medical history, tobacco use, and 
alcohol consumption, and recorded anthropometric measures. Diet in the year prior to 
diagnosis (cases)/interview (controls) was assessed using validated FFQs. The Study of 
Reflux Disease used the 131-item Fred Hutchinson Cancer Research Center FFQ [267] 
and the Epidemiology and Incidence of BE Study used the 110-item Block 1998 FFQ 
[268,269]. These FFQs were similar in design, and both assessed frequency of intake 
and portion size.  
 
Harmonization and Pooling 
Covariates derived from the study-specific interviews and anthropometry were 
harmonized previously for BEACON at the National Cancer Institute, as described 
elsewhere [85,308,309]. 
To harmonize dietary intake responses of the two BEACON studies examined 
here, FFQs were linked with the University of Minnesota Nutrition Coordinating Center 
database [278] to estimate grams per day of PUFA exposures. Thirteen exposure 
measures were assessed. Of these, nine were PUFA nutrient estimates including: ω-3; 
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ω-3 subtypes (α-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic 
acid (DHA), and docosapentaenoic acid (DPA)); ω-6; ω-6 subtypes (linoleic acid (LA), 
and arachidonic acid (AA)); and the ω-6:ω-3. The remaining four measures were 
assessments of PUFA-rich foods: tuna (tuna canned or fresh, tuna salad, tuna 
casserole), fried fish, baked/broiled fish (non-fried fish other than tuna and shellfish), 
and shellfish.  
As an example of the approach we used to estimate the PUFA nutrient 
measures, EPA intake from a single line item was first calculated (EPA intake for line 
item = frequency of intake x portion size of intake x EPA grams per 100 grams of line 
item). Intake of EPA per day for a participant was then calculated by summing up EPA 
intake for all line items. In some instances, the line items represented multiple foods 
items, in which case the individual foods were weighted according to the estimates of 
US consumption [310]. 
After the FFQ responses for PUFA intake were harmonized, we generated study-
specific quantiles of intake using control distributions within each study [282]. We then 
pooled the PUFA exposure variables by merging across quantiles for the two BE 
studies. For the PUFA nutrient exposure variables we created quartiles of exposure, 
and for the PUFA-rich food intake measures we used an ordinal categorization of non-
consumers and tertiles of exposure among consumers.  
 
Statistical Methods 
Multivariable-adjusted logistic regression [265] was used to estimate odds ratios 
(ORs) and 95% confidence intervals (CIs) for the associations between the PUFA 
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measures and the development of BE. Polytomous logistic regression [265] was used to 
estimate effect measures with BE classified by segment length: SSBE (<3 cm) and 
LSBE (≥3 cm). The Wald test was used to detect differences in associations by 
segment length [265]. Linear trends were examined by modeling PUFA as continuous 
variables. 
Confounders were identified by selecting potential confounders from the literature 
and creating a directed acyclic graph (DAG) [265]. Covariates considered in the DAG 
included age, sex, race, education, obesity, cigarette smoking, alcohol use, total energy 
intake, fruit and vegetable intake, GERD symptoms, and NSAID use. Covariates 
included in the final models were the matching factors of the two parent studies (age (±3 
years for western Washington, and 5-year age groups for northern California) and sex 
(male, female)), study indicator (northern California, western Washington), plus the 
DAG-identified confounders (education (≤high school, technical school or some 
university, ≥university), and total energy intake (kcal, continuous)).  
We examined potential effect measure modification (EMM) between total ω-3 
and ω-6 intake, as well as exploring EMM by the inflammation-related factors of BMI 
(≥25kg/m2, <25kg/m2 [292]), WC (≤94cm, >94cm for men, and ≤80cm, >80cm for 
women [293]), NSAID use (ever regular use, never regular use), cigarette smoking 
(ever, never), and GERD symptom frequency (≥weekly, <weekly reflux). WC 
assessments were available only for the northern California Epidemiology and 
Incidence of BE Study, and thus our WC models were restricted to the northern 
California participants. EMM was assessed on a multiplicative scale by comparing 
models with and without interaction terms using the likelihood ratio test with a 
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significance level of 0.10 [265]. EMM was also assessed on the additive scale by using 
single referent models to obtain interaction contrast ratios (ICRs) and 95% CIs [265].  
For sensitivity analyses, we first considered potential confounding by other 
factors not identified as confounders using the DAG-identified approach. We added to 
the DAG-identified models established BE risk factors [66,78,80,81,85] of BMI 
(<25kg/m2, 25-29.9kg/m2, ≥30 kg/m2 [292]), cigarette smoking (former, current, never), 
and reflux symptom frequency (<once/week, once/week, once/week-<daily, ≥daily, 
never). Second, we conducted a sensitivity analysis that used the absolute value-based 
pooling approach deriving quantiles using all combined controls [282]. Third, we 
widened the acceptable caloric intake by only excluding participants in the highest and 
lowest 2.5% of daily caloric intake. The fourth sensitivity analysis was to use a random 
effects meta-analytic approach [265] to pool the study-specific effect estimates. In the 
final sensitivity analysis, we considered BE associations with white fish and dark fish, 
which was only available in the western Washington Study of Reflux Disease. For this 
particular sensitivity analysis, we categorized intake into consumers and non-
consumers due to small variability in intake.  
Analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, 
NC), and Stata software, version 15.0 (StataCorp LP, College Station, TX). 
 
Results 
The distribution of participant characteristics is shown by study and case-control 
status in Table 3.1. Those in the northern California Epidemiology and Incidence of BE 
Study were older, more likely to be male, non-white, experience reflux more frequently, 
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had a higher daily caloric intake and higher proportion of LSBE compared to the 
western Washington Study of Reflux Disease participants.  
When examining daily mean intake of PUFAs and fish by study (Table 3.2), there 
was a higher intake of ω-3, ω-6, and fried fish and a lower shellfish intake among the 
participants of the western Washington Study of Reflux Disease. The intake for cases 
and controls were similar for a majority of the PUFA measures within each of the two 
BE studies, with one exception; in the northern California Epidemiology and Incidence 
of BE study, controls reported eating more baked/broiled fish than cases.  
Table 3.3 presents the number of FFQ items and highest contributing (a 
combination of the most frequently eaten and PUFA-dense) foods for each PUFA 
measure by study. In both studies, the same food items were the highest contributors to 
both the ω-3 and ω-6 measures. For example, in the western Washington Study of 
Reflux disease, the two highest contributing line items for ω-3 and ω-6 were “beef, pork, 
lamb” and “chicken, turkey”.  
When we considered intake of specific PUFA-rich foods (Table 3.4), the risk of 
developing BE was reduced by 34% for those eating the highest amount of 
baked/broiled fish (ORT3vs.None=0.66, 95%CI=0.45-0.98, ptrend=0.06). Other measures of 
fish intake were not associated with BE. 
When we considered the PUFA nutrient measures, including the ω-6:ω-3 ratio 
(Table 3.5), there were no significant associations with BE. There was no evidence of 
EMM by any of the inflammation-related factors considered (BMI, WC, NSAID use, 
smoking, GERD symptom frequency) on the multiplicative or additive scales (Table 
3.6).  
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As shown in Table 3.7, associations between PUFA measures and BE differed 
by segment length. Increased intake of ω-3 was associated with a decreased risk of 
LSBE (OR>Medianvs.≤Median=0.62, 95%CI=0.40-0.96), and this differed significantly from 
SSBE (OR>Medianvs.≤Median=0.98, 95%CI=0.67-1.43; pheterogeneity=0.07). Also, higher intake 
of baked/broiled fish showed a suggestive inverse association with LSBE 
(ORConsumersvs.Non-consumers=0.68, 95%CI=0.51-1.02). However, in contrast to our 
hypotheses, higher intake of the ω-6 subtype AA was also associated with a decreased 
risk of LSBE (OR>Medianvs.≤Median=0.67, 95%CI=0.45-0.99), and was different from SSBE 
(OR>Medianvs.≤Median=1.08, 95%CI=0.77-1.54; pheterogeneity=0.03). No associations were 
observed with any other fish or PUFA measures, and none were found between PUFAs 
and SSBE. 
Results from the five sets of sensitivity analyses we conducted did not differ 
substantially from the results already shown, with a few exceptions. For the sensitivity 
analysis where we added BMI, cigarette smoking status, and reflux frequency to the 
DAG-driven adjustment models, the majority of effect estimates were not substantially 
altered, as shown in Table 3.8. Although the OR for tuna intake moved away from the 
null, interpretation of the effect estimate remained unchanged. Next, for the sensitivity 
analysis where we considered the absolute value-based pooling approach (deriving 
quantiles using all combined controls), most results (Table 3.9) were not substantially 
different from the results from the study-specific pooling approach shown in Tables 3.4 
and 3.5. However, for ω-3 there was a suggestive association with reduced risk of BE 
(ORQ4vs.Q1=0.61, 95%CI=0.36–1.03), which is slightly different from the null result we 
obtained when we used the study-specific pooled approach. The results from when we 
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excluded subjects who reported energy intake in the extreme 2.5% of intake (data not 
shown) and the results using the random effects meta-analytic approach (data not 
shown) did not differ substantially from the results shown in Tables 3.4 and 3.5. In the 
final sensitivity analysis examining white fish and dark fish, we found no associations 
with BE (data not shown).  
 
Discussion 
Consistent with our hypotheses, higher intake of baked/broiled fish, one of the 
most ω-3-dense food items, was associated with a significant 34% decrease in the risk 
of developing BE, and the association may be limited to patients diagnosed with LSBE. 
In contrast to our hypotheses, the ω-6 subtype AA was also inversely associated with 
LSBE. Intake of tuna (which included tuna salad/tuna casserole), fried fish, and other 
fish and PUFA nutrient measures were not associated with BE. 
An inverse association between ω-3-rich baked/broiled fish and BE is biologically 
plausible. Both families of PUFAs use the same metabolic pathways and are 
competitively inhibited by one another, by vying for binding sites on the same enzymes 
[23]. Because of this, higher intake of foods high in ω-3 fatty acids leads to decreased 
production of ω-6-derived byproducts. Experimental studies demonstrate that ω-6-
derived byproducts are highly metabolically active, have cancer-promoting properties, 
and are pro-inflammatory [212]. Further, increased presence of ω-3 subtypes can lower 
the expression of COX-2 [212], which has been implicated in a variety of human 
cancers [23,216]. However, there is currently no consensus for a positive association 
between ω-6 and chronic disease in humans [311]. Our unexpected finding of an 
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inverse association between ω-6 subtype AA with LSBE is inconsistent with our 
hypotheses, and may be due to chance. 
Previous studies examining intake of PUFA nutrients or foods with high levels of 
ω-3 (such as fish) in association with BE are scarce and inconsistent. Two studies, a 
case-control study conducted in Ireland [218] and a case-cohort study in the 
Netherlands [217], reported no association between fish intake and BE. The 
inconsistencies between our results and these studies may be due to the fact that we 
were able to distinguish between fried fish (which often add ω-6 in the form of oils [22]) 
and non-fried fish, while the previous studies did not. The Irish study also examined a 
measure of total PUFA intake (which combined ω-3 and ω-6 intake) with null results 
[218]. However, in a separate previous analysis, the Northern California Epidemiology 
and Incidence of BE (the data from which were included in the present pooled study) 
observed a suggestive inverse association between total PUFAs and BE [107]. A 
previous meta-analysis by Zhao et al. [219] combined results from the Northern 
California and Irish studies and observed no association between total PUFAs and BE. 
These results are similar to our results for ω-3 and ω-6, where null relationships were 
seen with BE overall. However one previous report, based on the Northern California 
Epidemiology and Incidence of BE Study, found that ω-3 was associated with a halving 
of BE risk [107]. This finding from the northern California study is similar to our pooled 
results for LSBE reported here, and results were consistent in sensitivity analyses when 
we restricted our models to the western Washington Study of Reflux Disease. 
Interestingly, more than half of the Northern California Epidemiology and Incidence of 
BE Study cases were diagnosed with LSBE, as opposed to only one quarter in the 
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western Washington Study of Reflux Disease. Differentiation between associations with 
LSBE and SSBE is important, because LSBE is both more strongly associated with 
reflux than SSBE, and is a stronger risk factor for the development of EA than SSBE. 
There are several limitations of our study. For example, we harmonized and 
pooled data in order to increase sample size, but there may be differences in data 
collection and management between the studies, which may have resulted in exposure 
misclassification. To mitigate this potential impact, we selected two US community-
based studies in BEACON with similar data collection procedures. Future studies 
should consider a design that insures a priori uniform field procedures for all study 
participants. Another concern centers on exposure assessment. Patients were asked to 
recall diet in the year prior to study interview, with the assumption that intake during this 
time period can be recalled with some accuracy and that it correlates with usual adult 
diet [296]. Nonetheless, it is possible that recent onset of clinical symptoms and any 
corresponding changes in diet would influence the accuracy of reporting usual adult diet 
among cases only. Future studies could consider a prospective cohort design in order to 
rule out recall bias as a possible reason for our study findings. Yet, such an approach 
would be costly to implement. Finally, our pooled population is primarily white and male, 
which limits generalizability. Although the rates of BE are the highest among this 
demographic group [117], future studies should consider expanding the racial and 
gender diversity of the target population.  
There are several strengths to the study presented here. A major strength is 
harmonizing and pooling of two existing studies, which is a very time- and cost-efficient 
design compared to undertaking a new field study effort. This approach is also superior 
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to conducting a meta-analysis, because creating uniform definitions for our exposure of 
interest and for the other covariates improves accuracy of the resulting estimates. Our 
pooled sample size is also larger than previous case-control studies [107,218], with 
more cases than the only case-cohort study [217], allowing us to provide more precise 
effect estimates and facilitates our examination of effect measure modification. Another 
strength of our study was the comprehensive use of multiple exposure measures, which 
allowed us to consider the complexity of this dietary exposure and helped to clarify 
previous findings. For example, prior to our study, no BE studies had considered 
cooking methods of ω-3-rich foods (such as fish), which can aid in unmasking potential 
associations (by separating, for example, broiled/baked from fried) [217,218]. A few 
previous studies considered overall PUFA intake [107,218,219], which overlooks 
important distinctions between ω-3 and ω-6, or examined ω-3 PUFAs only [107]. Ours 
is also the first BE study to explore ω-6 PUFAs, or to consider the relative ω-3 and ω-6 
balance (either the interaction or ratio). Another benefit is that we were able to identify a 
measure – baked/broiled fish – that was most strongly associated with BE risk, at least 
among a western US population. For example, contributors to ω-3 intake among 
respondents were not limited to foods known to be high in beneficial fatty acids such as 
fish, but were commonly the same foods also contributing to ω-6 (e.g.,” chicken, turkey;” 
and “beef, pork, lamb”, as shown in Table 3.3). This likely led to our inability to detect 
associations with either ω-3 or ω-6. Similarly, the parent study FFQs included a 
composite assessment of tuna, a fish with high levels of ω-3 [24], combining tuna with 
tuna casserole and tuna salad; the latter two are typically prepared with other foods high 
in ω-6 using contrasting cooking methods. Instead our strongest effect estimate was for 
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baked/broiled fish, where food items and the cooking method were clearly delineated. 
Future studies conducted among US populations should include assessments of PUFA-
rich foods such as fish, making sure to consider fish type as well as cooking or other 
preparation methods. Finally, both parent studies were conducted in western US coastal 
regions with increased opportunity for fish intake (western Washington, and northern 
California); this maximized heterogeneity in intake and enhanced our ability to detect 
differences, since US residents overall typically consume a low amount of fish [306].  
In summary, our pooled study of two US-based case-control studies of BE found 
that high intake of baked/broiled fish was associated with a 34% reduction of BE. 
Additionally, higher intake of baked/broiled fish, ω-3, and the ω-6 subtype AA, were 
associated with a 32-38% reduction of risk of LSBE. If our findings are confirmed, 
increasing non-fried fish intake could be a risk reduction strategy for BE, the precursor 
to an extremely fatal cancer.
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Table 3.1. Demographic characteristics of participants of two US-based case-control 
studies of BE 
 
Characteristic 
Study of Reflux Disease 
Epidemiology and 









Age (yrs) 54.8 (12.8) 53.4 (12.1) 62.4 (10.6) 62.4 (10.3) 
Sex 
    
     Male 105 (59.7) 119 (62.3) 216 (73.2) 203 (67.4) 
     Female 71 (40.3) 72 (37.7) 79 (26.8) 98 (32.6) 
Race 
    
     White 157 (89.2) 175 (91.6) 255 (86.4) 256 (85.1) 
     Other 19 (10.8) 16 (8.4) 45 (13.6) 40 (14.9) 
Education 
    
     ≤High school 46 (26.1) 34 (17.8) 78 (26.4) 58 (19.3) 
     Technical school or  
          some university 
9 (5.1) 6 (3.1) 135 (45.8) 114 (37.9) 
     ≥University 121 (68.8) 151 (79.1) 82 (27.8) 129 (42.9) 
BMI (kg/m2) 29.3 (5.2) 27.6 (5.1) 29.4 (5.5) 29.5 (5.7) 
Cigarette smoking 
status 
    
     Never 62 (35.2) 99 (51.8) 97 (33.0) 131 (43.5) 
     Former  89 (50.6) 63 (33.0) 157 (53.4) 132 (43.9) 
     Current 25 (14.2) 29 (15.2) 40 (13.6) 38 (12.6) 
NSAID use     
     Never 65 (37.1) 100 (52.4) 161 (54.6) 158 (52.8) 
     Ever 110 (62.9) 91 (47.6) 134 (45.4) 141 (47.2) 
Reflux frequency     
     <Weekly 102 (58.3) 167 (88.8) 115 (39.3) 245 (81.7) 
     ≥Weekly 73 (41.7) 21 (11.2) 178 (60.8) 55 (18.3) 
Total energy intake  









BE segment length     
     SSBE 132 (75.0) -- 109 (44.0) -- 
     LSBE 44 (25.0) -- 139 (56.1) -- 
Missing values (N): BMI (7), smoking status (1), NSAID use (3), reflux frequency (7), BE 
segment length (47) 
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Table 3.2. Daily mean intake of PUFAs and fish among participants of two US-based 
case-control studies of BE 
 
Measure 
Study of Reflux Disease 










Tuna (g/day) 7.59 (9.48) 6.91 (10.04) 7.76 (14.21) 8.43 (13.82) 





8.85 (9.24) 6.06 (12.03) 10.27 (23.74) 
Shellfish (g/day) 2.79 (4.49) 2.96 (4.30) 4.74 (8.07) 4.87 (7.91) 
ω-3 (g/day) 3.38 (2.48) 3.09 (2.28) 1.67 (0.94) 1.81 (0.92) 
     ALA (g/day) 2.81 (1.95) 2.60 (1.94) 1.57 (0.88) 1.68 (0.83) 
     EPA (g/day) 0.11 (0.15) 0.09 (0.09) 0.02 (0.03) 0.03 (0.04) 
     DHA (g/day) 0.28 (0.40) 0.25 (0.27) 0.07 (0.07) 0.09 (0.13) 






15.03 (10.61) 16.17 (9.88) 





14.93 (10.57) 16.06 (9.84) 
     AA (g/day) 0.97 (1.11) 0.86 (0.94) 0.10 (0.07) 0.11 (0.08) 
ω-6:ω-3 8.78 (1.79) 8.84 (1.97) 8.94 (3.18) 9.07 (3.46) 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
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Table 3.3. Number of FFQ items and foods with highest contribution for PUFA nutrient 
and fish intake measures among control participants (N=492) of two US-based case-
control studies of BE 
 
Measure 
Study of Reflux Disease  
(N=131 line items) 
Epidemiology and Incidence of 
BE 










contributing FFQ items 
Tuna 1 
Canned tuna, tuna salad, 
tuna casserole 
1 
Tuna, tuna salad, tuna 
casserole 
Fried fish 1 
Fried fish/shellfish, fish 
sandwich,  
1 Fried fish, fish sandwich 
Baked/broiled 
fish 
2 White fish; dark oily fish 1 Other fish, not fried 
Shellfish 1 Shellfish  2 Oysters; other shellfish 
ω-3 116 




spreads; salad dressing; 
French fries, fried 




spreads; cooking fat 
(e.g. Pam, olive oil, lard); 
salty snacks; other fish, 
not fried 
     ALA 116 




spreads; salad dressing; 
French fries, fried 




spreads; cooking fat 
(e.g. Pam, olive oil, lard); 
snacks like chips, 
popcorn; spinach 
     EPA 36 
Chicken, turkey; dark oily 
fish; beef, pork, lamb; 
white fish; shellfish 
32 
Other fish, not fried; 
shellfish (not oysters); 
oysters; chicken, turkey; 
Chinese or other Asian 
food 
     DHA 38 
Chicken, turkey; dark oily 
fish; eggs; white fish; 
fried fish/shellfish, fish 
sandwich 
33 
Other fish, not fried; 
eggs, including egg 
biscuits; tuna, tuna 
salad, tuna casserole; 
fried fish; chicken, turkey 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 




Table 3.3 (cont’d). Number of FFQ items and foods with highest contribution for PUFA 
nutrient and fish intake measures among control participants (N=492) of two US-based 




Study of Reflux Disease  
(N=131 line items) 
 
Epidemiology and 
Incidence of BE 









Five highest contributing 
FFQ items 
     DPA 30 
Chicken, turkey; beef, 
pork, lamb; dark oily fish; 
Swiss, cheddar, cream 
cheeses; white fish 
26 
Other fish, not fried; chicken, 
turkey; beef; fried chicken; 
Chinese or other Asian food 
ω-6 118 
Chicken, turkey; beef, 
pork, lamb; mayonnaise, 
mayonnaise type spreads; 
peanut butter, peanuts, 
other nuts/seeds; salad 
dressing 
102 
Peanuts, other nuts/seeds; 
salad dressing; snacks like 
chips, popcorn; mayonnaise, 
sandwich spreads; cooking 
fat (e.g. Pam, olive oil, lard) 
     LA 118 
Chicken, turkey; beef, 
pork, lamb; mayonnaise 
and mayonnaise type 
spreads; peanut butter, 
peanuts, other nuts/seeds; 
salad dressing 
102 
Peanuts, other nuts/seeds; 
salad dressing; snacks like 
chips, popcorn; mayonnaise, 
sandwich spreads; cooking 
fat (e.g. Pam, olive oil, lard) 
     AA 60 
Chicken, turkey; beef, 
pork, lamb; eggs; dark oily 
fish; ground meat (e.g. 
hamburgers, meatloaf) 
52 
Eggs, including egg biscuits; 
chicken, turkey; other fish, 
not fried; lunchmeat; beef 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
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Table 3.4. Odds ratios and 95% confidence intervals for associations between PUFAs 
using fish intake measures and development of BE among participants of two US-based 








Tuna    
     None 89 85 1.0 
     T1 174 183 0.89 (0.61, 1.31) 
     T2 105 117 0.90 (0.60, 1.35) 
     T3 103 107 0.95 (0.62, 1.44) 
   ptrend=0.94 
Fried fish    
     None 169 186 1.0 
     T1 115 122 1.01 (0.72, 1.42) 
     T2 113 109 1.13 (0.80, 1.59) 
     T3 74 75 1.08 (0.72, 1.62) 
  ptrend=0.76 
Baked/broiled fish   
     None 189 98 1.0 
     T1 85 140 0.92 (0.64, 1.32) 
     T2 98 121 0.68 (0.46, 1.01) 
     T3 99 133 0.66 (0.45, 0.98) 
   ptrend=0.06 
Shellfish    
     None 131 129 1.0 
     T1 123 113 1.04 (0.72, 1.51) 
     T2 76 97 0.77 (0.51, 1.16) 
     T3 141 153 0.90 (0.63, 1.30) 
   ptrend=0.75 
* Model adjusted for age, sex, education, caloric intake, and study indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 
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Table 3.5. Odds ratios and 95% confidence intervals for associations between PUFA 
nutrient measures and development of BE among participants of two US-based case-








ω-3    
     Q1 121 123 1.0 
     Q2 129 122 1.10 (0.76, 1.60) 
     Q3 106 124 0.89 (0.59, 1.34) 
     Q4 115 123 0.94 (0.57, 1.54) 
   ptrend=0.59 
ALA    
     Q1 124 123 1.0 
     Q2 134 124 1.10 (0.76, 1.59) 
     Q3 100 123 0.79 (0.52, 1.20) 
     Q4 113 122 0.86 (0.52, 1.42) 
   ptrend=0.67 
EPA    
     Q1 136 124 1.0 
     Q2 126 123 0.93 (0.65, 1.33) 
     Q3 110 122 0.90 (0.62, 1.31) 
     Q4 99 123 0.79 (0.53, 1.18) 
   ptrend=0.56 
DHA    
     Q1 136 124 1.0 
     Q2 115 122 0.87 (0.60, 1.25) 
     Q3 125 123 1.03 (0.71, 1.49) 
     Q4 95 123 0.78 (0.52, 1.17) 
   ptrend=0.79 
DPA    
     Q1 129 123 1.0 
     Q2 119 122 0.90 (0.62, 1.29) 
     Q3 116 123 0.94 (0.64, 1.38) 
     Q4 107 124 0.88 (0.59, 1.32) 
   ptrend=0.28 
ω-6    
     Q1 123 123 1.0 
     Q2 114 123 0.89 (0.61, 1.31) 
     Q3 131 124 1.04 (0.70, 1.57) 
     Q4 103 122 0.80 (0.48, 1.33) 
   ptrend=0.54 
* Model adjusted for age, sex, education, caloric intake, and study indicator 
Q1-Q4 are quartiles derived from controls’ distribution of intake 
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Table 3.5 (cont’d). Odds ratios and 95% confidence intervals for associations between 
PUFA nutrient measures and development of BE among participants of two US-based 








LA    
     Q1 123 122 1.0 
     Q2 115 124 0.88 (0.60, 1.29) 
     Q3 129 124 1.03 (0.68, 1.54) 
     Q4 104 122 0.80 (0.48, 1.33) 
   ptrend=0.56 
AA    
     Q1 117 122 1.0 
     Q2 127 124 1.03 (0.71, 1.49) 
     Q3 104 123 0.89 (0.60, 1.31) 
     Q4 123 123 1.08 (0.70, 1.65) 
   ptrend=0.22 
ω-6:ω-3    
     Q1 117 124 1.0 
     Q2 108 122 0.93 (0.64, 1.35) 
     Q3 130 124 1.12 (0.78, 1.61) 
     Q4 116 122 1.05 (0.73, 1.52) 
   ptrend=0.72 
* Model adjusted for age, sex, education, caloric intake, and study indicator 
 
Table 3.6. Odds ratios and 95% confidence intervals for associations between PUFAs and development of BE when 







Multiplicative scale Additive scale 




ORs* (95% CIs) 
ICR (95% CI) 
ω-3 ω-6 
      





≤Median 33 33 0.90 (0.74, 1.10) 
 
0.90 (0.74, 1.10) 
 
>Median >Median 201 213 1.0 
 
0.85 (0.70, 1.04) 
 
 
≤Median 20 34 0.79 (0.59, 1.07) 0.21 0.68 (0.44, 1.05) -0.08 (-0.22, 0.07) 
BMI (kg/m2) Baked/broiled fish 
    





>Median 153 174 0.81 (0.69, 0.94) 
 
0.81 (0.69, 0.94) 
 
<25 ≤Median 59 66 1.0 
 
0.82 (0.70, 0.95) 
 
 
>Median 35 63 0.78 (0.59, 1.02) 0.60 0.63 (0.45, 0.88) 0.01 (-0.08, 0.10) 
WC** (cm) Baked/broiled fish 
    





>Median 72 96 0.83 (0.72, 0.96) 
 
0.83 (0.72, 0.96) 
 
≤Recommendations ≤Median 51 48 1.0 
 
0.77 (0.67, 0.90) 
 
 
>Median 20 42 0.85 (0.66, 1.09) 0.80 0.66 (0.48, 0.89) 0.05 (-0.04, 0.14) 
* Adjusted for age, sex, caloric intake, and study indicator 
** WC data available in the Epidemiology and Incidence of BE study only 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 













Table 3.6 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFAs and development of BE 








Multiplicative scale Additive scale 
 




ORs* (95% CIs) 
ICR (95% CI) 
NSAID use Baked/broiled fish 
  





>Median 105 119 0.84 (0.74, 0.96) 
 
0.84 (0.74, 0.96) 
 
Never ≤Median 143 141 1.0 
 
0.91 (0.80, 1.04) 
 
  >Median 82 117 0.83 (0.69, 1.00) 0.91 0.76 (0.60, 0.96) 0.01 (-0.09, 0.11) 
Smoking status Baked/broiled fish     
Ever ≤Median 244 153 1.0  1.0  
 >Median 167 118 0.87 (0.76, 1.00)  0.87 (0.76, 1.00)  
Never ≤Median 37 100 1.0  0.78 (0.68, 0.89)  
 >Median 20 117 0.95 (0.77, 1.16) 0.24 0.74 (0.58, 0.94) 0.08 (-0.01, 0.18) 
Reflux frequency Baked/broiled fish     
≥Weekly ≤Median 158 51 1.0  1.0  
 >Median 93 25 0.95 (0.81, 1.12)  0.95 (0.81, 1.12)  
<Weekly ≤Median 123 202 1.0  0.38 (0.32, 0.45)  
 >Median 94 210 0.84 (0.71, 0.99) 0.11 0.32 (0.25, 0.40) -0.01 (-0.14, 0.12) 
* Adjusted for age, sex, caloric intake, and study indicator 
** WC data available in the Epidemiology and Incidence of BE study only 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 






Table 3.7. ORs and 95% CIs for PUFAs and development of BE characterized by BE segment length* among participants 
of two US-based case-control studies of BE 
 
Measure 









Ratio of OR** 
pheterogeneity 
Tuna        
Non-consumers 85 49 1.0 37 1.0 
0.73 (0.44, 1.21) 0.22 
Consumers 407 192 0.97 (0.65, 1.45) 146 0.70 (0.45, 1.10) 
Fried Fish        
Non-consumers 186 90 1.0 68 1.0 
0.84 (0.55, 1.27) 0.40 
Consumers 306 151 1.10 (0.79, 1.53) 115 0.92 (0.64, 1.33) 
Baked/broiled fish        
Non-consumers 98 55 1.0 53 1.0 
0.76 (0.48, 1.21) 0.25 
Consumers 394 186 0.90 (0.61, 1.32) 130 0.68 (0.51, 1.02) 
Shellfish        
Non-consumers 129 80 1.0 42 1.0 
1.18 (0.74, 1.90) 0.49 
Consumers 363 161 0.90 (0.63, 1.29) 141 1.06 (0.69, 1.63) 
ω-3 
     
  
≤Median 245 120 1.0 106 1.0 
0.63 (0.39, 1.04) 0.07 
>Median 247 121 0.98 (0.67, 1.43) 77 0.62 (0.40, 0.96) 
ALA 
     
  
≤Median 247 128 1.0 105 1.0 
0.78 (0.47, 1.29) 0.33 
>Median 245 113 0.83 (0.56, 1.23) 78 0.65 (0.41, 1.00) 
EPA 
     
  
≤Median 247 129 1.0 106 1.0 
0.81 (0.53, 1.25) 0.34 
>Median 245 112 0.92 (0.66, 1.30) 77 0.75 (0.51, 1.10) 
* Missing values (N): BE segment length (47) 
** Adjusted for age, sex, caloric intake, education, and study indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 






Table 3.7 (cont’d). ORs and 95% CIs for PUFAs and development of BE characterized by BE segment length* among 
participants of two US-based case-control studies of BE 
 
Measure 
  Short-segment BE(<3cm) Long-segment BE (≥3cm) 









OR** (95%CI) pheterogeneity 
DHA 
     
  
≤Median 246 123 1.0 104 1.0 
0.77 (0.50, 1.19) 0.25 
>Median 246 118 1.03 (0.74 1.44) 79 0.80 (0.54, 1.17) 
DPA 
     
  
≤Median 245 120 1.0 106 1.0 
0.69 (0.44, 1.08) 0.10 
>Median 247 121 1.06 (0.75, 1.50) 77 0.73 (0.50, 1.08) 
ω-6 
     
  
≤Median 246 111 1.0 102 1.0 
0.56 (0.34, 0.93) 0.02 
>Median 246 130 1.27 (0.87 1.86) 81 0.71 (0.46, 1.11) 
LA    
 
   
≤Median 246 112 1.0 102 1.0 
0.58 (0.35, 0.95) 0.03 
>Median 246 129 1.23 (0.84, 1.81) 81 0.71 (0.46, 1.10) 
AA    
 
   
≤Median 246 117 1.0 105 1.0 
0.62 (0.39, 0.97) 0.03 
>Median 246 124 1.08 (0.77, 1.54) 78 0.67 (0.45, 0.99) 
ω-6:ω-3        
≤Median 246 113 1.0 85 1.0 
0.92 (0.61, 1.38) 0.68 
>Median 246 128 1.18 (0.86, 1.62) 98 1.08 (0.76, 1.54) 
* Missing values (N): BE segment length (47) 
** Adjusted for age, sex, caloric intake, education, and study indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 






Table 3.8. Odds ratios and 95% confidence intervals for associations between PUFAs 
using fish intake measures and development of BE among participants of two US-based 








Tuna    
     None 89 85 1.0 
     T1 174 183 0.80 (0.52, 1.23) 
     T2 105 117 0.71 (0.45, 1.13) 
     T3 103 107 0.77 (0.48, 1.23) 
   ptrend=0.61 
Fried fish    
     None 169 186 1.0 
     T1 115 122 1.06 (0.72, 1.54) 
     T2 113 109 1.03 (0.69, 1.52) 
     T3 74 75 1.12 (0.71, 1.76) 
   ptrend=0.76 
Baked/broiled fish   
     None 189 98 1.0 
     T1 85 140 0.82 (0.55 1.23) 
     T2 98 121 0.78 (0.50, 1.21) 
     T3 99 133 0.68 (0.44, 1.06) 
   ptrend=0.08 
Shellfish    
     None 131 129 1.0 
     T1 123 113 1.12 (0.74, 1.69) 
     T2 76 97 0.71 (0.45, 1.13) 
     T3 141 153 0.93 (0.62, 1.40) 
   ptrend=0.61 
ω-3    
     Q1 121 123 1.0 
     Q2 129 122 1.16 (0.76, 1.77) 
     Q3 106 124 0.92 (0.58, 1.46) 
     Q4 115 123 0.95 (0.55, 1.65) 
   ptrend=0.86 
* Model adjusted for age, sex, education, BMI, reflux frequency, smoking status, caloric 
intake and study indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 




Table 3.8 (cont’d). Odds ratios and 95% confidence intervals for associations between 
PUFAs using fish intake measures and development of BE among participants of two 








ALA    
     Q1 124 123 1.0 
     Q2 134 124 1.15 (0.75, 1.75) 
     Q3 100 123 0.82 (0.51, 1.32) 
     Q4 113 122 0.84 (0.48, 1.46) 
   ptrend=0.79 
EPA    
     Q1 136 124 1.0 
     Q2 126 123 0.96 (0.64, 1.44) 
     Q3 110 122 0.87 (0.57, 1.33) 
     Q4 99 123 0.74 (0.47, 1.15) 
   ptrend=0.96 
DHA    
     Q1 136 124 1.0 
     Q2 115 122 0.91 (0.60, 1.36) 
     Q3 125 123 1.07 (0.70, 1.61) 
     Q4 95 123 0.77 (0.49, 1.20) 
   ptrend=0.86 
DPA    
     Q1 129 123 1.0 
     Q2 119 122 0.82 (0.54, 1.23) 
     Q3 116 123 0.94 (0.61, 1.43) 
     Q4 107 124 0.87 (0.56, 1.37) 
   ptrend=0.59 
ω-6    
     Q1 123 123 1.0 
     Q2 114 123 0.89 (0.58, 1.37) 
     Q3 131 124 0.90 (0.57, 1.42) 
     Q4 103 122 0.65 (0.37, 1.14) 
   ptrend=0.71 
* Model adjusted for age, sex, education, BMI, reflux frequency, smoking status, caloric 
intake and study indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 




Table 3.8 (cont’d). Odds ratios and 95% confidence intervals for associations between 
PUFAs using fish intake measures and development of BE among participants of two 








LA    
     Q1 123 122 1.0 
     Q2 115 124 0.90 (0.58, 1.38) 
     Q3 129 124 0.87 (0.55, 1.38) 
     Q4 104 122 0.66 (0.37, 1.16) 
   ptrend=0.68 
AA    
     Q1 117 122 1.0 
     Q2 127 124 0.95 (0.63, 1.44) 
     Q3 104 123 0.84 (0.54, 1.30) 
     Q4 123 123 0.98 (0.61, 1.58) 
   ptrend=0.57 
ω-6:ω-3    
     Q1 117 124 1.0 
     Q2 108 122 0.89 (0.59, 1.36) 
     Q3 130 124 0.92 (0.61, 1.39) 
     Q4 116 122 0.92 (0.61, 1.40) 
   ptrend=0.29 
* Model adjusted for age, sex, education, BMI, reflux frequency, smoking status, caloric 
intake and study indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 
Q1-Q4 are quartiles derived from controls’ distribution of intake 
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Table 3.9. Odds ratios and 95% confidence intervals for associations between PUFA 
nutrient measures and development of BE among participants of two US-based case-








Tuna    
     None 89 85 1.0 
     T1 155 163 0.88 (0.59, 1.31) 
     T2 124 137 0.89 (0.60, 1.33) 
     T3 103 107 0.93 (0.61, 1.43) 
   ptrend=0.94 
Fried fish    
     None 169 186 1.0 
     T1 136 129 1.14 (0.81, 1.62) 
     T2 60 69 0.94 (0.62, 1.44) 
     T3 106 108 1.12 (0.78, 1.61) 
   ptrend=0.76 
Baked/broiled fish   
     None 121 98 1.0 
     T1 152 136 0.94 (0.65, 1.36) 
     T2 99 130 0.63 (0.42, 0.94) 
     T3 99 128 0.69 (0.46, 1.02) 
   ptrend=0.06 
Shellfish    
     None 131 129 1.0 
     T1 154 154 0.94 (0.66, 1.34) 
     T2 86 96 0.86 (0.57, 1.30) 
     T3 100 113 0.88 (0.60, 1.30) 
   ptrend=0.75 
ω-3    
     Q1 142 123 1.0 
     Q2 106 123 0.72 (0.50, 1.06) 
     Q3 118 123 0.77 (0.51, 1.16) 
     Q4 105 123 0.61 (0.36, 1.03) 
   ptrend=0.59 
* Model adjusted for age, sex, education, caloric intake, study indicator, and number of 
FFQ items for each exposure 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 
Q1-Q4 are quartiles derived from controls’ distribution of intake 
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Table 3.9 (cont’d). Odds ratios and 95% confidence intervals for associations between 
PUFA nutrient measures and development of BE among participants of two US-based 








ALA    
     Q1 128 123 1.0 
     Q2 122 123 0.98 (0.67, 1.43) 
     Q3 103 123 0.81 (0.53, 1.24) 
     Q4 118 123 0.87 (0.52, 1.47) 
   ptrend=0.67 
EPA    
     Q1 143 123 1.0 
     Q2 96 123 0.71 (0.48, 1.03) 
     Q3 130 123 0.98 (0.66, 1.44) 
     Q4 102 123 0.80 (0.50, 1.27) 
   ptrend=0.56 
DHA    
     Q1 140 123 1.0 
     Q2 118 123 0.88 (0.61, 1.27) 
     Q3 113 123 0.86 (0.58, 1.27) 
     Q4 100 123 0.77 (0.50, 1.19) 
   ptrend=0.79 
DPA    
     Q1 148 123 1.0 
     Q2 99 123 0.70 (0.48, 1.01) 
     Q3 108 123 0.75 (0.50, 1.12) 
     Q4 116 123 0.82 (0.48, 1.38) 
   ptrend=0.28 
ω-6    
     Q1 127 123 1.0 
     Q2 120 123 0.95 (0.65, 1.39) 
     Q3 117 123 0.88 (0.57, 1.36) 
     Q4 107 123 0.81 (0.48, 1.36) 
   ptrend=0.54 
* Model adjusted for age, sex, education, caloric intake, study indicator, and number of 
FFQ items for each exposure 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 




Table 3.9 (cont’d). Odds ratios and 95% confidence intervals for associations between 
PUFA nutrient measures and development of BE among participants of two US-based 








LA    
     Q1 127 123 1.0 
     Q2 119 123 0.94 (0.64, 1.37) 
     Q3 119 123 0.90 (0.59, 1.39) 
     Q4 106 123 0.80 (0.47, 1.35) 
   ptrend=0.56 
AA    
     Q1 134 123 1.0 
     Q2 101 123 0.79 (0.54, 1.15) 
     Q3 117 123 0.85 (0.57, 1.28) 
     Q4 119 123 0.99 (0.59, 1.68) 
   ptrend=0.22 
ω-6:ω-3    
     Q1 117 123 1.0 
     Q2 115 123 0.98 (0.68, 1.42) 
     Q3 123 123 1.08 (0.75, 1.57) 
     Q4 116 123 1.03 (0.71, 1.49) 
   ptrend=0.72 
* Model adjusted for age, sex, education, caloric intake, study indicator, and number of 
FFQ items for each exposure 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 
Q1-Q4 are quartiles derived from controls’ distribution of intake 
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CHAPTER IV: FISH AND POLYUNSATURATED FATTY ACID DIETARY INTAKE 




Esophageal adenocarcinoma (EA)/gastric cardia adenocarcinoma (GCA) 
incidence in the United States (US) has rapidly increased over the last few decades 
[18], one of the most pronounced increases in cancer incidence over this time period 
[19]. These tumors are also highly fatal, with a median survival of ~11 months [2]. EA 
typically occurs in the lower third of the esophagus near the gastroesophageal junction 
[10]. GCA is a tumor of the metaplastic junctional epithelium, in the portion of the 
stomach closest to the gastroesophageal junction [7]. EA and GCA are often considered 
related entities due to their anatomically adjacent positions, similar histological features, 
risk factors, and treatments, and poor survival [123]. 
 Established risk factors for EA/GCA include increasing age [169], white race 
[169], male sex [169], reflux symptoms [143], obesity [154], and cigarette smoking [161]. 
The first three are non-modifiable, while clinically diagnosed gastroesophageal reflux 
disease is a chronic condition requiring treatment and maintenance therapy with 
frequent relapse [238]. Obesity and cigarette smoking are two potentially modifiable 
factors; however, weight loss [239] and smoking cessation [240] are difficult to achieve 
and, especially for weight loss [239], difficult to maintain. Several factors associated with 
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reduced risk of EA/GCA have been identified, including Helicobacter pylori [76] (a 
bacterial infection of the gastric mucosa which predisposes to gastric adenocarcinoma 
[312]), and nonsteroidal anti-inflammatory drugs (NSAIDs [284]; but are problematic 
because of well-known gastric side effects [244]). Two additional risk reduction factors 
that may be promising as potential intervention strategies include physical activity [157], 
and perhaps fruits and vegetables [165]. Factors associated with EA/GCA prognosis, 
other than clinical parameters such as stage [181] and treatment [182], are relatively 
understudied but include an inverse association with obesity [188]. 
Another factor that may be associated with decreased risk of EA/GCA is fish 
intake, which is high in ω-3 polyunsaturated fatty acids (PUFAs) [8]. Several, but not all, 
epidemiologic studies have shown that diets high in fish intake are inversely associated 
with EA and GCA incidence [221,225]. The ω-3 fatty acids, which are essential dietary 
fats [8], are hypothesized to partially account for any risk reductions due to their 
demonstrated anti-carcinogenic properties in experimental studies [8]. In addition to the 
beneficial ω-3 fatty acids, the PUFA family also includes ω-6 fatty acids (vegetable oils, 
lard, etc., are examples of ω-6-rich foods [8]), which have demonstrated carcinogenic 
properties in experimental studies [8]. Trends in PUFA consumption have generally 
paralleled trends observed for EA/GCA. PUFA intake has drastically changed over time, 
with marked increase in ω-6 consumption over the last century [25]. Additionally PUFA 
intake varies by geography. Intake of ω-6 in a typical western diet greatly outweighs ω-
3, with ω-6:ω-3 intake ratios ranging between 15:1 and 20:1 [37]. In Asian countries, 
where incidence rates of EA and GCA are low [35], ratios are estimated to be 4:1-6:1 
[37]. The ω-3 and ω-6 PUFAs compete for the same binding sites on enzymes in 
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metabolic pathways, particularly through inflammation and oxidative stress, and are 
known to play a role in carcinogenesis and cancer progression [212].  
We hypothesized that higher intake of non-fried fish and other measures of ω-3 
PUFAs would be associated with reduced risk of EA/GCA incidence and mortality, while 
ω-6 or the balance of ω-3 and ω-6 PUFAs (which are dominated by ω-6 intake [25]) 
would be associated with increased risk. If associations with dietary intake of PUFAs 
are confirmed, increasing ω-3 intake and/or decreasing ω-6 intake may have the 
potential to decrease the burden associated with EA/GCA. To examine our hypotheses, 




We used resources from two member studies of the International Barrett’s and 
Esophageal Adenocarcinoma Consortium (BEACON): the US Multicenter Study [173] 
and the Los Angeles County (LAC) Multiethnic Study [260]. These studies were chosen 
because of their similarities in study design, participant selection, interview methods, 
and food frequency questionnaire (FFQ) structure. Participating institutions received 
study approval from their respective Institutional Review Boards.  Details of the included 
studies have been published previously [173,260], and are summarized below. 
 
Study Populations 
The US Multicenter Study was conducted from 1993-1995 in Connecticut, New 
Jersey, and western Washington state [173]. Case patients were 30-79 years old, 
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diagnosed with first primary EA/GCA, and identified through rapid reporting systems to 
state and hospital cancer registries. Controls were population-based, sampled using 
modified Waksberg random telephone digit dialing [261] for those 30-64 years and 
through Health Care Financing Administration rosters for those 65 and older, and 
frequency matched with cases on age, sex, and in New Jersey, race.  
The LAC Multiethnic Study was conducted from 1992-1997 [260]. Case patients 
were aged 30-74 years, newly diagnosed with first primary EA/GCA, and identified by 
the LAC Cancer Surveillance Program. Neighborhood controls, who were identified 
through an algorithm based on case address, were matched to cases on age (±5 
years), sex, and race. 
In the current study, we excluded respondents without dietary intake assessment 
and those with estimated energy intakes outside of ±3 standard deviations on the log 
scale from the individual study means. Thus, our final population size consisted of 488 
EA case patients, 512 GCA case patients, and 1995 control participants. 
Both parent studies included follow-up components to determine vital status of 
the EA/GCA case patients. Mortality and date of death were determined through linkage 
with the National Death Index, through 2000 for the US Multicenter Study [181] and 
2004 for the LAC Multiethnic Study. An event was defined as death from any cause 
during follow-up, and participants alive at the end of follow-up were considered 
censored. Overall survival time was calculated in months from the date of diagnosis 
until date of death/censoring. Due to the aggressive nature and short survival (average 
of less than a year) of these cancers [2], all-cause mortality approximates EA/GCA-
specific mortality. The US Multicenter Study identified 460 deaths and the LAC 
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Multiethnic Study identified 424 deaths, for a total of 884 deaths among the 1027 
EA/GCA patients in our pooled study. 
 
Study Interviews 
Before the interview, informed consent was obtained from all participants or their 
proxy respondent.  Trained interviewers administered structured questionnaires 
assessing demographic information, lifestyle behaviors (including cigarette smoking and 
alcohol use), anthropometric measures, and medical history. Diet history was collected 
using validated FFQs [270,271]. The US Multicenter Study used a modified 104-item 
Fred Hutchinson Cancer Research Center FFQ [270], where a medium portion size was 
assumed and dietary intake was assessed three to five years prior to diagnosis date 
(cases) or interview date (controls). The LAC Multiethnic Study used the 124-item 
University of Hawaii FFQ [271], where portion size was ascertained and dietary intake 
was assessed one year prior to date of EA/GCA diagnosis for cases and same 
reference date for controls.  
 
Exposure Assessment 
We harmonized dietary responses by linking study-specific FFQs with the 
University of Minnesota Nutrition Coordinating Center nutrient database [278] to 
estimate grams of intake per day of PUFA exposures. The 13 PUFA measures used 
were: baked/broiled fish (non-fried fish other than tuna and shellfish); fried fish; tuna 
(tuna/tuna salad/tuna casserole); shellfish; ω-3; ω-3 subtypes (α-linolenic acid (ALA), 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic 
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acid (DPA)); ω-6; ω-6 subtypes (linoleic acid (LA) and arachidonic acid (AA)); and ω-
6:ω-3 ratio. 
As an example, DHA intake from a single line item was calculated as follows: 
DHA intake for line item = reported average frequency of intake x reported average 
portion size x DHA nutrient grams per 100 grams of line item. Intake of DHA per day for 
a participant would then be calculated by summing DHA intake for all line items. Many 
line items represented multiple foods, and in those cases the foods were weighted 
according to estimates of US consumption [310]. 
From the harmonized PUFA intakes, we generated study-specific quantiles of 
intake using the control distributions within each of the studies [282]. The PUFA 
exposure quantiles were then pooled by merging across the quantiles for the two 
studies. For the PUFA-rich food measures, we used an ordinal categorization of non-
consumers and tertiles of exposure among consumers. For the PUFA nutrient 
measures, we used quartiles of exposure.  
Other covariates used in the pooled study reported here were derived from the 
parent study-specific questionnaires, and were harmonized as previously described 
[143,154,161,284].   
 
Statistical Methods 
Logistic regression and polytomous logistic regression [265] were used to 
estimate odds ratios (ORs) and their 95% confidence intervals (CIs) for associations 
between PUFAs and risk of EA and GCA development. Cox proportional hazards 
regression models [265] were used to estimate hazard ratios (HRs) and their 95% CIs 
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for associations between PUFAs and the risk of mortality after EA/GCA. The 
proportional hazards assumption was assessed by using an interaction between 
exposure and follow-up time [265]. Linear trends were examined by modeling exposure 
variables as continuous variables.  
Study indicator [282] and total energy intake (kcal/day) [265] were included in all 
models. The matching factors (age (continuous), sex (women/men), and race 
(white/black/Hispanic/other)) were included in all logistic regression models. Additional 
confounders were selected using outcome-specific directed acyclic graphs (DAGs) 
[265]. Potential confounders for EA/GCA development included covariates that could 
possibly impact any of the exposure-outcome associations considered, such as 
education, obesity, reflux symptom frequency, cigarette smoking, alcohol use, fruit and 
vegetable intake, and proxy status. Potential confounders for mortality after EA/GCA 
included age, education, obesity, reflux symptom frequency, cigarette smoking, proxy 
status, and disease stage. The final DAG-identified minimally sufficient adjustment set 
for EA/GCA development included education (<high school/high school/some 
college/college) and proxy status (proxy/non-proxy). The final DAG-identified 
adjustment set for mortality after EA/GCA included age (continuous), education (<high 
school/high school/some college/college), and proxy status (proxy/non-proxy).  
For both outcomes (EA/GCA development and mortality after EA/GCA), 
modification was assessed for factors thought to act through carcinogenic mechanisms 
involving inflammation and oxidative stress [154,284,313,314], and included body mass 
index (BMI; <25.0 kg/m2/≥25.0 kg/m2 [292]), NSAID use (never regular users/ever 
regular users), cigarette smoking status (never/former/current), and reflux symptom 
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frequency (<once per week/≥once per week). Modification was assessed on the 
multiplicative scale by comparing models with and without interaction terms using the 
likelihood ratio statistic with a significance level of 0.05 [265]. Modification was also 
assessed on the additive scale by using single referent models to obtain interaction 
contrast ratios (ICRs) and 95% CIs [265]. Interactions between ω-3 and ω-6 were 
assessed using the same approaches. 
Five sensitivity analyses were conducted for both outcomes (EA/GCA 
development and mortality after EA/GCA). First, we augmented our models by including 
additional confounders in our models, specifically known risk factors (in addition to the 
adjustment set identified by DAG). For EA/GCA development we added BMI, reflux 
frequency, and cigarette smoking status; and for mortality after EA/GCA we added BMI. 
For the second sensitivity analysis we used the absolute value-based pooling approach, 
deriving quantiles among all combined controls (EA/GCA development) or all case 
patients (mortality after EA/GCA), rather than use the study-specific pooling approach 
described above [282]. In the third sensitivity analysis we examined associations with 
proxy respondents removed from the analysis. Fourth, we widened the acceptable 
caloric intake by excluding only participants in the highest and lowest 2.5% of daily 
caloric intake (rather than outside of ±3 standard deviations on the log scale as the cut-
off values for the main analyses). For the fifth sensitivity analysis we used a random 
effects meta-analytic approach [265] to pool study-specific estimates. 
Analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, 




Characteristics of participants by study and by case-control status are shown in 
Table 4.1. The two studies had similar distributions of age, sex, BMI, cigarette smoking 
status, and use of proxy interviews. The LAC Multiethnic study had a higher proportion 
of non-white participants, higher educational attainment, lower NSAID use, more 
frequent reflux symptoms, and higher daily caloric intake when compared to the US 
Multicenter Study.  
Table 4.2 shows daily mean intake of PUFAs and fish by study and by case-
control status. Among controls, the US Multicenter Study had higher intake of ω-6 and 
lower intake of ω-3. These differences combined to yield a higher average of ω-6:ω-3 
intake in the US Multicenter Study. The only other major difference was for 
baked/broiled fish, where controls in the LAC Multiethnic Study had higher intake.   
Table 4.3 presents food items that were the highest contributing (a combination 
of the most frequently eaten and PUFA-dense) line items to the PUFA exposure 
variables. Many of the same foods were high contributors to both ω-3 and ω-6 intake. 
For example, mayonnaise and creamy dressings were primary ω-3 and ω-6 contributors 
in both studies. Additionally, because of the approach used in the parent study FFQs, 
the tuna variable included items typically made with mayonnaise (tuna salad) or other 
creamy dressings (tuna casserole) as well as fresh and canned tuna. In comparison, the 
baked/broiled fish variable included only non-fried fish. 
When we examined associations between the PUFA measures and the risk of 
developing EA or GCA, results from single and polytomous logistic regression models 
did not substantially differ, thus only those from the polytomous models are shown here. 
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Higher intake of baked/broiled fish was associated with an ~30% reduced risk of 
developing EA (ORT3vs.None=0.67, 95%CI=0.44-1.01, ptrend=0.3) and GCA 
(ORT3vs.None=0.69, 95%CI=0.48-0.99, ptrend=0.4) (Table 4.4). In contrast, tuna had a 
positive association with EA development (ORT3vs.None=1.46, 95%CI=1.00-2.13, 
ptrend=0.9), but not GCA (ORT3vs.None=0.89, 95%CI=0.63-1.24, ptrend=0.9). Fried fish had 
a positive association with GCA (ORConsumersvs.Non=1.33, 95%CI=1.06-1.66), but not EA 
(ORConsumersvs.Non=1.00, 95%CI=0.80-1.26).  EA and GCA development was positively 
associated with ω-6 intake (ORQ4vs.Q1=2.62, 95%CI=1.73-3.97, ptrend=0.003 and 
ORQ4vs.Q1=1.45, 95%CI=0.99-2.13, ptrend=0.04, respectively). In contrast to our 
hypotheses, ω-3 intake also was associated with an increased risk of developing EA 
(ORQ4vs.Q1=2.58, 95%CI=1.73-3.84, ptrend=0.005) and GCA (ORQ4vs.Q1=1.72, 
95%CI=1.18-2.51, ptrend=0.2). There was no evidence of interaction between ω-3 and ω-
6, nor modification by any factors examined (Table 4.5).   
We found no association between the risk of mortality after EA and GCA and 
baked/broiled fish or most of the other dietary factors examined, with few exceptions 
(Table 4.6). In contrast to our hypotheses, the ω-6:ω-3 ratio was inversely associated 
with decreased EA mortality (HRQ4vs.Q1=0.76, 95%CI=0.58-0.99, ptrend=0.07), but not 
GCA mortality (HRQ4vs.Q1=1.21, 95%CI=0.92-1.61, ptrend=0.06). Consistent with our 
hypotheses, EPA (HRQ4vs.Q1=0.77, 95%CI=0.58-1.03, ptrend=0.3) and DHA 
(HRQ4vs.Q1=0.72, 95%CI=0.54-0.96, ptrend=0.08) were associated with decreased EA 
mortality; but, in contrast to our hypotheses, these ω-3 subtypes were not associated 
with GCA mortality. There was no evidence of interaction or modification by any factors 
examined (Table 4.7).  
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In sensitivity analyses, when we added to our models known risk factors for 
EA/GCA (BMI, reflux frequency, and smoking for EA/GCA development, and BMI for 
mortality after EA/GCA) that were not DAG-identified as confounders, findings (Tables 
4.8 and 4.9) were similar to those shown in Tables 4.4 and 4.6. Results generated in 
the other sensitivity analyses outlined in the Methods (data not shown) were also not 
substantially different from the primary results presented.    
 
Discussion 
In this pooled study of US-based participants, higher intake of baked/broiled fish 
was associated with a 31-33% reduced risk of developing EA and GCA, and ω-6 was 
positively associated a 2.6-fold increased risk of developing EA and 45% increased risk 
of developing GCA, all of which were consistent with our hypotheses. However, in 
contrast to our hypotheses, ω-3 was positively associated with a 2.6-fold increased risk 
of developing EA and 72% increased risk of developing GCA, whereas ω-6:ω-3 was 
associated with a 24% reduction in the risk of EA mortality. 
Our findings on baked/broiled fish (which are ω-3-dense foods [8]) and ω-6 fatty 
acids are biologically plausible. The families of PUFAs, ω-3 and ω-6, compete for the 
same binding sites on enzymes, but they have very different biochemical roles [8,212]. 
In experimental studies, higher levels of ω-3 fatty acids decrease production of ω-6-
derived byproducts and produce ω-3-derived molecules which are considered less 
biologically active [212]; ω-3 also has been associated with lower expression of COX-2 
and COX-2 inhibitors which have been shown to suppress tumor growth, angiogenesis, 
and metastasis [212]. Excess ω-6 is considered carcinogenesis-promoting in 
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experimental studies, and the byproducts have been shown to increase inflammation, 
angiogenesis, cellular proliferation and reduce apoptosis [8,212]. However, in humans, 
ω-6 intake has been inconsistently linked to chronic diseases [311]. 
Our biologically plausible results on baked/broiled fish are consistent with some 
[221,225], but not all previous epidemiologic studies [218,222,223,227]. A case-control 
study from Nebraska found a substantial decrease in risk of EA comparing those 
consuming the highest quantities of fish (fresh, frozen, or canned) to those consuming 
the lowest (ORQ4vs.Q1=0.14, 95%CI=0.04-0.48, ptrend=0.0001) [221]. Using the National 
Institutes of Health-AARP Study, Daniel et al. found a decreased risk of EA 
(HRQ5vs.Q1=0.78, 95%CI=0.59-1.03, ptrend=0.06) with increased intake of fish (all types of 
fish/shellfish), but not for GCA [225]. However, the Factors Influencing the Barrett’s 
Adenocarcinoma Relationship (FINBAR) Study, found a suggested increase in risk of 
EA with higher intake of fish, but CIs were wide [218]. A second analysis using the 
FINBAR data examined the associations between intake of oily fish and EA and still 
reported null results [223]. A manuscript using the LAC Multiethnic Study, included in 
this pooled study, found no associations between fish/shellfish intake and EA or GCA 
[222]. Previous inconsistencies may be due to the fact that most did not account for 
cooking methods [218,222,227], which may mask associations with ω-3-rich foods such 
as fish, given that frying adds ω-6. A few previous studies also observed inconsistent 
results for overall PUFA intake [218,222,226,228,229]. However, we elected not to use 
this PUFA measure, given that in western countries it is largely a surrogate measure of 
ω-6.  
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In contrast to our hypotheses, we observed a positive association for EA 
development with ω-3 intake, whereas others have reported no association [226]. Also, 
we found no association with the relative balance of ω-3 and ω-6 in association with 
EA/GCA development, which we had hypothesized could help to clarify previous reports 
of no association with PUFA intake [218,222,226,228,229], given these PUFA subtypes 
compete for the same enzymes, and their metabolic products may have differential 
roles in the carcinogenic process [8,212]. We are first to report an inverse association 
between ω-6:ω-3 and EA mortality, which is also inconsistent with our hypotheses. 
These unexpected findings could arise from our inability to differentiate ω-3 from ω-6 
clearly when we used the nutrient-based measures (rather than the food-based 
measures that incorporated cooking methods), given that in our parent populations, 
many of the same foods were high in both PUFA types (e.g., meat, mayonnaise, salad 
dressing, potatoes, and baked goods, as shown in Table 4.3).  
  Several additional limitations require consideration when interpreting our results. 
First, the geographically based populations sampled in our two studies comprise 
relatively homogenous groups, largely whites, which enhances internal validity, but may 
limit generalizability. However, rates of EA/GCA are highest among this demographic 
[169], which allows for results to be generalizable to this high-risk group. Second, the 
time period assessed by the FFQs varied between one to five years prior to 
diagnosis/interview. Patients may have adjusted diet or altered recall due to 
unrecognized developing symptoms of these adenocarcinomas. However, as in most 
epidemiologic studies of dietary intake, we assumed participants did not change their 
diet during the latent period. Third, recall error is also a possibility due to the time period 
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assessed, but research has shown moderate correlation between current diet and diet 
three to ten years later [296]. Fourth, there may be some discrepancies in data 
collection, variable definitions, and data management across parent studies. We 
attempted to mitigate this concern by selecting two studies with similar designs and 
methodologic approaches. Also, we first harmonized individual responses across 
studies to ensure uniform definitions of all covariates prior to pooling. In addition, our 
results were similar to those shown here when in a sensitivity analysis we used random-
effects meta-analysis, which requires fewer assumptions regarding the true association 
than does fixed-effect meta-analysis. Fifth, another possible limitation is residual 
confounding. Although we broadly considered potential confounders for all possible 
exposure-outcome associations, we were unable to consider the influence of additional 
interaction terms because of model failure. Finally, in order to maximize our ability to 
capture the complexity of PUFA intake in association with multiple outcomes in the 
esophageal/adenocarcinoma cancer continuum, we considered multiple PUFA 
measures in association with multiple outcomes. However, all of our measures and 
outcome associations were selected based on biologic plausibility and thus we did not 
correct for multiple comparisons. 
Our pooled study has several additional strengths. Using a pooled approach, our 
study is larger than most existing studies [218,221-223,227-229]. The larger sample 
size gave us increased power to detect associations and resulted in more precise 
estimates of association. Also, a pooling approach allows for uniform definitions of 
exposures and covariates and improves accuracy of the resulting estimates. Further, 
the parent studies included in our pooled analysis were conducted in US coastal regions 
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allowing for increased opportunity for fish consumption. An additional strength of our 
pooled study is that both parent studies were population-based, which enhances study 
validity. Another strength of our study is that we used a variety of PUFA measures to 
better reflect the potential dual (carcinogenic and anti-carcinogenic properties) 
associated with fatty acid exposure in experimental studies [8]. This facilitated our ability 
to examine associations with an exposure – namely baked/broiled fish – that appeared 
to isolate the ω-3-rich fish from the ω-6-rich oils that are introduced using other cooking 
methods. 
In summary, our study pooled two US-based case-control studies of EA/GCA 
and observed that higher intake of baked/broiled fish was associated with an ~30% 
decrease in the risk of developing EA and GCA.  Also, intake of ω-6 and, surprisingly, 
ω-3 fatty acids were associated with an increased risk of EA/GCA development. Future 
studies should include improved PUFA measures, while also accounting for cooking 
methods, in order to isolate the potentially opposing properties of ω-3 and ω-6 PUFA 
intake. If confirmed, increasing non-fried fish intake may be a potential promising risk 
reduction strategy for these lethal cancers with increasing incidence in the US and other 
western countries.
  
Table 4.1. Characteristics of participants of two US-based case-control studies of EA/GCA 
 
Characteristic (N (%)) 



















     Male 235 (83.3) 218 (85.2) 549 (79.9) 197 (90.8) 226 (83.1) 990 (73.9) 






     White 268 (95.0) 243 (94.9) 617 (89.8) 168 (77.4) 206 (75.7) 836 (62.4) 






     <High school 62 (22.1) 54 (21.2) 128 (18.6) 47 (21.7) 51 (18.8) 248 (18.5) 
     High school 90 (32.0) 84 (32.9) 174 (25.3) 50 (23.0) 67 (24.6) 249 (18.6) 
     Some college 75 (26.7) 59 (23.1) 174 (25.3) 61 (28.1) 85 (31.3) 384 (28.7) 
     College 54 (19.2) 58 (22.8) 211 (30.7) 59 (27.2) 69 (25.4) 459 (34.3) 
BMI (kg/m2)* 26.3 (4.1) 26.0 (4.3) 24.9 (3.4) 27.1 (5.2) 26.9 (5.3) 25.9 (4.6) 
Cigarette smoking status       
     Never 56 (20.4) 44 (17.9) 213 (32.4) 48 (22.1) 78 (28.7) 536 (40.0) 
     Former  141 (51.3) 121 (49.2) 294 (44.8) 103 (47.5) 120 (44.1) 583 (43.5) 
     Current 78 (28.4) 81 (32.9) 150 (22.8) 66 (30.4) 74 (27.2) 221 (16.5) 
NSAID use       
     Never 183 (67.8) 151 (60.6) 408 (60.0) 153 (71.2) 174 (64.4) 913 (68.2) 
     Ever 87 (32.2) 98 (39.4) 272 (40.0) 62 (28.8) 96 (35.6) 425 (31.8) 
* Mean (SD) 








Table 4.1 (cont’d). Characteristics of participants of two US-based case-control studies of EA/GCA 
Characteristic (N (%)) 













Reflux frequency       
     <Weekly 181 (69.6) 205 (84.4) 570 (88.2) 121 (56.3) 191 (72.1) 1127 (84.3) 
     ≥Weekly 79 (30.4) 38 (15.6) 76 (11.8) 94 (43.7) 74 (27.9) 210 (15.7) 
Total energy intake 













Proxy interview 87 (30.9) 66 (25.8) -- 65 (30.0) 84 (30.9) -- 
* Mean (SD) 






Table 4.2. Daily mean intake of PUFAs and fish among participants of two US-based case-control studies of EA/GCA 
 
Measure (mean (SD)) 













Tuna (g/day) 11.17 (13.33) 11.47 (15.03) 10.21 (13.63) 9.16 (12.95) 9.66 (18.77) 10.44 (17.25) 
Fried fish (g/day) 3.98 (6.84) 5.61 (6.39) 4.96 (8.70) 4.78 (13.03) 5.83 (13.94) 5.21 (10.36) 
Baked/broiled fish (g/day) 7.71 (8.68) 7.86 (8.97) 8.78 (10.10) 9.14 (12.83) 9.18 (18.04) 10.65 (16.97) 
Shellfish (g/day) 2.38 (3.20) 2.59 (3.85) 2.71 (4.11) 4.12 (8.38) 5.87 (13.82) 4.10 (8.42) 
ω-3 (g/day) 2.64 (1.32) 2.73 (1.60) 2.39 (1.42) 3.46 (4.15) 2.84 (1.76) 2.74 (2.11) 
     ALA (g/day) 2.35 (1.12) 2.44 (1.36) 2.10 (1.21) 3.30 (4.08) 2.67 (1.72) 2.58 (2.07) 
     EPA (g/day) 0.06 (0.06) 0.06 (0.07) 0.06 (0.06) 0.04 (0.05) 0.04 (0.05) 0.04 (0.04) 
     DHA (g/day) 0.16 (0.17) 0.16 (0.21) 0.16 (0.17) 0.10 (0.09) 0.10 (0.10) 0.10 (0.09) 
     DPA (g/day) 0.10 (0.11) 0.10 (0.13) 0.09 (0.11) 0.02 (0.01) 0.02 (0.01) 0.02 (0.01) 
ω-6 (g/day) 24.71 (13.62) 25.68 (16.75) 22.47 (14.39) 24.47 (39.82) 19.41 (13.19) 18.41 (16.22) 
     LA (g/day) 24.02 (13.01) 25.0 (16.0) 21.85 (13.75) 24.29 (39.64) 19.26 (13.12) 18.26 (16.14) 
     AA (g/day) 0.69 (0.75) 0.72 (0.84) 0.62 (0.77) 0.18 (0.20) 0.16 (0.10) 0.14 (0.10) 
ω-6:ω-3 9.35 (1.94) 9.38 (1.84) 9.38 (2.07) 6.91 (1.52) 6.85 (1.45) 6.81 (1.39) 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 







Table 4.3. Number of FFQ items and foods with highest contribution for PUFA nutrient and fish intake measures among 













Five highest contributing FFQ items 
Tuna 1 
Canned tuna, tuna salad, tuna 
casserole 
1 
Canned tuna salmon, sardines, mackerel, 
plain, salad, or casserole 
Fried fish 1 Fried fish/shellfish, fish sandwich 1 Fried/breaded fish sticks, fillets, patties 
Baked/broiled 
fish 
1 Other fish, broiled, baked 1 Other fresh or frozen fish, broiled, baked 
Shellfish 1 Shellfish, not fried 1 Shellfish  
ω-3 104 
Beef, veal, lamb, pork (not ham); 
chicken, turkey; mayonnaise, 
mayonnaise type spreads; salad 
dressing; French fries, fried 
potatoes 
112 
Margarine on vegetables, rice; mayonnaise 
or creamy salad dressing; other potatoes, 
baked, boiled, mashed; cornbread, corn 
muffin, corn tortilla; doughnuts, cookies, 
cakes, pastries 
     ALA 104 
Beef, veal, lamb, pork (not ham); 
chicken, turkey; mayonnaise, 
mayonnaise type spreads; salad 
dressing; French fries, fried 
potatoes 
111 
Margarine on vegetables, rice; mayonnaise 
or creamy salad dressing; other potatoes, 
baked, boiled, mashed; cornbread, corn 
muffin, corn tortilla; doughnuts, cookies, 
cakes, pastries 
     EPA 31 
Chicken, turkey; other fish, broiled, 
baked; beef, veal, lamb, pork (not 
ham); shellfish, not fried; smoked 
fish or lox 
31 
Canned tuna salmon, sardines, mackerel, 
plain, salad, or casserole; shellfish; other 
fresh or frozen fish broiled, baked; salted, 
preserved, pickled fish; chicken, turkey 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 






Table 4.3 (cont’d). Number of FFQ items and foods with highest contribution for PUFA nutrient and fish intake measures 













Five highest contributing FFQ items 
     DHA 33 
Chicken, turkey; other fish, broiled, 
baked; eggs; canned tuna, tuna salad, 
tuna casserole; fried fish/shellfish, fish 
sandwich 
31 
Other fresh or frozen fish broiled, baked; 
canned tuna salmon, sardines, mackerel, plain, 
salad, or casserole; fried eggs, scrambled, 
omelet; shellfish; chicken, turkey 
     DPA 28 
Chicken, turkey; beef, veal, lamb, pork 
(not ham); other fish, broiled, baked; 
cheese, cheese spreads; non-smoked 
poultry lunchmeat 
26 
Chicken, turkey; beef; other fresh or frozen fish 
broiled, baked; canned tuna salmon, sardines, 
mackerel, plain, salad, or casserole; tacos, 
tostadas, fajitas 
ω-6 109 
Chicken, turkey; beef, veal, lamb, pork 
(not ham); mayonnaise, mayonnaise 
type spreads; salad dressing; peanut 
butter, peanuts, nuts/seeds 
116 
Mayonnaise or creamy salad dressing; 
cornbread, corn muffin, corn tortilla; other 
potatoes, baked, boiled, mashed; salty snacks, 
peanuts, chips, pretzels; doughnuts, cookies, 
cakes, pastries 
     LA 109 
Chicken, turkey; beef, veal, lamb, pork 
(not ham); mayonnaise, mayonnaise 
type spreads; salad dressing; peanut 
butter, peanuts, nuts/seeds 
116 
Mayonnaise or creamy salad dressing; 
cornbread, corn muffin, corn tortilla; other 
potatoes, baked, boiled, mashed; salty snacks, 
peanuts, chips, pretzels; doughnuts, cookies, 
cakes, pastries 
     AA 48 
Beef, veal, lamb, pork (not ham); 
chicken, turkey; eggs; ground beef 
(e.g. hamburger, meatballs); liver, 
other organ meats 
53 
Fried eggs, scrambled, omelet; chicken, turkey; 
cornbread, corn muffin, corn tortilla; other eggs 
boiled, poached; beef 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 








Table 4.4. Odds ratios and 95% confidence intervals for associations between PUFA 
measures and risk of developing EA/GCA among participants of two US-based case-











Tuna      
     None 504 77 1.0 124 1.0 
     T1 386 96 1.54 (1.06, 2.24) 90 0.91 (0.64, 1.27) 
     T2 714 231 1.58 (1.13, 2.21) 216 0.98 (0.73, 1.32) 
     T3 423 95 1.46 (1.00, 2.13) 98 0.89 (0.63, 1.24) 
   ptrend=0.92  ptrend=0.86 
Fried fish      
     Non- 
     consumers 
1086 268 1.0 251 1.0 
     Consumers 941 231 1.00 (0.80, 1.26) 277 1.33 (1.06, 1.66) 
      
Baked/broiled fish     
     None 662 151 1.0 194 1.0 
     T1 352 79 1.01 (0.72, 1.43) 79 0.72 (0.52, 1.00) 
     T2 688 222 1.05 (0.79, 1.41) 191 0.73 (0.56, 0.97) 
     T3 325 47 0.67 (0.44, 1.01) 64 0.69 (0.48, 0.99) 
   ptrend=0.32  ptrend=0.36 
Shellfish      
     Non- 
     consumers 
966 203 1.0 229 1.0 
     Consumers 1061 296 1.22 (0.96, 1.55) 299 1.13 (0.90, 1.43) 
ω-3      
     Q1 507 75 1.0 101 1.0 
     Q2 507 126 1.98 (1.38, 2.83) 128 1.40 (1.01, 1.95) 
     Q3 507 131 1.89 (1.30, 2.74) 134 1.34 (0.95, 1.89) 
     Q4 506 167 2.58 (1.73, 3.84) 165 1.72 (1.18, 2.51) 
   ptrend=0.004  ptrend=0.19 
* Model adjusted for age, sex, race, education, caloric intake, proxy status, and study 
indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 
Q1-Q4 are quartiles derived from controls’ distribution of intake 
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Table 4.4 (cont’d). Odds ratios and 95% confidence intervals for associations between 
PUFA measures and risk of developing EA/GCA among participants of two US-based 











ALA      
     Q1 507 68 1.0 99 1.0 
     Q2 506 125 2.01 (1.39, 2.91) 121 1.26 (0.90, 1.76) 
     Q3 508 141 2.21 (1.51, 3.23) 143 1.47 (1.04, 2.07) 
     Q4 506 165 2.82 (1.86, 4.28) 165 1.69 (1.15, 2.49) 
   ptrend=0.005  ptrend=0.28 
EPA      
     Q1 507 117 1.0 139 1.0 
     Q2 507 132 1.13 (0.82, 1.56) 140 0.96 (0.71, 1.30) 
     Q3 507 127 1.14 (0.83, 1.59) 120 0.87 (0.63, 1.18) 
     Q4 506 123 1.22 (0.87, 1.70) 129 1.00 (0.73, 1.37) 
   ptrend=0.25  ptrend=0.09 
DHA      
     Q1 507 136 1.0 147 1.0 
     Q2 507 108 0.83 (0.61, 1.15) 129 0.88 (0.65, 1.18) 
     Q3 507 142 1.20 (0.88, 1.64) 129 0.97 (0.72, 1.32) 
     Q4 506 113 0.92 (0.66, 1.28) 123 0.86 (0.63, 1.18) 
   ptrend=0.49  ptrend=0.21 
DPA      
     Q1 507 99 1.0 122 1.0 
     Q2 507 121 1.37 (0.98, 1.92) 129 1.17 (0.85, 1.60) 
     Q3 507 149 1.80 (1.29, 2.50) 140 1.28 (0.94, 1.76) 
     Q4 506 130 1.41 (0.99, 2.01) 137 1.17 (0.84, 1.64) 
   ptrend=0.05  ptrend=0.04 
ω-6      
     Q1 507 68 1.0 107 1.0 
     Q2 507 132 1.97 (1.37, 2.84) 122 1.14 (0.82, 1.58) 
     Q3 507 137 2.07 (1.41, 3.03) 137 1.17 (0.83, 1.66) 
     Q4 506 162 2.62 (1.73, 3.97) 162 1.45 (0.99, 2.13) 
   ptrend=0.003  ptrend=0.04 
* Model adjusted for age, sex, race, education, caloric intake, proxy status, and study 
indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 




Table 4.4 (cont’d). Odds ratios and 95% confidence intervals for associations between 
PUFA measures and risk of developing EA/GCA among participants of two US-based 











LA      
     Q1 506 69 1.0 107 1.0 
     Q2 508 134 1.94 (1.35, 2.79) 126 1.16 (0.84, 1.61) 
     Q3 507 134 1.95 (1.33, 2.86) 133 1.11 (0.79, 1.57) 
     Q4 506 162 2.57 (1.69, 3.89) 162 1.44 (0.98, 2.12) 
   ptrend=0.003  ptrend=0.05 
AA      
     Q1 506 86 1.0 113 1.0 
     Q2 507 132 1.71 (1.21, 2.41) 121 1.12 (0.81, 1.55) 
     Q3 508 127 1.57 (1.10, 2.23) 139 1.27 (0.92, 1.76) 
     Q4 506 154 2.10 (1.45, 3.03) 155 1.52 (1.08, 2.15) 
   ptrend=0.01  ptrend=0.007 
ω-6:ω-3      
     Q1 507 129 1.0 116 1.0 
     Q2 506 120 1.01 (0.74, 1.39) 148 1.41 (1.04, 1.91) 
     Q3 507 125 0.94 (0.69, 1.29) 144 1.20 (0.88, 1.64) 
     Q4 507 125 1.01 (0.73, 1.38) 120 1.05 (0.76, 1.44) 
   ptrend=0.76  ptrend=0.98 
* Model adjusted for age, sex, race, education, caloric intake, proxy status, and study 
indicator 
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 
Q1-Q4 are quartiles derived from controls’ distribution of intake 
  
Table 4.5. Odds ratios and 95% confidence intervals for associations between PUFAs and risk of developing EA and 
GCA when examining modification among participants of two US-based case-control studies of EA/GCA 
 
Modifier Exposure Cases 
Controls 
N=2027 
Multiplicative scale Additive Scale 




ORs* (95% CIs) 
Additive ICR        
(95% CI) 
Esophageal adenocarcinoma (N=499 cases)    
ω-3 ω-6 
      





≤Median 172 903 0.90 (0.77, 1.06) 
 
0.90 (0.77, 1.06) 
 
>Median >Median 270 902 1.0 
 
1.10 (0.93, 1.29) 
 
 
≤Median 28 111 0.89 (0.71, 1.12) 0.84 0.97 (0.69, 1.37) -0.03 (-0.18, 0.13) 
BMI (kg/m2) Baked/broiled fish 
     





>Median 478 147 0.97 (0.87, 1.08) 
 
0.97 (0.87, 1.08) 
 
<25 ≤Median 493 96 1.0 
 
0.77 (0.69, 0.85) 
 
 
>Median 538 99 0.94 (0.80, 1.10) 0.57 0.72 (0.60, 0.87) -0.02 (-0.06, 0.06) 
NSAID use Baked/broiled fish 
     





>Median 355 72 0.96 (0.86, 1.07) 
 
0.96 (0.86, 1.07) 
 
Never ≤Median 654 166 1.0 
 
1.18 (1.06, 1.32) 
 
 
>Median 667 170 1.00 (0.88, 1.13) 0.50 1.18 (1.00, 1.39) 0.04 (-0.09, 0.16) 
Smoking status Baked/broiled fish      
Ever ≤Median 653 199 1.0  1.0  
 >Median 595 189 0.99 (0.88, 1.12)  0.99 (0.88, 1.12)  
Never ≤Median 340 47 1.0  0.73 (0.65, 0.83)  
 >Median 409 57 0.96 (0.78, 1.19) 0.65 0.71 (0.56, 0.89) -0.02 (-0.09, 0.06) 
* Adjusted for age, sex, race, caloric intake, and study indicator 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 








Table 4.5 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFAs and risk of developing EA 
and GCA when examining modification among participants of two US-based case-control studies of EA/GCA 
 
Modifier Exposure Cases 
Controls 
N=2027 
Multiplicative scale Additive Scale 




ORs* (95% CIs) 
Additive ICR        
(95% CI) 




    





>Median 127 93 1.02 (0.90, 1.15) 
 
1.02 (0.90, 1.15) 
 
<Weekly ≤Median 821 158 1.0 
 
0.52 (0.47, 0.59) 
 
  >Median 876 144 0.90 (0.80, 1.02) 0.09 0.48 (0.40, 0.57) -0.06 (-0.16, 0.04) 
Gastric cardia adenocarcinoma (N=528 cases)    
ω-3 ω-6       
≤Median >Median 30 111 1.0  1.0  
 ≤Median 199 903 0.96 (0.82, 1.12)  0.96 (0.82, 1.12)  
>Median >Median 269 902 1.0  1.05 (0.90,1.23)  
 ≤Median 30 111 0.97 (0.78, 1.21) 0.86 1.02 (0.74, 1.42) 0.01 (-0.15, 0.17) 
BMI (kg/m2) Baked/broiled fish     
25+  ≤Median 492 167 1.0  1.0  
 >Median 478 128 0.86 (0.77, 0.95)  0.86 (0.77, 0.95)  
<25 ≤Median 493 120 1.0  0.84 (0.76, 0.93)  
 >Median 538 103 0.86 (0.74, 1.00) 0.95 0.72 (0.60, 0.86) 0.03 (-0.05, 0.10) 
NSAID use Baked/broiled fish     
Ever ≤Median 342 97 1.0  1.0  
 >Median 355 97 0.87 (0.79, 0.97)  0.87 (0.79, 0.97)  
Never ≤Median 654 192 1.0  0.99 (0.89, 1.10)  
 >Median 667 133 0.80 (0.71, 0.91) 0.10 0.79 (0.67, 0.94) -0.07 (-0.15, 0.02) 
* Adjusted for age, sex, race, caloric intake, and study indicator 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 






Table 4.5 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFAs and risk of developing EA 




Modifier Exposure Cases 
Controls 
N=2027 
Multiplicative scale Additive Scale 




ORs* (95% CIs) 
Additive ICR        
(95% CI) 
Gastric cardia adenocarcinoma (N=528 cases)   
Smoking 
status 
Baked/broiled fish     
Ever ≤Median 653 229 1.0  1.0  
 >Median 595 167 0.87 (0.78, 0.98)  0.87 (0.78, 0.98)  
Never ≤Median 340 60 1.0  0.78 (0.70, 0.88)  
 >Median 409 62 0.87 (0.72, 1.06) 1.0 0.68 (0.55, 0.85) 0.03 (-0.04, 0.10) 
Reflux 
frequency 
Baked/broiled fish     
≥Weekly ≤Median 159 63 1.0  1.0  
 >Median 127 49 0.87 (0.76, 0.99)  0.87 (0.76, 0.99)  
<Weekly ≤Median 821 223 1.0  0.75 (0.66, 0.85)  
  >Median 876 173 0.83 (0.74, 0.93) 0.49 0.63 (0.53, 0.74) 0.004 (-0.10, 0.10) 
* Adjusted for age, sex, race, caloric intake, and study indicator 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 






Table 4.6. Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality* following 














Tuna       
     None 77 66 1.0 124 100 1.0 
     T1 143 126 1.21 (0.88, 1.65) 129 117 1.00 (0.76, 1.33) 
     T2 179 159 1.21 (0.89, 1.66) 174 144 0.98 (0.74, 1.28) 
     T3 100 83 1.02 (0.73, 1.43) 101 89 1.16 (0.86, 1.57) 
   ptrend=0.30   ptrend=0.44 
Fried fish       
     Non-consumers 268 239 1.0 251 224 1.0 
     Consumers 231 195 0.95 (0.78, 1.16) 277 226 0.88 (0.72, 1.07) 
       
Baked/broiled fish      
     None 151 130 1.0 194 168 1.0 
     T1 79 69 1.10 (0.82, 1.49) 79 67 0.98 (0.73, 1.31) 
     T2 221 191 1.00 (0.78, 1.27) 186 155 0.84 (0.65, 1.10) 
     T3 48 44 0.80 (0.55, 1.16) 69 60 0.99 (0.73, 1.35) 
   ptrend=0.08   ptrend=0.76 
Shellfish       
     Non-consumers 203 176 1.0 229 197 1.0 
     Consumers 296 258 1.01 (0.83, 1.24) 299 253 0.92 (0.75, 1.13) 
* Missing (N): vital status (5) 
** Model adjusted for age, education, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 







Table 4.6 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality* 















ω-3       
     Q1 116 99 1.0 141 118 1.0 
     Q2 129 118 1.19 (0.90, 1.57) 127 115 1.05 (0.80, 1.37) 
     Q3 126 108 0.97 (0.72, 1.31) 131 115 0.73 (0.55, 0.96) 
     Q4 128 109 1.03 (0.74, 1.45) 129 102 0.76 (0.55, 1.04) 
   ptrend=0.21   ptrend=0.53 
ALA       
     Q1 117 102 1.0 140 117 1.0 
     Q2 126 110 0.96 (0.73, 1.27) 131 118 1.12 (0.87, 1.46) 
     Q3 123 110 0.98 (0.72, 1.31) 132 115 0.71 (0.53, 0.94) 
     Q4 133 112 0.90 (0.64, 1.25) 125 100 0.80 (0.58, 1.10) 
   ptrend=0.26   ptrend=0.45 
EPA       
     Q1 119 105 1.0 138 120 1.0 
     Q2 129 113 0.92 (0.70, 1.20) 128 109 0.99 (0.76, 1.30) 
     Q3 127 109 0.85 (0.65, 1.13) 130 107 0.86 (0.66, 1.13) 
     Q4 124 107 0.77 (0.58, 1.03) 132 114 1.15 (0.87, 1.51) 
   ptrend=0.29   ptrend=0.36 
* Missing (N): vital status (5) 
** Model adjusted for age, education, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 






Table 4.6 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality* 















DHA       
     Q1 127 110 1.0 129 114 1.0 
     Q2 111 97 0.98 (0.74, 1.31) 146 118 0.73 (0.56, 0.95) 
     Q3 137 121 1.15 (0.88, 1.50) 121 105 1.04 (0.79, 1.37) 
     Q4 124 106 0.72 (0.54, 0.96) 132 113 1.00 (0.76, 1.32) 
   ptrend=0.08   ptrend=0.53 
DPA       
     Q1 84 75 1.0 108 90 1.0 
     Q2 97 84 1.23 (0.89, 1.70) 115 103 0.95 (0.71, 1.28) 
     Q3 130 110 0.92 (0.67, 1.27) 122 103 0.89 (0.65, 1.20) 
     Q4 188 165 0.90 (0.66, 1.24) 183 154 0.99 (0.74, 1.34) 
   ptrend=0.49   ptrend=0.57 
ω-6       
     Q1 111 97 1.0 147 122 1.0 
     Q2 134 120 1.13 (0.86, 1.49) 122 110 1.04 (0.80, 1.36) 
     Q3 122 103 0.82 (0.61, 1.11) 135 117 0.87 (0.66, 1.14) 
     Q4 132 114 0.84 (0.60, 1.19) 124 101 0.83 (0.59, 1.15) 
   ptrend=0.14   ptrend=0.68 
* Missing (N): vital status (5) 
** Model adjusted for age, education, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 







Table 4.6 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality* 















LA       
     Q1 112 99 1.0 145 120 1.0 
     Q2 131 115 1.04 (0.79, 1.37) 125 112 1.06 (0.81, 1.38) 
     Q3 124 106 0.82 (0.61, 1.11) 133 116 0.89 (0.67, 1.17) 
     Q4 132 114 0.81 (0.57, 1.14) 125 102 0.85 (0.61, 1.19) 
   ptrend=0.14   ptrend=0.68 
AA       
     Q1 117 104 1.0 139 118 1.0 
     Q2 132 112 1.13 (0.85, 1.49) 125 109 0.89 (0.67, 1.17) 
     Q3 127 109 0.82 (0.62, 1.10) 130 112 0.93 (0.70, 1.22) 
     Q4 123 109 1.01 (0.74, 1.37) 134 111 0.88 (0.65, 1.18) 
   ptrend=0.89   ptrend=0.76 
ω-6:ω-3       
     Q1 135 119 1.0 122 106 1.0 
     Q2 116 99 0.93 (0.71, 1.22) 141 112 0.94 (0.71, 1.23) 
     Q3 114 103 0.86 (0.65, 1.12) 142 122 1.24 (0.95, 1.62) 
     Q4 134 113 0.76 (0.58, 0.99) 123 110 1.21 (0.92, 1.61) 
   ptrend=0.07   ptrend=0.06 
* Missing (N): vital status (5) 
** Model adjusted for age, education, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 







Table 4.7. Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following a 
diagnosis of EA and GCA when examining effect measure modification among participants of two US-based case-control 
studies of EA/GCA with follow-up for cases 
 
Modifier Exposure Cases Events 
Multiplicative Scale Additive Scale 




HRs** (95% CIs) 
Additive ICR        
(95% CI) 
Esophageal adenocarcinoma (N=499 cases, N=434 deaths)    
ω-3 ω-6 
      





≤Median 214 189 1.03 (0.68, 1.54) 
 
1.03 (0.68, 1.54) 
 
>Median >Median 223 189 1.0 
 
0.93 (0.63, 1.39) 
 
 
≤Median 31 28 1.09 (0.72, 1.63) 0.84 1.02 (0.60, 1.72) 0.06 (-0.49, 0.61) 
BMI (kg/m2) Ratio 
      





>Median 138 115 0.95 (0.74, 1.21) 
 
0.96 (0.75, 1.23) 
 
<25 ≤Median 86 77 1.0 
 
1.23 (0.93, 1.63) 
 
 
>Median 109 99 1.08 (0.80, 1.46) 0.53 1.34 (1.03, 1.73) 0.15 (-0.30, 0.59) 
NSAID use Ratio 
      





>Median 66 55 1.04 (0.73, 1.49) 
 
1.04 (0.73, 1.49) 
 
Never ≤Median 159 141 1.0 
 
1.15 (0.86, 1.53) 
 
 
>Median 177 156 1.01 (0.81, 1.27) 0.89 1.17 (0.88, 1.55) -0.03 (-0.48. 0.43) 
Smoking status Ratio       
Ever ≤Median 186 162 1.0  1.0  
 >Median 202 176 1.08 (0.87, 1.34)  1.08 (0.87, 1.34)  
Never ≤Median 59 51 1.0  1.14 (0.83, 1.56)  
 >Median 45 39 0.92 (0.60, 1.41) 0.51 1.05 (0.74, 1.49) -0.17 (-0.69, 0.35) 
* Missing (N): vital status (5) 
** Adjusted for caloric intake and study indicator 







Table 4.7 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following 
a diagnosis of EA and GCA when examining modification among participants of two US-based case-control studies of 
EA/GCA with follow-up for cases 
 
Modifier Exposure Cases Events 
Multiplicative Scale Additive Scale 




HRs** (95% CIs) 
Additive ICR        
(95% CI) 
Esophageal adenocarcinoma (N=499 cases, N=434 deaths)    
Reflux frequency Ratio 
      





>Median 92 79 1.16 (0.83, 1.61) 
 
1.16 (0.83, 1.61) 
 
<Weekly ≤Median 152 138 1.0 
 
1.40 (1.04, 1.88) 
 
  >Median 150 131 0.98 (0.77, 1.24) 0.42 1.36 (1.01, 1.85) 0.19 (-0.70, 0.32) 
Gastric cardia adenocarcinoma (N=528 cases, N=450 deaths)    
ω-3 ω-6       
≤Median >Median 27 25 1.0  1.0  
 ≤Median 242 208 0.76 (0.50, 1.17)  0.76 (0.50, 1.17)  
>Median >Median 233 193 1.0  0.65 (0.42, 0.99)  
 ≤Median 26 24 1.12 (0.72, 1.72) 0.22 0.72 (0.41, 1.27) 0.31 (-0.11, 0.73) 
BMI (kg/m2) Ratio       
25+  ≤Median 141 117 1.0  1.0  
 >Median 154 129 0.97 (0.75, 1.25)  0.97 (0.75, 1.25)  
<25 ≤Median 117 109 1.0  1.42 (1.09, 1.85)  
 >Median 106 87 0.67 (0.50, 0.89) 0.05 0.95 (0.71, 1.26) -0.44 (-0.90, 0.02) 
* Missing (N): vital status (5) 
** Adjusted for caloric intake and study indicator 











Table 4.7 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following 
a diagnosis of EA and GCA when examining modification among participants of two US-based case-control studies of 
EA/GCA with follow-up for cases 
 
Modifier Exposure Cases Events 
Multiplicative Scale Additive Scale 




HRs** (95% CIs) 
Additive ICR        
(95% CI) 
NSAID use Ratio       
Ever ≤Median 95 84 1.0  1.0  
 >Median 99 82 0.84 (0.61, 1.14)  0.84 (0.61, 1.14)  
Never ≤Median 165 143 1.0  1.06 (0.81, 1.39)  
 >Median 160 132 0.83 (0.65, 1.06) 1.00 0.88 (0.67, 1.17) -0.01 (-0.38, 0.35) 
Smoking status Ratio       
Ever ≤Median 191 171 1.0  1.0  
 >Median 205 171 0.81 (0.65, 1.00)  0.81 (0.65, 1.00)  
Never ≤Median 67 56 1.0  0.93 (0.69, 1.26)  
 >Median 55 44 0.85 (0.57 1.27) 0.82 0.79 (0.56, 1.11) 0.05 (-0.33, 0.44) 
Reflux frequency Ratio       
≥Weekly ≤Median 55 45 1.0  1.0  
 >Median 57 40 0.82 (0.53, 1.26)  0.82 (0.53, 1.26)  
<Weekly ≤Median 201 178 1.0  1.38 (1.00, 1.92)  
  >Median 195 168 0.84 (0.68, 1.04) 0.92 1.16 (0.83, 1.63) -0.03 (-0.44, 0.37) 
* Missing (N): vital status (5) 
** Adjusted for caloric intake and study indicator 










Table 4.8. Odds ratios and 95% confidence intervals for associations between PUFAs and risk of developing EA/GCA 
among participants of two US-based case-control studies of EA/GCA, adjusting for additional covariates 
 
Measure 









Tuna      
     None 504 77 1.0 124 1.0 
     T1 386 96 1.54 (1.04, 2.27) 90 0.92 (0.65, 1.30) 
     T2 714 231 1.60 (1.13, 2.27) 216 0.98 (0.72, 1.33) 
     T3 423 95 1.39 (0.94, 2.07) 98 0.90 (0.63, 1.28) 
   ptrend=0.87  ptrend=0.72 
Fried fish      
     Non-consumers 1086 268 1.0 251 1.0 
     Consumers 941 231 0.97 (0.76, 1.23) 277 1.35 (1.07, 1.70) 
      
Baked/broiled fish     
     None 662 151 1.0 194 1.0 
     T1 352 79 1.09 (0.76, 1.56) 79 0.78 (0.55, 1.10) 
     T2 688 222 1.12 (0.83, 1.53) 191 0.82 (0.61, 1.09) 
     T3 325 47 0.69 (0.45, 1.07) 64 0.76 (0.52, 1.10) 
   ptrend=0.38  ptrend=0.62 
Shellfish      
     Non-consumers 966 203 1.0 229 1.0 
     Consumers 1061 296 1.19 (0.93, 1.53) 299 1.14 (0.90, 1.45) 
* Model adjusted for age, education, BMI, GERD symptom frequency, cigarette smoking status, proxy status,  
  caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 







Table 4.8 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFAs and risk of developing 
EA/GCA among participants of two US-based case-control studies of EA/GCA, adjusting for additional covariates 
 
Measure 









ω-3      
     Q1 507 75 1.0 101 1.0 
     Q2 507 126 2.07 (1.43, 3.00) 128 1.45 (1.03, 2.04) 
     Q3 507 131 1.90 (1.29, 2.80) 134 1.34 (0.94, 1.91) 
     Q4 506 167 2.43 (1.60, 3.69) 165 1.65 (1.12, 2.44) 
   ptrend=0.004  ptrend=0.25 
ALA      
     Q1 507 68 1.0 99 1.0 
     Q2 506 125 2.19 (1.49, 3.21) 121 1.34 (0.95, 1.89) 
     Q3 508 141 2.25 (1.51, 3.34) 143 1.48 (1.04, 2.11) 
     Q4 506 165 2.71 (1.76, 4.20) 165 1.68 (1.13, 2.50) 
   ptrend=0.004  ptrend=0.34 
EPA      
     Q1 507 117 1.0 139 1.0 
     Q2 507 132 1.27 (0.91, 1.78) 140 1.11(0.82, 1.52) 
     Q3 507 127 1.22 (0.87, 1.72) 120 0.92 (0.66, 1.27) 
     Q4 506 123 1.30 (0.92, 1.84) 129 1.09 (0.79, 1.51) 
   ptrend=0.45  ptrend=0.23 
* Model adjusted for age, education, BMI, GERD symptom frequency, cigarette smoking status, proxy status,  
  caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 








Table 4.8 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFAs and risk of developing 
EA/GCA among participants of two US-based case-control studies of EA/GCA, adjusting for additional covariates 
 
Measure 









DHA      
     Q1 507 136 1.0 147 1.0 
     Q2 507 108 0.94 (0.67, 1.31) 129 1.03 (0.76, 1.41) 
     Q3 507 142 1.28 (0.92, 1.77) 129 1.11 (0.81, 1.51) 
     Q4 506 113 1.01 (0.71, 1.43) 123 0.96 (0.69, 1.34) 
   ptrend=0.47  ptrend=0.25 
DPA      
     Q1 507 99 1.0 122 1.0 
     Q2 507 121 1.44 (1.01, 2.04) 129 1.23 (0.89, 1.70) 
     Q3 507 149 1.79 (1.27, 2.53) 140 1.35 (0.97, 1.87) 
     Q4 506 130 1.41 (0.98, 2.05) 137 1.13 (0.79, 1.59) 
   ptrend=0.11  ptrend=0.08 
ω-6      
     Q1 507 68 1.0 107 1.0 
     Q2 507 132 2.13 (1.46, 3.11) 122 1.23 (0.88, 1.72) 
     Q3 507 137 2.16 (1.46, 3.21) 137 1.24 (0.87, 1.76) 
     Q4 506 162 2.64 (1.72, 4.07) 162 1.48 (1.00, 2.20) 
   ptrend=0.001  ptrend=0.04 
* Model adjusted for age, education, BMI, GERD symptom frequency, cigarette smoking status, proxy status,  
  caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 






Table 4.8 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFAs and risk of developing 
EA/GCA among participants of two US-based case-control studies of EA/GCA, adjusting for additional covariates 
 
Measure 









LA      
     Q1 506 69 1.0 107 1.0 
     Q2 508 134 2.11 (1.45, 3.07) 126 1.25 (0.90, 1.75) 
     Q3 507 134 2.03 (1.37, 3.01) 133 1.17 (0.82, 1.67) 
     Q4 506 162 2.59 (1.68, 3.98) 162 1.47 (0.99, 2.18) 
   ptrend=0.001  ptrend=0.04 
AA      
     Q1 506 86 1.0 113 1.0 
     Q2 507 132 1.77 (1.24, 2.54) 121 1.16 (0.83, 1.62) 
     Q3 508 127 1.63 (1.13, 2.35) 139 1.32 (0.94, 1.84) 
     Q4 506 154 2.04 (1.39, 2.98) 155 1.44 (1.01, 2.06) 
   ptrend=0.04  ptrend=0.02 
ω-6:ω-3      
     Q1 507 129 1.0 116 1.0 
     Q2 506 120 0.97 (0.70, 1.35) 148 1.40 (1.02, 1.92) 
     Q3 507 125 0.98 (0.71, 1.37) 144 1.23 (0.90, 1.70) 
     Q4 507 125 1.07 (0.77, 1.49) 120 1.09 (0.79, 1.52) 
   ptrend=0.41  ptrend=0.73 
* Model adjusted for age, education, BMI, GERD symptom frequency, cigarette smoking status, proxy status,  
  caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from controls’ distribution of intake 








Table 4.9. Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following a 
diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














Tuna       
     None 77 66 1.0 124 100 1.0 
     T1 143 126 1.21 (0.88, 1.66) 129 117 1.00 (0.75, 1.32) 
     T2 179 159 1.20 (0.88, 1.64) 174 144 0.99 (0.76, 1.31) 
     T3 100 83 1.03 (0.74, 1.45) 101 89 1.17 (0.87, 1.58) 
   ptrend=0.33   ptrend=0.37 
Fried fish       
     Non-consumers 268 239 1.0 251 224 1.0 
     Consumers 231 195 0.95 (0.78, 1.16) 277 226 0.87 (0.72, 1.06) 
       
Baked/broiled fish      
     None 151 130 1.0 194 168 1.0 
     T1 79 69 1.08 (0.80, 1.47) 79 67 0.97 (0.72, 1.30) 
     T2 221 191 1.02 (0.79, 1.30) 186 155 0.84 (0.65, 1.10) 
     T3 48 44 0.78 (0.53, 1.14) 69 60 0.97 (0.71, 1.31) 
   ptrend=0.07   ptrend=0.61 
* Missing (N): vital status (5)  
** Model adjusted for age, education, BMI, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 








Table 4.9 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following 
a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














Shellfish       
     Non-consumers 203 176 1.0 229 197 1.0 
     Consumers 296 258 1.01 (0.82, 1.25) 299 253 0.91 (0.74, 1.11) 
ω-3       
     Q1 116 99 1.0 141 118 1.0 
     Q2 129 118 1.24 (0.93, 1.64) 127 115 1.05 (0.80, 1.37) 
     Q3 126 108 1.01 (0.75, 1.36) 131 115 0.75 (0.56, 0.99) 
     Q4 128 109 1.07 (0.76, 1.50) 129 102 0.75 (0.54, 1.03) 
   ptrend=0.17   ptrend=0.45 
ALA       
     Q1 117 102 1.0 140 117 1.0 
     Q2 126 110 1.01 (0.76, 1.34) 131 118 1.13 (0.87, 1.47) 
     Q3 123 110 0.97 (0.72, 1.31) 132 115 0.73 (0.55, 0.97) 
     Q4 133 112 0.93 (0.67, 1.30) 125 100 0.79 (0.57, 1.10) 
   ptrend=0.19   ptrend=0.38 
* Missing (N): vital status (5)  
** Model adjusted for age, education, BMI, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 










Table 4.9 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following 
a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














EPA       
     Q1 119 105 1.0 138 120 1.0 
     Q2 129 113 0.93 (0.70, 1.22) 128 109 1.00 (0.76, 1.31) 
     Q3 127 109 0.87 (0.66, 1.15) 130 107 0.86 (0.66, 1.14) 
     Q4 124 107 0.79 (0.59, 1.05) 132 114 1.14 (0.87, 1.50) 
   ptrend=0.30   ptrend=0.42 
DHA       
     Q1 127 110 1.0 129 114 1.0 
     Q2 111 97 1.03 (0.77, 1.37) 146 118 0.74 (0.57, 0.96) 
     Q3 137 121 1.17 (0.90, 1.54) 121 105 1.06 (0.80, 1.39) 
     Q4 124 106 0.74 (0.56, 1.00) 132 113 1.01 (0.76, 1.33) 
   ptrend=0.11   ptrend=0.60 
DPA       
     Q1 84 75 1.0 108 90 1.0 
     Q2 97 84 1.28 (0.92, 1.77) 115 103 0.95 (0.71, 1.28) 
     Q3 130 110 0.94 (0.68, 1.30) 122 103 0.89 (0.65, 1.20) 
     Q4 188 165 0.94 (0.69, 1.30) 183 154 1.00 (0.74, 1.36) 
   ptrend=0.55   ptrend=0.62 
* Missing (N): vital status (5)  
** Model adjusted for age, education, BMI, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 







Table 4.9 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following 
a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














ω-6       
     Q1 111 97 1.0 147 122 1.0 
     Q2 134 120 1.14 (0.86, 1.51) 122 110 1.05 (0.80, 1.36) 
     Q3 122 103 0.86 (0.64, 1.18) 135 117 0.88 (0.67, 1.17) 
     Q4 132 114 0.84 (0.60, 1.20) 124 101 0.83 (0.59, 1.16) 
   ptrend=0.12   ptrend=0.79 
LA       
     Q1 112 99 1.0 145 120 1.0 
     Q2 131 115 1.06 (0.80, 1.40) 125 112 1.06 (0.81, 1.39) 
     Q3 124 106 0.87 (0.64, 1.18) 133 116 0.90 (0.68, 1.20) 
     Q4 132 114 0.81 (0.57, 1.15) 125 102 0.85 (0.61, 1.20) 
   ptrend=0.11   ptrend=0.79 
AA       
     Q1 117 104 1.0 139 118 1.0 
     Q2 132 112 1.18 (0.89, 1.57) 125 109 0.88 (0.67, 1.15) 
     Q3 127 109 0.87 (0.65, 1.17) 130 112 0.93 (0.71, 1.23) 
     Q4 123 109 1.06 (0.77, 1.45) 134 111 0.89 (0.66, 1.20) 
   ptrend=0.90   ptrend=0.78 
* Missing (N): vital status (5)  
** Model adjusted for age, education, BMI, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 







Table 4.9 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFAs and mortality* following 
a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














ω-6:ω-3       
     Q1 135 119 1.0 122 106 1.0 
     Q2 116 99 0.93 (0.71, 1.23) 141 112 0.95 (0.72, 1.25) 
     Q3 114 103 0.90 (0.68, 1.17) 142 122 1.25 (0.96, 1.64) 
     Q4 134 113 0.77 (0.59, 1.00) 123 110 1.23 (0.93, 1.63) 
   ptrend=0.10   ptrend=0.06 
* Missing (N): vital status (5)  
** Model adjusted for age, education, BMI, proxy status, caloric intake, and study indicator  
Tuna includes tuna fresh and canned, tuna salad, and tuna casserole 
Baked/broiled fish describes non-fried fish that is neither tuna nor shellfish 
T1-T3 are tertiles derived from cases’ distribution of intake 








CHAPTER V: DISCUSSION 
 
Overview 
The objectives of this dissertation were to examine the associations between 
PUFAs and the three outcomes along the BE-EA continuum: BE, EA/GCA, and 
mortality following a diagnosis of EA/GCA. Chapter I provides the background on these 
diseases, on PUFAs, and on the limited existing research assessing PUFAs and 
BE/EA/GCA, despite the biologic plausibility for these associations. In Chapter II, I 
describe the pooled study methods used to achieve my dissertation objectives. Chapter 
III reports my findings for the associations between PUFAs and the risk of developing 
BE (Aim 1), while Chapter IV focuses on the results for the risk of developing EA/GCA 
(Aim 2) and mortality following an EA/GCA diagnosis (Aim 3). In Chapter V, I 
summarize my dissertation results, compare them to the existing literature, address 
both the limitations and strengths of this study, discuss the public health impact, and 
propose potential directions for future research. The significance of this dissertation is 
that the incidence of BE [4,9,58,59] and EA/GCA [4,7,16-21] are increasing among 
Western populations, while the prognosis of EA/GCA is very poor [2-7]. Identifying 
potential modifiable risk factors where a risk reduction strategy may be implemented to 
reduce the disease burden is crucial. My dissertation is innovative and improves upon 
existing research for several reasons. First, it is innovative because I assessed PUFA 
intake more comprehensively by using a variety of measures, rather than focusing on a 
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single measurement. In addition to examining the ω-3 and ω-6 PUFAs intake, I explored 
the ratio as a representation of the relative balance between the two PUFA types. I also 
assessed specific PUFA-rich food items, and was able to consider cooking methods. 
Additionally, this study was the first to examine the associations between PUFAs and 
mortality following a diagnosis of EA/GCA. Finally, by pooling four existing U.S.-based 
studies, I was able to increase study power to facilitate examination of associations with 
these relatively rare outcomes. 
 
Summary of Results and Comparison to Existing Literature 
A summary of the results from my dissertation is shown in Figure 5.1.  
 For Aim 1, higher intake of baked/broiled fish was associated with a 34% 
reduction in risk of developing BE; when stratifying by segment length, this decrease in 
risk appeared to be limited to those with LSBE. Two studies have examined fish intake 
and BE [217,218] and both reported no association. The inconsistencies between my 
findings and these previous studies may be that I was able to differentiate fish (which is 
rich in beneficial ω-3) by cooking methods (such as frying, which often add the 
potentially more detrimental ω-6 in the form of oils [22,205]), whereas the previous 
studies did not. Further assessments by segment length showed that higher intakes of 
ω-3 (OR>Medianvs.≤Median=0.62, 95%CI=0.40-0.96) and of the ω-6 subtype AA 
(OR>Medianvs.≤Median=0.67, 95%CI=0.45-0.99) were associated with a decreased risk of 
LSBE, and null associations with SSBE. One previous study using the Epidemiology 
and Incidence of BE Study (which is included in my pooled study) found that ω-3 was 
associated with a halving of BE risk [107]. This finding is similar to my pooled results for 
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LSBE reported here, and in sensitivity analyses when we restricted our models to the 
Study of Reflux Disease the risk was decreased with a comparable estimate. No 
previous studies have examined BE with ω-6 or any PUFA subtype. 
 For Aim 2, baked/broiled fish was also associated with an approximately 30% 
decreased risk of developing EA and GCA. In contrast, tuna appeared to increase risk 
of EA development (ORT3vs.None=1.46, 95%CI=1.00-2.13), but not with GCA. Similarly 
fried fish was associated with an increased risk with GCA (ORConsumersvs.Non=1.33, 
95%CI=1.06-1.66), but not with EA. Existing studies examining fish intake and EA/GCA 
have found no associations [222,225,227,230]. Similar to what was previously 
mentioned for BE, the inconsistencies between my results and previous reports are 
most likely due to the inability of others to account for fish cooking methods, which may 
mask associations. The risk of developing EA and GCA was increased in association 
with ω-6 intake (ORQ4vs.Q1=2.62, 95%CI=1.73-3.97 and ORQ4vs.Q1=1.45, 95%CI=0.99-
2.13, respectively). However, ω-3 intake was also associated with an increased risk of 
developing EA and GCA (ORQ4vs.Q1=2.58, 95%CI=1.73-3.84 and ORQ4vs.Q1=1.72, 
95%CI=1.18-2.51, respectively). No studies have examined ω-6 with EA/GCA, and the 
one study that assessed the association between ω-3 intake and EA/GCA found no 
associations. This difference may be explained by the parent assessment methods, 
where specific food items that were high contributors to ω-3 intake (such as tuna) were 
grouped with foods that also include high amounts of ω-6 (such as tuna casserole and 
tuna salad). Similarly, at least among the American-based study populations included in 
my pooled study, intake of foods that were high in ω-3 were the same foods that were 
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also high in ω-6 (for example, “beef, veal, lamb, pork” and “mayonnaise or creamy salad 
dressing”).  
Finally, for Aim 3, the ω-6:ω-3 was associated with a 24% decreased risk of EA 
mortality, but was associated with a suggestive 21% increase in risk of GCA mortality 
(particularly among those with BMI<25 who consume a diet with a high ω-6:ω-3). 
Because this was the first study to examine PUFAs with mortality following an EA/GCA 
diagnosis, there are no results for comparison.  
 
Limitations 
One major limitation of my pooled study was that the study populations are 
primarily white and male, which limits generalizability. However BE and EA/GCA 
primarily affect white males and rates of these diseases are highest among this 
demographic group [1,2,123,124,149,256], which allowed my results to be generalizable 
to this group. Additionally, my study pooled data from four studies that were population- 
or community-based, which enhanced generalizability. 
Another major limitation to consider was the dietary assessment method used in 
each of the four parent studies. Patients were asked to recall diet in the year prior to 
study interview using FFQs, with the assumption that intake during this time period can 
be recalled with some accuracy and that it correlates with usual adult diet [295-298]. 
Nonetheless, it is possible that recent onset of clinical symptoms and any corresponding 
changes in diet would influence the accuracy of reporting pre-diagnosis diet among 
cases only. However, dietary recommendations for patients experiencing reflux typically 
only target avoiding food items such as coffee, chocolate, spicy foods, highly acidic 
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foods, or fatty foods, in addition to any other food items that may exacerbate symptoms 
for an individual [315]. But it is important to note that there is no empirical evidence 
showing decrease of reflux symptoms by limiting those foods listed. Additionally, each 
of the parent studies’ FFQs was validated using diet records [268,270,274,275] or 
multiple 24-hour recalls [276,277]. 
As with all pooled studies, there may have been differences in data collection, 
variable definitions, and data management between the parent studies. These 
discrepancies could introduce misclassifications of outcomes, exposures, or covariates. 
However, the four studies were selected because of their high quality and similar data 
collection procedures. Also, several covariates have already been harmonized and 
pooled for BEACON [95,143,154,161,284], which was cost-efficient and also showed 
promise for the harmonization and pooling of the food frequency questionnaire data 
needed to complete this study. Additionally, this concern was alleviated by the study-
exposure interactions and meta-analytic approach I performed as a sensitivity analysis. 
In the EA/GCA cancer parent studies, proxy interviews were conducted with next 
of kin for subjects who were deceased or ill, roughly 30% of all cases used proxy 
interviews. There were no proxy interviews conducted in either of the BE parent studies. 
Although it has been shown that proxy- and self-report are similar [294], the use of 
proxies may have increased the probability of misclassification. However, studies have 
found that self-reported and proxy-reported information have good concordance for 
many of the variables used in this study [294,299-301]. Additionally, for the previous 
EA/GCA studies from BEACON, excluding proxy responses did not substantially 
change the effect estimates [173,227,228,302,303]. 
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The issue of multiple comparisons was considered. For all analyses, the multiple 
measures of PUFAs were used individually to determine associations between PUFAs 
and the BE-EA continuum outcomes. There was a likelihood of observing statistically 
significant results due to chance because of the large number of comparisons in my 
study. I did not adjust for the multiple comparisons for each single association examined 
because it would have reduced statistical power. I assessed each of the associations 
individually based on biologic plausibility, consistency with current research, and 
consistency across the cancer continuum [295,304,305].  
Finally, because diet is a complex exposure, I had to consider other elements 
that could be driving results seen in my study. For example, the highest contributing 
food items to ω-3 intake were not limited to foods known to be high in beneficial fatty 
acids such as fish, but were commonly the same foods also contributing to ω-6. This no 
doubt hindered my ability to detect associations with either ω-3 or ω-6:ω-3 ratio. 
Similarly, the parent study FFQs included a composite assessment of tuna, a fish with 
high levels of ω-3 [24], combining tuna with tuna casserole and tuna salad; the latter 
two are typically prepared with other foods high in ω-6 using contrasting cooking 
methods. Identifying the particular food items that were the most frequently consumed 
sources of PUFAs allowed me to consider if there are other factors that may be 
contributing to the associations observed. 
 
Strengths 
A major strength of this dissertation is the harmonization and pooling of existing 
case-control studies of BE and EA/GCA. This approach was time- and cost-efficient 
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compared to beginning a new field study effort, and was superior to a meta-analytic 
approach because of our uniform definitions for exposures and covariates. The pooled 
sample size was larger than previous case-control studies [107,217,218,221-224,226], 
resulting in increased statistical power to evaluate associations between PUFAs and 
BE-EA/GCA continuum outcomes and allowed for more precise estimates. 
Previous studies examining PUFAS and BE/EA/GCA focused on one outcome 
along the continuum [107,217,221-223,226], this study was the first to examine multiple 
outcomes and more specifically the first to examine mortality following an EA/GCA 
diagnosis. My dissertation was the first to examine all three outcomes, and allowed for 
identification of windows along the disease continuum to implement potential risk 
reduction strategies. 
Another strength of my study was the comprehensive use of multiple measures, 
which allowed me to better capture the complexity of this dietary exposure and helped 
to clarify previous findings. Most existing studies examined fish intake (a major source 
of long-chain ω-3 fatty acids) as the only PUFA measure [217,221-223,225-227,233], 
without examining cooking methods, which can mask potential associations (such as 
with frying, which adds ω-6 fatty acids). I was able to use information on cooking 
method and identify a measure – baked/broiled fish – that was most strongly associated 
with BE/EA/GCA risk, at least among the US populations included in my pooled study. A 
few existing studies considered overall PUFAs [107,218,226], which overlook important 
distinctions between beneficial ω-3 and potentially deleterious ω-6, or examined ω-3 
PUFAs only [107,226]. My study was the first to examine ω-6 PUFAs and the first to 
consider the relative ω-3 and ω-6 balance, which was particularly important because ω-
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3 and ω-6 are competitively inhibited by each other and may promote or suppress 
pathogenesis [8,49,212,216].  
Finally, all four parent studies were conducted in US coastal regions with 
increased opportunity for fish intake (LAC, WA, CT, and NJ); this maximized 
heterogeneity in intake and enhanced my ability to detect differences, since US subjects 
typically consume small amounts of fish [306]. 
 
Public Health Impact 
The incidence of EA/GCA has been increasing, particularly in westernized 
countries, [4,7,16-21], and it is expected to continue to increase over time [2,53,135]. 
The incidence of BE, the only known precursor to these cancers, has also been 
increasing [4,9,58,59]. Many of the major risk factors for these diseases are non-
modifiable, or not easily modifiable. Identification of risk reduction strategies for these 
diseases could have high public health impact, given the poor prognoses of these 
cancers [2-7]. If the results of my dissertation are confirmed, there is a potential to 




Future studies should consider improvements in the following areas: study 
design, study populations, and exposure assessment.  
 The case-control study design that I employed here was time- and cost-efficient 
approach, and allowed for adequate sample sizes for the three main outcomes. 
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However, I had to pool four case-control studies in order to achieve my objectives. 
Future studies could consider a cohort design, which could begin with those initially 
without BE/EA/GCA and examine the three outcomes I examined, as well as the risk of 
EA/GCA among those who develop BE. Additionally, using a single cohort study would 
allow for a priori uniform field procedures for all study participants, which cannot be 
guaranteed in a pooled study. A cohort design would also rule out recall bias as a 
possible reason for my study findings, since usual adult diet could be captured before 
disease onset, and allow for multiple measures of diet with time. 
 Future studies should aim to examine more diverse populations. My study 
population was primarily white and male, which is the group with highest incidence rates 
of these disease in the US. However, in order to enhance generalizability of the 
findings, future studies could expand the racial and gender diversity of the target 
population. The study population used here is a US population that consumes a typical 
westernized diet. In the future, researchers should consider populations with different 
dietary intake distributions, particularly populations that consume greater quantities of 
ω-3s or fish such as Asian or Mediterranean populations.  
 While the exposure measures used in my study are an improvement upon the 
existing literature, future studies can continue to progress on PUFA exposure 
assessment. Because my study was the first to examine the relative balance between 
ω-3 and ω-6, future studies (particularly among those using populations with different 
PUFA intake) should further investigate the ω-6:ω-3 and the interaction between the 
two, specifically to confirm the potential relationships I found between the ω-6:ω-3 and 
EA and GCA mortality. Most importantly, dietary assessment methods used in these 
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future studies should include more detailed assessments of PUFA-rich foods, making 
sure to consider fish type (e.g., marine fish, dark and oily fish, white fish) as well as 
cooking methods or other preparation methods. Finally, if possible future studies should 




My dissertation was the first to comprehensively examine the associations 
between PUFAs and the outcomes along the BE-EA continuum. This was achieved by 
using pooled resources from four population- or community-based case-control studies 
of BE and EA/GCA in the US. Each of the parent studies was a member of BEACON 
and was conducted using similar procedures. In order to better capture the complexity 
of this dietary exposure and to improve upon the inconsistencies of existing research, I 
used a variety of PUFA measures, both nutrient-based and PUFA-rich food items, and 
examined the relative balance between ω-3 and ω-6. I found that higher intake of 
baked/broiled fish was associated with a ~30% reduction in risk of developing 
BE/EA/GCA, while ω-3 and ω-6 intakes were associated with an increased risk of 
EA/GCA. The ω-6:ω-3 was inversely associated with EA mortality, however it was 
positively associated with GCA mortality. If my findings are confirmed, increasing 
baked/broiled fish intake could be a promising risk reduction strategy for the BE and 
EA/GCA and may reduce the burden of these highly lethal cancers. 
 







APPENDIX: ADDITIONAL TABLES 
 
Appendix Table 1. Odds ratios and 95% confidence intervals for associations between 
PUFA measures and development of BE among participants of two US-based case-control 
studies of BE 
 
Measure 
Study of Reflux Disease Epidemiology and Incidence of BE 
OR* (95%CI) OR* (95%CI) 
Tuna   
     None 1.0 1.0 
     T1 0.99 (0.54, 1.80) 0.68 (0.40, 1.17) 
     T2 1.29 (0.72, 2.31) 0.60 (0.33, 1.10) 
     T3 1.16 (0.64, 2.10) 0.71 (0.38, 1.32) 
Fried fish   
     None 1.0 1.0 
     T1 1.10 (0.63, 1.92) 0.95 (0.62, 1.46) 
     T2 1.27 (0.71, 2.26) 1.03 (0.66, 1.60) 
     T3 1.37 (0.69, 2.70) 0.94 (0.56, 1.57) 
Baked/broiled fish   
     None 1.0 1.0 
     T1 0.77 (0.39, 1.51) 0.94 (0.61, 1.45) 
     T2 0.72 (0.38, 1.33) 0.61 (0.36, 1.04) 
     T3 0.78 (0.41, 1.50) 0.57 (0.34, 0.93) 
Shellfish   
     None 1.0 1.0 
     T1 0.89 (0.51, 1.56) 1.20 (0.72, 2.02) 
     T2 0.82 (0.40, 1.67) 0.78 (0.46, 1.33) 
     T3 0.84 (0.48, 1.47) 1.01 (0.61, 1.67) 
ω-3   
     Q1 1.0 1.0 
     Q2 1.18 (0.62, 2.24) 1.06 (0.66, 1.70) 
     Q3 1.28 (0.65, 2.50) 0.68 (0.40, 1.16) 
     Q4 1.68 (0.81, 3.47) 0.58 (0.29, 1.17) 
ALA   
     Q1 1.0 1.0 
     Q2 1.44 (0.77, 2.69) 0.95 (0.60, 1.52) 
     Q3 1.13 (0.56, 2.28) 0.63 (0.37, 1.07) 
     Q4 1.72 (0.81, 3.62) 0.50 (0.25, 1.00) 
EPA   
     Q1 1.0 1.0 
     Q2 1.21 (0.66, 2.22) 0.81 (0.52, 1.28) 
     Q3 1.49 (0.80, 2.76) 0.66 (0.41, 1.07) 
     Q4 1.06 (0.56, 2.02) 0.68 (0.41, 1.14) 




Appendix Table 1 (cont’d). Odds ratios and 95% confidence intervals for associations 
between PUFA measures and development of BE among participants of two US-based case-
control studies of BE 
 
Measure 
Study of Reflux Disease Epidemiology and Incidence of BE 
OR* (95%CI) OR* (95%CI) 
DHA   
     Q1 1.0 1.0 
     Q2 0.78 (0.42, 1.41) 0.89 (0.56, 1.40) 
     Q3 1.25 (0.69, 2.28) 0.91 (0.56, 1.46) 
     Q4 0.97 (0.53, 1.80) 0.67 (0.39, 1.15) 
DPA   
     Q1 1.0 1.0 
     Q2 1.25 (0.68, 2.30) 0.76 (0.48, 1.20) 
     Q3 1.21 (0.65, 2.28) 0.82 (0.51, 1.33) 
     Q4 1.44 (0.76, 2.71) 0.64 (0.37, 1.11) 
ω-6   
     Q1 1.0 1.0 
     Q2 1.34 (0.70, 2.56) 0.71 (0.44, 1.15) 
     Q3 1.82 (0.93, 3.59) 0.71 (0.42, 1.20) 
     Q4 1.75 (0.84, 3.67) 0.39 (0.19, 0.82) 
LA   
     Q1 1.0 1.0 
     Q2 1.32 (0.69, 2.52) 0.70 (0.43, 1.13) 
     Q3 1.87 (0.95, 3.69) 0.68 (0.40, 1.15) 
     Q4 1.76 (0.84, 3.69) 0.39 (0.19, 0.82) 
AA   
     Q1 1.0 1.0 
     Q2 1.11 (0.60, 2.06) 0.99 (0.62, 1.57) 
     Q3 1.31 (0.70, 2.47) 0.67 (0.40, 1.11) 
     Q4 1.45 (0.75, 2.80) 0.87 (0.49, 1.55) 
ω-6:ω-3   
     Q1 1.0 1.0 
     Q2 0.86 (0.47, 1.56) 1.00 (0.62, 1.61) 
     Q3 0.89 (0.49, 1.62) 1.26 (0.79, 2.01) 
     Q4 1.04 (0.58, 1.87) 1.08 (0.66, 1.75) 










Appendix Table 2. Odds ratios and 95% confidence intervals for associations between 
PUFA measures and development of BE among participants of two US-based case-control 








Tuna    
     None 82 80 1.0 
     T1 167 177 0.91 (0.61, 1.35) 
     T2 104 114 0.93 (0.61, 1.42) 
     T3 92 104 0.90 (0.58, 1.39) 
   ptrend=0.81 
Fried fish    
     None 158 181 1.0 
     T1 108 118 1.03 (0.73, 1.46) 
     T2 111 105 1.22 (0.85, 1.73) 
     T3 68 71 1.11 (0.74, 1.69) 
   ptrend=0.91 
Baked/broiled fish   
     None 112 91 1.0 
     T1 146 138 0.89 (0.61, 1.28) 
     T2 93 117 0.67 (0.45, 1.01) 
     T3 94 129 0.66 (0.44, 0.98) 
   ptrend=0.16 
Shellfish    
     None 122 124 1.0 
     T1 121 109 1.09 (0.75, 1.59) 
     T2 69 94 0.74 (0.49, 1.13) 
     T3 133 148 0.93 (0.64, 1.35) 
   ptrend=0.57 
ω-3    
     Q1 112 119 1.0 
     Q2 126 118 1.19 (0.81, 1.75) 
     Q3 103 119 0.99 (0.64, 1.52) 
     Q4 104 119 1.01 (0.61, 1.69) 
   ptrend=0.54 
ALA    
     Q1 116 118 1.0 
     Q2 131 120 1.17 (0.80, 1.71) 
     Q3 92 118 0.81 (0.52, 1.26) 
     Q4 106 119 0.93 (0.56, 1.56) 
   ptrend=0.60 






Appendix Table 2 (cont’d). Odds ratios and 95% confidence intervals for associations 
between PUFA measures and development of BE among participants of two US-based case-








EPA    
     Q1 129 119 1.0 
     Q2 121 119 0.95 (0.66, 1.37) 
     Q3 100 118 0.87 (0.59, 1.28) 
     Q4 95 119 0.84 (0.56, 1.25) 
   ptrend=0.60 
DHA    
     Q1 128 119 1.0 
     Q2 109 119 0.87 (0.60, 1.26) 
     Q3 121 119 1.09 (0.74, 1.58) 
     Q4 87 118 0.80 (0.53, 1.20) 
   ptrend=0.76 
DPA    
     Q1 121 118 1.0 
     Q2 114 119 0.92 (0.63, 1.33) 
     Q3 109 119 0.97 (0.66, 1.44) 
     Q4 101 119 0.94 (0.62, 1.43) 
   ptrend=0.25 
ω-6    
     Q1 116 118 1.0 
     Q2 109 120 0.92 (0.62, 1.36) 
     Q3 129 119 1.15 (0.75, 1.75) 
     Q4 91 118 0.82 (0.49, 1.39) 
   ptrend=0.69 
LA    
     Q1 116 119 1.0 
     Q2 110 118 0.94 (0.64, 1.39) 
     Q3 127 120 1.14 (0.75, 1.74) 
     Q4 92 118 0.84 (0.50, 1.41) 
   ptrend=0.73 












Appendix Table 2 (cont’d). Odds ratios and 95% confidence intervals for associations 
between PUFA measures and development of BE among participants of two US-based case-








AA    
     Q1 108 119 1.0 
     Q2 125 118 1.15 (0.79, 1.68) 
     Q3 99 120 0.93 (0.63, 1.39) 
     Q4 113 118 1.16 (0.75, 1.79) 
   ptrend=0.18 
ω-6:ω-3    
     Q1 110 118 1.0 
     Q2 102 119 0.92 (0.63, 1.34) 
     Q3 126 120 1.15 (0.80, 1.67) 
     Q4 107 118 1.04 (0.71, 1.52) 
   ptrend=0.62 





Appendix Table 3. Odds ratios and 95% confidence intervals for associations between 
PUFA measures and development of BE among participants of two US-based case-control 







OR* (95%CI) I2 (%) pheterogeneity 
Tuna      
     None 89 85 1.0   
     T1 174 183 0.80 (0.54, 1.19)   
     T2 105 117 0.86 (0.57, 1.30)   
     T3 103 107 0.90 (0.59, 1.37) 0 0.50 
Fried fish      
     None 169 186 1.0   
     T1 115 122 0.99 (0.71, 1.39)   
     T2 113 109 1.11 (0.78, 1.57)   
     T3 74 75 1.07 (0.71, 1.61) 0 0.96 
Baked/broiled fish      
     None 189 98 1.0   
     T1 85 140 0.91 (0.63, 1.30)   
     T2 98 121 0.69 (0.46, 1.03)   
     T3 99 133 0.66 (0.45, 0.98) 0 0.65 
Shellfish      
     None 131 129 1.0   
     T1 123 113 1.06 (0.73, 1.54)   
     T2 76 97 0.82 (0.53, 1.25)   
     T3 141 153 0.95 (0.65, 1.37) 0 0.91 
ω-3      
     Q1 121 123 1.0   
     Q2 129 122 1.13 (0.78, 1.65)   
     Q3 106 124 0.87 (0.58, 1.32)   
     Q4 115 123 0.98 (0.59, 1.62) 37.7 0.16 
ALA      
     Q1 124 123 1.0   
     Q2 134 124 1.11 (0.79, 2.72)   
     Q3 100 123 0.94 (0.59, 1.51)   
     Q4 113 122 0.89 (0.53, 1.47) 50.1 0.07 
EPA      
     Q1 136 124 1.0   
     Q2 126 123 0.96 (0.67, 1.37)   
     Q3 110 122 0.89 (0.61, 1.29)   
     Q4 99 123 0.79 (0.53, 1.18) 20.7 0.28 
DHA      
     Q1 136 124 1.0   
     Q2 115 122 0.85 (0.59, 1.23)   
     Q3 125 123 1.00 (0.69, 1.45)   
     Q4 95 123 0.77 (0.51, 1.15) 0 0.80 
* Model adjusted for age, sex, education, caloric intake, and study indicator 
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Appendix Table 3 (cont’d). Odds ratios and 95% confidence intervals for associations 
between PUFA measures and development of BE among participants of two US-based case-







OR* (95%CI) I2 (%) pheterogeneity 
DPA      
     Q1 129 123 1.0   
     Q2 119 122 0.94 (0.66, 1.36)   
     Q3 116 123 0.96 (0.66, 1.41)   
     Q4 107 124 0.90 (0.75, 1.17) 28.3 0.22 
ω-6      
     Q1 123 123 1.0   
     Q2 114 123 0.92 (0.63, 1.36)   
     Q3 131 124 1.01 (0.67, 1.52)   
     Q4 103 122 0.84 (0.50, 1.41) 70.0 0.005 
LA      
     Q1 123 122 1.0   
     Q2 115 124 0.92 (0.63, 1.35)   
     Q3 129 124 0.98 (0.65, 1.48)   
     Q4 104 122 0.84 (0.50, 1.41) 71.0 0.004 
AA      
     Q1 117 122 1.0   
     Q2 127 124 1.05 (0.72, 1.52)   
     Q3 104 123 0.88 (0.59, 1.30)   
     Q4 123 123 1.07 (0.70, 1.65) 9.8 0.35 
ω-6:ω-3      
     Q1 117 124 1.0   
     Q2 108 122 0.93 (0.64, 1.35)   
     Q3 130 124 1.06 (0.74, 1.53)   
     Q4 116 122 1.03 (0.71, 1.50) 0 0.95 















Appendix Table 4. Comparison of cutpoints for quantiles based on control intake between 
study-specific and absolute value-based quantiles for assessing associations between 
PUFAs and development of BE 
 
Measure 
Study of Reflux  
Disease  
Quantiles 
Epidemiology and  
Incidence of BE 
Quantiles 
Pooled Absolute  
Value-Based 
Quantiles 
Tuna (g/day)    
     None 0 0 0 
     T1 0.01 – <3.94 0.01 – <3.37 0.01 – <3.37 
     T2 3.94 – <8.66 3.37 – <8.42 3.37 – <8.42 
     T3 ≥8.66 ≥8.42 ≥8.42 
Fried fish (g/day)    
     None 0 0 0 
     T1 0.01 – <4.10 0.01 – <1.48 0.01 – <2.96 
     T2 4.10 – <9.56 1.48 – <5.92 2.96 – <6.15 
     T3 ≥9.56 ≥5.92 ≥6.15 
Baked/broiled fish (g/day)   
     None 0 0 0 
     T1 0.01 – <5.59 0.01 – <2.96 0.01 – <3.70 
     T2 5.59 – <12.12 2.96 – <11.84 3.70 – <12.12 
     T3 ≥12.12 ≥11.84 ≥12.12 
Shellfish (g/day)    
     None 0 0 0 
     T1 0.01 – <2.41 0.01 – <2.23 0.01 – <2.41 
     T2 2.41 – <5.62 2.23 – <4.47 2.41 – <5.59 




     Q1 <1.42 <1.13 <1.25 
     Q2 1.42 – <2.44 1.13 – <1.64 1.25 – <1.82 
     Q3 2.44 – <4.02 1.64 – <2.27 1.82 – <2.84 
     Q4 ≥4.02 ≥2.27 ≥2.84 
ALA (g/day)    
     Q1 <1.21 <1.06 <1.12 
     Q2 1.21 – <2.12 1.06 – <1.55 1.12 – <1.67  
     Q3 2.12 – <3.53 1.55 – <2.11 1.67 – <2.45 
     Q4 ≥3.53 ≥2.11 ≥2.45 
EPA (g/day)    
     Q1 <0.027 <0.010 <0.013 
     Q2 0.027 – <0.065 0.010 – <0.018 0.013 – <0.027 
     Q3 0.065 – <0.132 0.018 – <0.035 0.027 – <0.065 




Appendix Table 4 (cont’d). Comparison of cutpoints for quantiles based on control intake 
between study-specific and absolute value-based quantiles for assessing associations 
between PUFAs and development of BE 
 
Measure 
Study of Reflux  
Disease 
Quantiles 
Epidemiology and  
Incidence of BE 
Quantiles 






     Q1 <0.064 <0.030 <0.036 
     Q2 0.064 – <0.149 0.030 – <0.051 0.036 – <0.073 
     Q3 0.149 – <0.354 0.051 – <0.098 0.073 – <0.165 




     Q1 <0.031 <0.008 <0.010 
     Q2 0.031 – <0.095 0.008 – <0.012 0.010 – <0.021 
     Q3 0.095 – <0.220 0.012 – <0.024 0.021 – <0.067 




     Q1 <11.17 <9.35 <9.94 
     Q2 11.17 – <20.36 9.35 – <13.84 9.94 – <15.84 
     Q3 20.36 – <37.76 13.84 – <20.53 15.84 – <25.88 




     Q1 <10.96 <9.24 <9.87 
     Q2 10.96 – <19.98 9.24 – <13.71 9.87 – <15.59 
     Q3 19.98 – <36.41 13.71 – <20.38 15.59 – <25.28 




     Q1 <0.152 <0.055 <0.067 
     Q2 0.152 – <0.531 0.055 – <0.088 0.067 – <0.124 
     Q3 0.531 – <1.206 0.088 – <0.133 0.124 – <0.357 




     Q1 <7.50 <7.18  <7.28 
     Q2 7.50 – <8.53 7.18 – <8.27 7.28 – <8.37 
     Q3 8.53 – <9.98 8.27 – <10.04 8.37 – <10.04 





Appendix Table 5. Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of developing 
EA/GCA among participants of two US-based case-control studies of EA/GCA 
 
Measure 









Tuna     
     None 1.0 1.0 1.0 1.0 
     T1 1.06 (0.55, 2.05) 0.77 (0.42, 1.42) 1.87 (1.20, 2.89) 0.97 (0.65, 1.45) 
     T2 1.75 (1.03, 2.99) 1.05 (0.65, 1.71) 1.24 (0.79, 1.94) 0.88 (0.59, 1.31) 
     T3 1.97 (1.04, 3.71) 1.23 (0.68, 2.22) 1.09 (0.68, 1.74) 0.73 (0.48, 1.11) 
Fried fish     
     Non- 
     consumers 
1.0 1.0 1.0 1.0 
     Consumers 0.99 (0.72, 1.38) 1.35 (0.96, 1.89) 0.98 (0.70, 1.37) 1.32 (0.97, 1.78) 
Baked/broiled fish     
     None 1.0 1.0 1.0 1.0 
     T1 1.10 (0.64, 1.89) 0.86 (0.49, 1.50) 0.85 (0.54, 1.33) 0.67 (0.44, 1.00) 
     T2 0.93 (0.62, 1.41) 0.86 (0.57, 1.29) 1.11 (0.73, 1.71) 0.53 (0.34, 0.82) 
     T3 0.51 (0.23, 1.13) 0.72 (0.35, 1.47) 0.73 (0.46, 1.16) 0.65 (0.43, 0.98) 
Shellfish     
     Non- 
     consumers 
1.0 1.0 1.0 1.0 
     Consumers 1.01 (0.72, 1.43) 0.93 (0.65, 1.31) 1.38 (0.99, 1.90) 1.33 (0.99, 1.80) 
ω-3     
     Q1 1.0 1.0 1.0 1.0 
     Q2 2.42 (1.47, 3.99) 1.53 (0.94, 2.49) 1.44 (0.87, 2.39) 1.15 (0.74, 1.78) 
     Q3 1.97 (1.16, 3.34) 1.08 (0.63, 1.83) 1.46 (0.86, 2.47) 1.23 (0.78, 1.95) 
     Q4 2.97 (1.74, 5.09) 2.40 (1.43, 4.03) 1.95 (1.07, 3.55) 0.88 (0.50, 1.55) 









Appendix Table 5 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 
developing EA/GCA among participants of two US-based case-control studies of EA/GCA 
 
Measure 









ALA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 2.44 (1.45, 4.09) 1.71 (1.04, 2.80) 1.62 (0.97, 2.70) 0.89 (0.57, 1.41) 
     Q3 2.60 (1.52, 4.43) 1.14 (0.67, 1.95) 1.53 (0.90, 2.61) 1.39 (0.89, 2.18) 
     Q4 3.48 (1.96, 6.17) 2.65 (1.53, 4.57) 2.06 (1.12, 3.77) 0.85 (0.48, 1.50) 
EPA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 1.18 (0.76, 1.85) 0.90 (0.58, 1.41) 1.02 (0.66, 1.58) 0.98 (0.66, 1.46) 
     Q3 1.47 (0.94, 2.30) 0.95 (0.60, 1.49) 0.78 (0.49, 1.26) 0.72 (0.47, 1.11) 
     Q4 1.26 (0.80, 2.00) 1.16 (0.74, 1.80) 1.11 (0.69, 1.77) 0.86 (0.55, 1.33) 
DHA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.90 (0.58, 1.41) 0.84 (0.54, 1.31) 0.67 (0.43, 1.05) 0.85 (0.57, 1.27) 
     Q3 1.34 (0.87, 2.06) 0.95 (0.61, 1.48) 0.93 (0.60, 1.43) 0.85 (0.57, 1.28) 
     Q4 1.09 (0.70, 1.72) 1.09 (0.70, 1.70) 0.67 (0.42, 1.08) 0.67 (0.43, 1.05) 
DPA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 1.89 (1.19, 3.00) 1.11 (0.70, 1.75) 0.89 (0.54, 1.45) 1.10 (0.72, 1.70) 
     Q3 1.92 (1.21, 3.04) 1.18 (0.76, 1.86) 1.61 (1.02, 1.55) 1.35 (0.88, 2.07) 
     Q4 1.71 (1.06, 2.75) 1.27 (0.80, 1.99) 1.12 (0.66, 1.90) 1.08 (0.66, 1.76) 
ω-6     
     Q1 1.0 1.0 1.0 1.0 
     Q2 2.27 (1.37, 3.75) 1.32 (0.82, 2.14) 1.65 (0.99, 2.75) 0.90 (0.58, 1.39) 
     Q3 2.37 (1.39, 4.04) 1.14 (0.68, 1.91) 1.47 (0.85, 2.55) 1.01 (0.64, 1.60) 
     Q4 2.81 (1.63, 4.82) 1.81 (1.08, 3.03) 2.15 (1.13, 4.11) 0.97 (0.54, 1.74) 







Appendix Table 5 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 
developing EA/GCA among participants of two US-based case-control studies of EA/GCA 
 
Measure 









LA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 2.19 (1.33, 3.61) 1.35 (0.84, 2.18) 1.66 (0.99, 2.77) 0.92 (0.59, 1.42) 
     Q3 2.13 (1.25, 3.62) 1.04 (0.61, 1.75) 1.46 (0.85, 2.53) 0.98 (0.62, 1.56) 
     Q4 2.69 (1.56, 4.62) 1.77 (1.05, 2.97) 2.18 (1.14, 4.15) 0.97 (0.54, 1.74) 
AA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 1.90 (1.18, 3.06) 0.77 (0.48, 1.23) 1.35 (0.83, 2.22) 1.48 (0.95, 2.32) 
     Q3 1.39 (0.85, 2.26) 0.84 (0.53, 1.34) 1.67 (1.02, 2.74) 1.79 (1.14, 2.83) 
     Q4 2.11 (1.32, 3.40) 1.21 (0.78, 1.89) 2.03 (1.14, 3.64) 2.03 (1.18, 3.50) 
ω-6:ω-3     
     Q1 1.0 1.0 1.0 1.0 
     Q2 1.12 (0.73, 1.74) 1.41 (0.87, 2.26) 0.91 (0.58, 1.43) 1.32 (0.88, 1.98) 
     Q3 1.00 (0.64, 1.56) 1.36 (0.86, 2.13) 0.88 (0.56, 1.38) 1.17 (0.77, 1.78) 
     Q4 0.94 (0.60, 1.47) 1.08 (0.67, 1.73) 1.03 (0.66, 1.59) 1.07 (0.69, 1.64) 



















Appendix Table 6. Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of developing 












Tuna      
     None 504 77 1.0 124 1.0 
     T1 493 141 1.53 (1.07, 2.17) 120 0.86 (0.63, 1.19) 
     T2 490 143 1.68 (1.18, 2.38) 143 1.05 (0.77, 1.44) 
     T3 540 138 1.41 (0.99, 2.01) 141 0.89 (0.65, 1.22) 
Fried fish      
     Non- 
     consumers 
1086 268 1.0 251 1.0 
     Consumers 941 231 1.00 (0.80, 1.26) 277 1.22 (1.06, 1.66) 
Baked/broiled fish     
     None 662 151 1.0 194 1.0 
     T1 450 116 0.92 (0.67, 1.27) 122 0.74 (0.55, 1.00) 
     T2 548 175 1.14 (0.84, 1.53) 141 0.73 (0.54, 0.97) 
     T3 367 57 0.73 (0.40, 1.08) 71 0.68 (0.48, 0.97) 
Shellfish      
     Non- 
     consumers 
966 203 1.0 229 1.0 
     Consumers 1061 296 1.22 (0.96, 1.55) 299 1.13 (0.90, 1.43) 
ω-3      
     Q1 507 84 1.0 110 1.0 
     Q2 507 124 1.61 (1.13, 2.28) 125 1.17 (0.84, 1.61) 
     Q3 506 130 1.78 (1.24, 2.55) 139 1.34 (0.96, 1.87) 
     Q4 507 161 2.29 (1.55, 3.38) 154 1.46 (1.00, 2.12) 
* Model adjusted for age, sex, race, education, proxy status, caloric intake, study indicator, and number of FFQ items for each  







Appendix Table 6 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 













ALA      
     Q1 506 83 1.0 102 1.0 
     Q2 508 121 1.64 (1.15, 2.33) 124 1.29 (0.93, 1.79) 
     Q3 506 139 1.91 (1.33, 2.74) 153 1.55 (1.10, 2.17) 
     Q4 507 156 2.47 (1.66, 3.69) 149 1.61 (1.09, 2.37) 
EPA      
     Q1 506 104 1.0 132 1.0 
     Q2 508 123 1.13 (0.81, 1.58) 130 0.92 (0.68, 1.26) 
     Q3 507 144 1.38 (0.99, 1.92) 132 0.95 (0.70, 1.30) 
     Q4 506 128 1.22 (0.86, 1.72) 134 1.00 (0.73, 1.38) 
DHA      
     Q1 507 122 1.0 141 1.0 
     Q2 507 109 0.93 (0.67, 1.29) 124 0.87 (0.64, 1.18) 
     Q3 507 133 1.29 (0.94, 1.77) 131 1.01 (0.74, 1.37) 
     Q4 506 135 1.07 (0.77, 1.49) 132 0.91 (0.66, 1.24) 
DPA      
     Q1 506 77 1.0 104 1.0 
     Q2 507 98 1.14 (0.79, 1.65) 112 0.98 (0.70, 1.37) 
     Q3 508 137 1.43 (0.99, 2.06) 148 1.17 (0.84, 1.64) 
     Q4 506 187 1.51 (1.02, 2.25) 164 1.10 (0.75, 1.59) 
ω-6      
     Q1 507 59 1.0 94 1.0 
     Q2 507 123 2.14 (1.46, 3.14) 123 1.30 (0.93, 1.82) 
     Q3 507 139 2.22 (1.49, 3.32) 140 1.26 (0.88, 1.80) 
     Q4 506 178 2.87 (1.86, 4.43) 171 1.59 (1.07, 2.38) 
* Model adjusted for age, sex, race, education, proxy status, caloric intake, study indicator, and number of FFQ items for each  






Appendix Table 6 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 













LA      
     Q1 507 59 1.0 94 1.0 
     Q2 506 124 2.14 (1.45, 3.14) 123 1.29 (0.92, 1.81) 
     Q3 507 139 2.25 (1.51, 3.36) 140 1.28 (0.89, 1.83) 
     Q4 507 177 2.89 (1.87, 4.47) 171 1.62 (1.08, 2.41) 
AA      
     Q1 507 68 1.0 96 1.0 
     Q2 507 107 1.79 (1.23, 2.60) 123 1.35 (0.97, 1.89) 
     Q3 507 129 1.96 (1.33, 2.89) 129 1.25 (0.88, 1.79) 
     Q4 506 195 2.23 (1.49, 3.34) 180 1.50 (1.03, 2.19) 
ω-6:ω-3      
     Q1 505 79 1.0 124 1.0 
     Q2 492 139 0.84 (0.58, 1.21) 120 1.07 (0.77, 1.50) 
     Q3 490 143 1.06 (0.74, 1.52) 143 1.17 (0.83, 1.64) 
     Q4 540 138 1.06 (0.72, 1.56) 141 1.04 (0.71, 1.50) 
* Model adjusted for age, sex, race, education, proxy status, caloric intake, study indicator, and number of FFQ items for each  

















Appendix Table 7. Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of developing 












Tuna      
     None 504 54 1.0 86 1.0 
     T1 386 64 1.41 (0.94, 2.12) 69 0.97 (0.68, 1.38) 
     T2 714 160 1.53 (1.06, 2.19) 159 1.00 (0.73, 1.37) 
     T3 423 69 1.51 (1.01, 2.25) 64 0.84 (0.59, 1.21) 
   ptrend=0.84  ptrend=0.91 
Fried fish      
     Non- 
     consumers 
1086 178 1.0 163 1.0 
     Consumers 941 169 0.94 (0.74, 1.21) 215 1.41 (1.11, 1.78) 
      
Baked/broiled fish      
     None 662 105 1.0 130 1.0 
     T1 352 56 0.97 (0.67, 1.40) 58 0.75 (0.52, 1.06) 
     T2 688 156 1.03 (0.76, 1.41) 145 0.75 (0.56, 1.00) 
     T3 325 30 0.65 (0.41, 1.02) 45 0.71 (0.48, 1.03) 
   ptrend=0.30  ptrend=0.44 
Shellfish      
     Non- 
     consumers 
966 137 1.0 159 1.0 
     Consumers 1061 210 1.23 (0.95, 1.59) 219 1.13 (0.88, 1.44) 
ω-3      
     Q1 507 51 1.0 72 1.0 
     Q2 507 97 2.02 (1.37, 2.97) 97 1.37 (0.97, 1.95) 
     Q3 507 85 1.88 (1.25, 2.83) 90 1.34 (0.93, 1.94) 
     Q4 506 114 2.58 (1.67, 3.98) 119 1.72 (1.15, 2.56) 
   ptrend=0.01  ptrend=0.21 






Appendix Table 7 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 












ALA      
     Q1 507 49 1.0 70 1.0 
     Q2 506 92 1.96 (1.32, 2.90) 89 1.27 (0.89, 1.82) 
     Q3 508 91 2.07 (1.38, 3.11) 101 1.54 (1.07, 2.21) 
     Q4 506 115 2.71 (1.74, 4.23) 118 1.74 (1.16, 2.62) 
   ptrend=0.01  ptrend=0.32 
EPA      
     Q1 507 80 1.0 100 1.0 
     Q2 507 87 1.13 (0.80, 1.59) 100 0.97 (0.71, 1.33) 
     Q3 507 94 1.24 (0.88, 1.76) 81 0.80 (0.57, 1.12) 
     Q4 506 86 1.24 (0.87, 1.77) 97 0.99 (0.71, 1.37) 
   ptrend=0.38  ptrend=0.07 
DHA      
     Q1 507 93 1.0 103 1.0 
     Q2 507 75 0.82 (0.58, 1.16) 93 0.89 (0.65, 1.22) 
     Q3 507 105 1.24 (0.90, 1.73) 92 0.94 (0.68, 1.30) 
     Q4 506 74 0.89 (0.62, 1.27) 90 0.89 (0.64, 1.24) 
   ptrend=0.55  ptrend=0.21 
DPA      
     Q1 507 61 1.0 86 1.0 
     Q2 507 91 1.56 (1.08, 2.24) 90 1.05 (0.75, 1.47) 
     Q3 507 111 1.94 (1.35, 2.78) 105 1.21 (0.87, 1.68) 
     Q4 506 84 1.47 (0.99, 2.17) 97 1.14 (0.80, 1.62) 
   ptrend=0.07  ptrend=0.04 








Appendix Table 7 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 












ω-6      
     Q1 507 47 1.0 79 1.0 
     Q2 507 103 2.13 (1.44, 3.15) 86 1.06 (0.75, 1.50) 
     Q3 507 85 1.96 (1.29, 2.99) 100 1.24 (0.86, 1.77) 
     Q4 506 112 2.71 (1.73, 4.24) 113 1.41 (0.94, 2.12) 
   ptrend=0.01  ptrend=0.04 
LA      
     Q1 506 48 1.0 79 1.0 
     Q2 508 103 2.06 (1.40, 3.05) 90 1.10 (0.78, 1.55) 
     Q3 507 83 1.86 (1.22, 2.82) 96 1.17 (0.81, 1.68) 
     Q4 506 113 2.67 (1.71, 4.18) 113 1.39 (0.93, 2.09) 
   ptrend=0.01  ptrend=0.05 
AA      
     Q1 506 55 1.0 81 1.0 
     Q2 507 103 1.87 (1.29, 2.71) 86 1.03 (0.73, 1.45) 
     Q3 508 84 1.60 (1.09, 2.36) 98 1.26 (0.89, 1.77) 
     Q4 506 105 2.12 (1.42, 3.16) 113 1.52 (1.06, 2.19) 
   ptrend=0.02  ptrend=0.01 
ω-6:ω-3      
     Q1 507 87 1.0 81 1.0 
     Q2 506 87 0.98 (0.70, 1.37) 116 1.45 (1.05, 2.00) 
     Q3 507 85 0.95 (0.68, 1.33) 100 1.20 (0.86, 1.67) 
     Q4 507 88 1.02 (0.73, 1.42) 81 1.04 (0.74, 1.46) 
   ptrend=0.68  ptrend=0.93 








Appendix Table 8. Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of developing 












Tuna      
     None 482 74 1.0 119 1.0 
     T1 364 91 1.51 (1.03, 2.22) 88 0.93 (0.66, 1.31) 
     T2 688 226 1.56 (1.11, 2.19) 208 0.98 (0.73, 1.33) 
     T3 406 92 1.41 (0.96, 2.06) 92 0.88 (0.63, 1.25) 
   ptrend=0.79  ptrend=0.88 
Fried fish      
     Non- 
     consumers 
1041 255 1.0 242 1.0 
     Consumers 899 228 1.10 (0.80, 1.28) 265 1.31 (1.05, 1.65) 
      
Baked/broiled fish      
     None 621 144 1.0 185 1.0 
     T1 342 77 0.99 (0.70, 1.41) 76 0.69 (0.49, 0.96) 
     T2 656 215 1.02 (0.76, 1.38) 185 0.72 (0.54, 0.95) 
     T3 321 47 0.65 (0.43, 0.99) 61 0.65 (0.45, 0.94) 
   ptrend=0.26  ptrend=0.30 
Shellfish      
     Non- 
     consumers 
932 197 1.0 222 1.0 
     Consumers 1008 286 1.20 (0.94, 1.53) 285 1.13 (0.89, 1.43) 











Appendix Table 8 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 
developing EA and GCA among participants of two US-based case-control studies of EA/GCA, using caloric exclusions of the 











ω-3      
     Q1 485 70 1.0 101 1.0 
     Q2 485 122 2.05 (1.42, 2.96) 123 1.44 (1.03, 2.00) 
     Q3 486 125 1.88 (1.28, 2.77) 131 1.44 (1.01, 2.04) 
     Q4 484 166 2.52 (1.68, 3.80) 152 1.76 (1.20, 2.58) 
   ptrend=0.01  ptrend=0.39 
ALA      
     Q1 486 65 1.0 95 1.0 
     Q2 484 121 1.99 (1.37, 2.90) 120 1.38 (0.98, 1.94) 
     Q3 486 131 2.02 (1.37, 2.98) 141 1.61 (1.13, 2.29) 
     Q4 484 166 2.60 (1.71, 3.96) 151 1.78 (1.20, 2.64) 
   ptrend=0.01  ptrend=0.49 
EPA      
     Q1 486 116 1.0 138 1.0 
     Q2 484 122 1.01 (0.73, 1.40) 137 0.95 (0.70, 1.29) 
     Q3 485 126 1.12 (0.81, 1.55) 114 0.86 (0.63, 1.19) 
     Q4 485 119 1.12 (0.80, 1.57) 118 0.94 (0.68, 1.29) 
   ptrend=0.36  ptrend=0.17 
DHA      
     Q1 485 132 1.0 145 1.0 
     Q2 485 103 0.81 (0.58, 1.12) 126 0.88 (0.65, 1.20) 
     Q3 486 136 1.15 (0.84, 1.58) 127 0.99 (0.73, 1.34) 
     Q4 484 112 0.91 (0.65, 1.27) 109 0.80 (0.58, 1.11) 
   ptrend=0.64  ptrend=0.37 







Appendix Table 8 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 
developing EA and GCA among participants of two US-based case-control studies of EA/GCA, using caloric exclusions of the 











DPA      
     Q1 485 93 1.0 122 1.0 
     Q2 485 121 1.43 (1.01, 2.01) 123 1.12 (0.82, 1.54) 
     Q3 485 143 1.80 (1.29, 2.53) 137 1.31 (0.95, 1.80) 
     Q4 485 126 1.39 (0.97, 2.00) 125 1.12 (0.80, 1.58) 
   ptrend=0.08  ptrend=0.15 
ω-6      
     Q1 484 61 1.0 105 1.0 
     Q2 487 128 2.12 (1.46, 3.10) 122 1.23 (0.89, 1.71) 
     Q3 483 136 2.19 (1.47, 3.26) 130 1.23 (0.86, 1.75) 
     Q4 486 158 2.63 (1.71, 4.05) 150 1.53 (1.03, 2.27) 
   ptrend=0.01  ptrend=0.17 
LA      
     Q1 486 63 1.0 104 1.0 
     Q2 483 130 2.12 (1.46, 3.08) 123 1.28 (0.92, 1.78) 
     Q3 486 129 2.02 (1.36, 3.00) 130 1.25 (0.88, 1.78) 
     Q4 485 161 2.66 (1.74, 4.07) 150 1.59 (1.07, 2.36) 
   ptrend=0.01  ptrend=0.18 
AA      
     Q1 485 81 1.0 117 1.0 
     Q2 484 132 1.76 (1.24, 2.50) 112 1.03 (0.74, 1.43) 
     Q3 487 123 1.57 (1.10, 2.25) 135 1.27 (0.92, 1.76) 
     Q4 484 147 1.99 (1.37, 2.90) 143 1.47 (1.04, 2.08) 
   ptrend=0.02  ptrend=0.06 








Appendix Table 8 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 
developing EA and GCA among participants of two US-based case-control studies of EA/GCA, using caloric exclusions of the 











ω-6:ω-3      
     Q1 485 121 1.0 112 1.0 
     Q2 486 120 1.07 (0.77, 1.47) 142 1.40 (1.03, 1.91) 
     Q3 483 120 0.93 (0.67, 1.29) 138 1.18 (0.86, 1.62) 
     Q4 486 122 1.05 (0.76, 1.45) 115 1.08 (0.78, 1.49) 
   ptrend=0.61  ptrend=0.94 










Appendix Table 9. Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of developing 









OR* (95%CI) I2 (%) pheterogeneity 
Cases 
N=528 
OR* (95%CI) I2 (%) pheterogeneity 
Tuna          
     None 504 77 1.0   124 1.0   
     T1 386 96 1.57 (1.09, 2.26)   90 0.90 (0.64, 1.26)   
     T2 714 231 1.43 (1.01, 2.02)   216 0.94 (0.70, 1.28)   
     T3 423 95 1.34 (0.92, 1.95) 8.0 0.37 98 0.86 (0.62, 1.22) 0 0.73 
Fried fish          
     Non- 
     consumers 
1086 268 1.0   251 1.0   
     Consumers 941 231 0.99 (0.78, 1.25) 0 0.96 277 1.33 (1.06, 1.67) 0 0.92 
Baked/broiled fish         
     None 662 151 1.0   194 1.0   
     T1 352 79 0.95 (0.67, 1.34)   79 0.73 (0.52, 1.01)   
     T2 688 222 1.02 (0.76, 1.37)   191 0.68 (0.51, 0.92)   
     T3 325 47 0.66 (0.44, 0.99) 0 0.50 64 0.67 (0.46, 0.95) 0 0.66 
Shellfish          
     Non- 
     consumers 
966 203 1.0   229 1.0   
     Consumers 1061 296 1.19 (0.94, 1.51) 37.3 0.21 299 1.14 (0.91, 1.43) 58.7 0.12 
ω-3          
     Q1 507 75 1.0   101 1.0   
     Q2 507 126 1.87 (1.31, 2.67)   128 1.31 (0.94, 1.81)   
     Q3 507 131 1.69 (1.17, 2.46)   134 1.16 (0.82, 1.65)   
     Q4 506 167 2.46 (1.65, 3.68) 11.2 0.34 165 1.53 (1.04, 2.24) 41.2 0.13 









Appendix Table 9 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 









OR* (95%CI) I2 (%) pheterogeneity 
Cases 
N=528 
OR* (95%CI) I2 (%) pheterogeneity 
ALA          
     Q1 507 68 1.0   99 1.0   
     Q2 506 125 1.98 (1.37, 2.85)   121 1.20 (0.86, 1.68)   
     Q3 508 141 1.99 (1.37, 2.91)   143 1.28 (0.91, 1.81)   
     Q4 506 165 2.71 (1.79, 4.12) 19.1 0.29 165 1.53 (1.03, 2.27) 60.8 0.03 
EPA          
     Q1 507 117 1.0   139 1.0   
     Q2 507 132 1.10 (0.80, 1.50)   140 0.94 (0.70, 1.27)   
     Q3 507 127 1.09 (0.79, 1.52)   120 0.82 (0.60, 1.12)   
     Q4 506 123 1.18 (0.85, 1.65) 0 0.53 129 0.99 (0.73, 1.36) 0 0.78 
DHA          
     Q1 507 136 1.0   147 1.0   
     Q2 507 108 0.78 (0.57, 1.07)   129 0.85 (0.63, 1.14)   
     Q3 507 142 1.11 (0.82, 1.51)   129 0.89 (0.66, 1.21)   
     Q4 506 113 0.87 (0.63, 1.20) 29.5 0.21 123 0.86 (0.63, 1.17) 0 0.77 
DPA          
     Q1 507 99 1.0   122 1.0   
     Q2 507 121 1.32 (0.94, 1.85)   129 1.11 (0.81, 1.51)   
     Q3 507 149 1.66 (1.37, 2.01)   140 1.27 (0.93, 1.73)   
     Q4 506 130 1.41 (0.99, 2.01) 39.0 0.15 137 1.17 (0.84, 1.64) 0 0.98 
ω-6          
     Q1 507 68 1.0   107 1.0   
     Q2 507 132 1.94 (1.35, 2.78)   122 1.07 (0.77, 1.48)   
     Q3 507 137 1.88 (1.28, 2.75)   137 1.06 (0.75, 1.50)   
     Q4 506 162 2.51 (1.66, 3.81) 0 0.57 162 1.38 (0.94, 2.03) 3.4 0.40 







Appendix Table 9 (cont’d). Odds ratios and 95% confidence intervals for associations between PUFA measures and risk of 









OR* (95%CI) I2 (%) pheterogeneity 
Cases 
N=528 
OR* (95%CI) I2 (%) pheterogeneity 
LA          
     Q1 506 69 1.0   107 1.0   
     Q2 508 134 1.91 (1.34, 2.74)   126 1.09 (0.79, 1.51)   
     Q3 507 134 1.77 (1.21, 2.60)   133 1.01 (0.71, 1.42)   
     Q4 506 162 2.46 (1.63, 3.73) 0 0.68 162 1.36 (0.92, 2.00) 0 0.42 
AA          
     Q1 506 86 1.0   113 1.0   
     Q2 507 132 1.61 (1.14, 2.27)   121 1.09 (0.54, 2.16)   
     Q3 508 127 1.52 (1.07, 2.15)   139 1.23 (0.89, 1.71)   
     Q4 506 154 2.08 (1.44, 3.00) 0 0.72 155 1.49 (1.06, 2.10) 61.3 0.02 
ω-6:ω-3          
     Q1 507 129 1.0   116 1.0   
     Q2 506 120 1.01 (0.74, 1.39)   148 1.35 (0.99, 1.85)   
     Q3 507 125 0.94 (0.69, 1.29)   144 1.25 (0.92, 1.70)   
     Q4 507 125 0.98 (0.72, 1.34) 0 0.98 120 1.07 (0.78, 1.47) 0 0.93 


















Appendix Table 10. Comparison of cutpoints for quantiles between study-specific and 
absolute value-based quantiles for assessing associations between PUFAs and risk of 
developing EA and GCA in two US-based case-control studies 
 
Measure 






Pooled Absolute  
Value-Based 
Quantiles 
Tuna (g/day)    
     None 0 0 0 
     T1 0.01 – <3.45 0.01 – <5.59 0.01 – <5.59 
     T2 3.45 – <14.93 5.59 – <14.91 5.59 – <14.91 
     T3 ≥14.93 ≥14.91 ≥14.91 
Fried fish* (g/day)    
     Non-consumers 0 0 0 
     Consumers 8.61 (9.99) 12.81 (12.92) 11.04 (11.95) 
Baked/broiled fish (g/day)   
     None 0 0 0 
     T1 0.01 – <3.61 0.01 – <7.46 0.01 – <7.21 
     T2 3.61 – <15.63 7.46 – <18.64 7.21 – <15.63 
     T3 ≥15.63 ≥18.64 ≥15.63 
Shellfish* (g/day)    
     Non-consumers 0 0 0 
     Consumers 3.75 (4.41) 9.74 (10.65) 6.93 (8.85) 
ω-3 (g/day)    
     Q1 <1.41 <1.59 <1.53 
     Q2 1.41 – <2.11 1.59 – <2.32 1.53 – <2.24 
     Q3 2.11 – <2.97 2.32 – <3.25 2.24 – <3.19 




     Q1 <1.26 <1.46 <1.40 
     Q2 1.26 – <1.91 1.46 – <2.14 1.40 – <2.05 
     Q3 1.91 – <2.63 2.14 – <3.07 2.05 – <2.94 




     Q1 <0.020 <0.014 <0.016 
     Q2 0.020 – <0.036 0.014 – <0.028 0.016 – <0.030 
     Q3 0.036 – <0.071 0.028 – <0.049 0.030 – <0.056 




     Q1 <0.053 <0.045 <0.047 
     Q2 0.053 – <0.095 0.045 – <0.081 0.047 – <0.085 
     Q3 0.095 – <0.193 0.081 – <0.137 0.085 – <0.149 
     Q4 ≥0.193 ≥0.137 ≥0.149 
* Variables did not have enough variability to categorize into quantiles, mean (SD) shown 
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Appendix Table 10 (cont’d). Comparison of cutpoints for quantiles between study-specific 
and absolute value-based quantiles for assessing associations between PUFAs and risk of 
developing EA and GCA in two US-based case-control studies 
 
Measure 












     Q1 <0.019 <0.010 <0.012 
     Q2 0.019 – <0.046 0.010 – <0.015 0.012 – <0.019 
     Q3 0.046 – <0.128 0.015 – <0.023 0.019 – <0.035 




     Q1 <12.53 <10.83 <11.28 
     Q2 12.53 – <19.23 10.83 – <15.25 11.28 – <16.47 
     Q3 19.23 – <28.54 15.25 – <21.93 16.47 – <24.03 




     Q1 <12.35 <10.74 <11.17 
     Q2 12.35 – <18.97 10.74 – <15.12 11.17 – <16.29 
     Q3 18.97 – <27.75 15.12 – <21.75 16.29 – <23.70 




     Q1 <0.120 <0.819 <0.090 
     Q2 0.120 – <0.312 0.819 – <0.121 0.090 – <0.140 
     Q3 0.312 – <0.862 0.121 – <0.178 0.140 – <0.250 




     Q1 <7.92 <5.90 <6.28 
     Q2 7.92 – <9.15 5.90 – <6.75 6.28 – <7.37 
     Q3 9.15 – <10.69 6.75 – <7.66 7.37 – <8.79 
     Q4 ≥10.69 ≥7.66 ≥8.79 




Appendix Table 11. Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality 
following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases 
 
Measure 









Tuna     
     None 1.0 1.0 1.0 1.0 
     T1 0.97 (0.60, 1.56) 0.72 (0.46, 1.12) 1.49 (0.97, 2.28) 1.28 (0.88, 1.87) 
     T2 0.87 (0.55, 1.37) 0.74 (0.48, 1.13) 1.90 (1.23, 2.95) 1.26 (0.88, 1.80) 
     T3 0.89 (0.53, 1.52) 0.95 (0.58, 1.55) 1.20 (0.77, 1.88) 1.16 (0.79, 1.71) 
Fried fish     
     Non-consumers 1.0 1.0 1.0 1.0 
     Consumers 1.09 (0.83, 1.43) 0.91 (0.68, 1.21) 0.72 (0.52, 1.00) 0.86 (0.65, 1.12) 
Baked/broiled fish     
     None 1.0 1.0 1.0 1.0 
     T1 1.29 (0.84, 1.99) 0.83 (0.51, 1.35) 1.01 (0.66, 1.55) 1.10 (0.76, 1.59) 
     T2 0.95 (0.68, 1.32) 0.68 (0.48, 0.97) 1.21 (0.82, 1.79) 1.04 (0.67, 1.60) 
     T3 0.98 (0.47, 2.04) 0.69 (0.37, 1.30) 0.89 (0.55, 1.45) 1.09 (0.77, 1.55) 
Shellfish     
     Non-consumers 1.0 1.0 1.0 1.0 
     Consumers 0.91 (0.69, 1.22) 0.65 (0.48, 0.88) 1.16 (0.85, 1.57) 1.19 (0.91, 1.55) 
ω-3     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.98 (0.67, 1.42) 1.05 (0.71, 1.54) 1.86 (1.19, 2.89) 1.09 (0.75, 1.59) 
     Q3 0.76 (0.52, 1.12) 0.71 (0.45, 1.11) 1.62 (0.98, 2.66) 0.74 (0.50, 1.08) 
     Q4 0.95 (0.63, 1.44) 0.78 (0.50, 1.21) 1.33 (0.74, 2.37) 0.67 (0.41, 1.10) 
ALA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.77 (0.53, 1.12) 1.20 (0.81, 1.78) 1.52 (0.98, 2.37) 1.11 (0.76, 1.60) 
     Q3 0.80 (0.54, 1.18) 0.78 (0.50, 1.22) 1.49 (0.91, 2.44) 0.66 (0.45, 0.95) 
     Q4 0.81 (0.54, 1.24) 0.90 (0.56, 1.45) 1.16 (0.65, 2.05) 0.66 (0.40, 1.08) 






Appendix Table 11 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 













EPA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.77 (0.54, 1.11) 0.76 (0.51, 1.13) 1.18 (0.77, 1.80) 1.32 (0.90, 1.95) 
     Q3 0.77 (0.53, 1.10) 0.73 (0.49, 1.08) 1.21 (0.78, 1.89) 0.99 (0.67, 1.45) 
     Q4 0.65 (0.45, 0.95) 0.85 (0.57, 1.25) 1.12 (0.78, 1.89) 1.58 (1.05, 2.37) 
DHA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.96 (0.66, 1.40) 0.50 (0.34, 0.74) 1.00 (0.64, 1.57) 1.04 (0.72, 1.50) 
     Q3 1.09 (0.76, 1.57) 1.01 (0.69, 1.50) 1.33 (0.89, 2.00) 1.06 (0.71, 1.58) 
     Q4 0.67 (0.46, 0.98) 0.79 (0.54, 1.15) 0.92 (0.57, 1.48) 1.23 (0.81, 1.87) 
DPA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 1.14 (0.70, 1.88) 1.32 (0.82, 2.12) 1.35 (0.87, 2.11) 0.76 (0.52, 1.12) 
     Q3 0.82 (0.51, 1.31) 0.99 (0.62, 1.59) 1.15 (0.74, 1.80) 0.82 (0.55, 1.23) 
     Q4 0.75 (0.49, 1.15) 0.95 (0.63, 1.44) 1.54 (0.90, 2.64) 1.18 (0.75, 1.87) 
ω-6     
     Q1 1.0 1.0 1.0 1.0 
     Q2 1.06 (0.74, 1.54) 1.41 (0.95, 2.09) 1.42 (0.91, 2.22) 0.79 (0.55, 1.15) 
     Q3 0.66 (0.43, 0.99) 0.89 (0.58, 1.35) 1.44 (0.87, 2.37) 0.85 (0.58, 1.25) 
     Q4 0.73 (0.48, 1.11) 0.84 (0.53, 1.35) 1.28 (0.69, 2.37) 0.82 (0.48, 1.42) 
LA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.99 (0.68, 1.42) 1.45 (0.97, 2.14) 1.33 (0.85, 2.08) 0.79 (0.54, 1.15) 
     Q3 0.69 (0.46, 1.04) 0.92 (0.60, 1.41) 1.37 (0.83, 2.27) 0.86 (0.59, 1.25) 
     Q4 0.70 (0.46, 1.06) 0.89 (0.56, 1.42) 1.24 (0.68, 2.27) 0.83 (0.48, 1.42) 






Appendix Table 11 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 













AA     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.96 (0.66, 1.40) 0.90 (0.59, 1.38) 1.56 (1.00, 2.43) 0.92 (0.62, 1.37) 
     Q3 0.67 (0.46, 0.99) 0.98 (0.66, 1.45) 1.31 (0.83, 2.07) 0.87 (0.58, 1.31) 
     Q4 0.83 (0.57, 1.21) 0.79 (0.54, 1.17) 1.81 (1.03, 3.21) 1.04 (0.63, 1.70) 
ω-6:ω-3     
     Q1 1.0 1.0 1.0 1.0 
     Q2 0.93 (0.64, 1.34) 0.82 (0.55, 1.23) 1.06 (0.69, 1.61) 1.04 (0.72, 1.52) 
     Q3 0.70 (0.48, 1.02) 1.00 (0.68, 1.47) 1.12 (0.74, 1.70) 1.51 (1.03, 2.21) 
     Q4 0.85 (0.60, 1.20) 0.95 (0.64, 1.41) 0.60 (0.40, 0.92) 1.60 (1.08, 2.38) 























Appendix Table 12. Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality 
following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














Tuna       
     None 77 66 1.0 124 100 1.0 
     T1 141 125 1.20 (0.87, 1.64) 120 110 1.00 (0.75, 1.33) 
     T2 143 127 1.18 (0.86, 1.62) 143 119 1.03 (0.78, 1.35) 
     T3 138 116 1.07 (0.78, 1.48) 141 121 1.08 (0.81, 1.44) 
Fried fish       
     Non-consumers 268 239 1.0 251 224 1.0 
     Consumers 231 195 0.95 (0.78, 1.16) 277 226 0.88 (0.72, 1.07) 
Baked/broiled fish       
     None 151 130 1.0 194 168 1.0 
     T1 111 97 1.08 (0.81, 1.42) 117 103 0.91 (0.70, 1.20) 
     T2 180 155 0.95 (0.74, 1.22) 146 117 0.87 (0.67, 1.13) 
     T3 57 52 0.93 (0.65, 1.32) 71 62 1.01 (0.75, 1.36) 
Shellfish       
     Non-consumers 203 176 1.0 229 197 1.0 
     Consumers 296 258 1.01 (0.82, 1.24) 299 253 0.92 (0.75, 1.13) 
ω-3       
     Q1 116 101 1.0 140 117 1.0 
     Q2 131 118 1.11 (0.84, 1.46) 126 114 1.03 (0.79, 1.34) 
     Q3 125 107 0.92 (0.69, 1.23) 133 117 0.73 (0.55, 0.97) 
     Q4 127 108 0.99 (0.71, 1.38) 129 102 0.76 (0.55, 1.04) 
* Model adjusted for age, education, proxy status, caloric intake, study indicator, and number of FFQ  










Appendix Table 12 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 














ALA       
     Q1 118 101 1.0 138 115 1.0 
     Q2 128 115 1.03 (0.78, 1.36) 129 117 1.19 (0.91, 1.55) 
     Q3 123 107 0.99 (0.74, 1.33) 135 116 0.71 (0.54, 0.94) 
     Q4 130 111 1.05 (0.75, 1.46) 126 102 0.84 (0.61, 1.16) 
EPA       
     Q1 115 100 1.0 142 125 1.0 
     Q2 126 113 1.03 (0.77, 1.36) 131 111 0.93 (0.71, 1.21) 
     Q3 134 113 0.88 (0.67, 1.17) 122 101 0.81 (0.61, 1.06) 
     Q4 124 108 0.83 (0.61, 1.12) 133 113 1.07 (0.81, 1.41) 
DHA       
     Q1 121 106 1.0 136 121 1.0 
     Q2 122 108 1.09 (0.82, 1.44) 135 114 0.93 (0.72, 1.21) 
     Q3 126 109 1.04 (0.78, 1.38) 131 106 0.81 (0.62, 1.07) 
     Q4 130 111 0.75 (0.56, 1.00) 126 109 1.05 (0.79, 1.40) 
DPA       
     Q1 108 95 1.0 149 126 1.0 
     Q2 124 107 1.07 (0.80, 1.44) 132 115 1.02 (0.79, 1.33) 
     Q3 133 118 0.98 (0.70, 1.35) 124 111 1.04 (0.77, 1.41) 
     Q4 134 114 0.79 (0.57, 1.11) 123 98 0.93 (0.67, 1.29) 
ω-6       
     Q1 110 98 1.0 147 119 1.0 
     Q2 128 113 0.98 (0.73, 1.31) 128 119 1.21 (0.93, 1.58) 
     Q3 131 113 0.85 (0.62, 1.16) 127 107 0.92 (0.69, 1.22) 
     Q4 130 110 0.72 (0.50, 1.04) 126 105 0.94 (0.67, 1.33) 
* Model adjusted for age, education, proxy status, caloric intake, study indicator, and number of FFQ  






Appendix Table 12 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 














LA       
     Q1 109 97 1.0 147 120 1.0 
     Q2 130 115 0.98 (0.74, 1.31) 127 116 1.15 (0.88, 1.50) 
     Q3 130 111 0.84 (0.62, 1.15) 128 109 0.92 (0.69, 1.22) 
     Q4 130 111 0.74 (0.52, 1.07) 126 105 0.92 (0.66, 1.30) 
AA       
     Q1 110 97 1.0 146 124 1.0 
     Q2 124 107 1.09 (0.81, 1.47) 134 117 1.07 (0.82, 1.40) 
     Q3 132 118 1.18 (0.86, 1.61) 125 109 0.83 (0.60, 1.13) 
     Q4 133 112 0.75 (0.53, 1.05) 123 100 0.91 (0.66, 1.26) 
ω-6:ω-3       
     Q1 119 106 1.0 138 113 1.0 
     Q2 119 107 0.88 (0.65, 1.19) 138 123 1.55 (1.18, 2.04) 
     Q3 129 106 0.73 (0.53, 1.00) 128 107 1.40 (1.01, 1.93) 
     Q4 132 115 0.63 (0.45, 0.90) 124 107 1.62 (1.14, 2.30) 
* Model adjusted for age, education, proxy status, caloric intake, study indicator, and number of FFQ  
















Appendix Table 13. Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality 
following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














Tuna       
     None 54 44 1.0 86 63 1.0 
     T1 97 81 0.94 (0.64, 1.39) 91 81 1.32 (0.94, 1.87) 
     T2 97 83 1.18 (0.80, 1.74) 105 82 1.24 (0.88, 1.75) 
     T3 99 77 0.97 (0.65, 1.45) 96 77 1.09 (0.77, 1.55) 
   ptrend=0.12   ptrend=0.93 
Fried fish       
     Non-consumers 178 151 1.0 163 136 1.0 
     Consumers 169 134 0.81 (0.63, 1.04) 215 167 0.91 (0.72, 1.16) 
       
Baked/broiled fish       
     None 105 86 1.0 130 104 1.0 
     T1 78 64 1.00 (0.71, 1.42) 88 75 1.17 (0.85, 1.61) 
     T2 126 102 0.99 (0.73, 1.35) 112 85 0.96 (0.70, 1.32) 
     T3 38 33 1.43 (0.92, 2.21) 48 39 1.01 (0.70, 1.47) 
   ptrend=0.84   ptrend=0.60 
Shellfish       
     Non-consumers 137 112 1.0 159 128 1.0 
     Consumers 210 173 1.08 (0.84, 1.39) 219 175 1.03 (0.81, 1.32) 
ω-3       
     Q1 82 67 1.0 99 77 1.0 
     Q2 91 79 1.42 (1.01, 1.99) 91 79 1.24 (0.89, 1.72) 
     Q3 84 66 0.95 (0.66, 1.37) 96 81 1.13 (0.79, 1.61) 
     Q4 90 73 1.05 (0.70, 1.57) 92 66 0.92 (0.62, 1.38) 
   ptrend=0.36   ptrend=0.79 






Appendix Table 13 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 














ALA       
     Q1 84 68 1.0 97 75 1.0 
     Q2 89 76 1.33 (0.95, 1.87) 93 82 1.41 (1.01, 1.96) 
     Q3 78 62 0.92 (0.63, 1.32) 102 83 1.12 (0.78, 1.59) 
     Q4 96 79 1.10 (0.75, 1.63) 86 63 1.01 (0.66, 1.54) 
   ptrend=0.34   ptrend=0.82 
EPA       
     Q1 80 66 1.0 102 86 1.0 
     Q2 84 71 1.20 (0.85, 1.70) 97 77 0.83 (0.61, 1.14) 
     Q3 99 79 1.06 (0.75, 1.49) 81 62 0.76 (0.54, 1.07) 
     Q4 84 69 1.07 (0.74, 1.56) 98 78 0.91 (0.65, 1.27) 
   ptrend=0.84   ptrend=0.57 
DHA       
     Q1 84 70 1.0 98 81 1.0 
     Q2 87 74 1.08 (0.77, 1.52) 94 76 0.92 (0.66, 1.26) 
     Q3 91 74 1.02 (0.72, 1.43) 90 67 0.75 (0.54, 1.04) 
     Q4 85 67 0.93 (0.64, 1.35) 96 79 1.00 (0.72, 1.40) 
   ptrend=0.82   ptrend=0.85 
DPA       
     Q1 74 61 1.0 107 85 1.0 
     Q2 91 76 1.18 (0.82, 1.69) 90 74 0.97 (0.71, 1.34) 
     Q3 93 78 1.37 (0.91, 2.06) 89 76 1.05 (0.75, 1.47) 
     Q4 89 70 1.02 (0.66, 1.57) 92 68 0.95 (0.64, 1.41) 
   ptrend=0.79   ptrend=0.41 







Appendix Table 13 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 














ω-6       
     Q1 77 65 1.0 104 79 1.0 
     Q2 90 76 1.02 (0.71, 1.45) 91 80 1.37 (0.98, 1.92) 
     Q3 88 71 1.01 (0.68, 1.49) 93 74 1.12 (0.78, 1.62) 
     Q4 92 73 0.84 (0.54, 1.30) 90 70 1.25 (0.81, 1.92) 
   ptrend=0.33   ptrend=0.22 
LA       
     Q1 77 65 1.0 104 79 1.0 
     Q2 91 76 1.00 (0.70, 1.43) 91 80 1.37 (0.98, 1.91) 
     Q3 86 70 1.04 (0.71, 1.54) 94 75 1.13 (0.79, 1.63) 
     Q4 93 74 0.84 (0.54, 1.30) 89 69 1.22 (0.79, 1.88) 
   ptrend=0.31   ptrend=0.22 
AA       
     Q1 77 64 1.0 104 84 1.0 
     Q2 88 73 1.24 (0.86, 1.79) 93 75 0.99 (0.71, 1.38) 
     Q3 93 78 1.34 (0.89, 2.00) 89 74 0.95 (0.67, 1.37) 
     Q4 89 70 1.01 (0.66, 1.54) 92 70 1.04 (0.70, 1.54) 
   ptrend=0.80   ptrend=0.28 
ω-6:ω-3       
     Q1 84 73 1.0 97 72 1.0 
     Q2 81 69 0.98 (0.68, 1.43) 100 86 1.34 (0.96, 1.87) 
     Q3 90 67 0.72 (0.48, 1.08) 91 71 1.14 (0.76, 1.69) 
     Q4 92 76 0.86 (0.56, 1.32) 90 74 1.42 (0.93, 2.15) 
   ptrend=0.60   ptrend=0.13 








Appendix Table 14. Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality 
following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 














Tuna       
     None 74 63 1.0 119 95 1.0 
     T1 132 116 1.22 (0.89, 1.69) 116 106 0.99 (0.74, 1.32) 
     T2 180 160 1.25 (0.91, 1.72) 177 146 0.98 (0.74, 1.30) 
     T3 97 80 1.03 (0.73, 1.45) 95 84 1.20 (0.88, 1.64) 
   ptrend=0.27   ptrend=0.36 
Fried fish       
     Non-consumers 255 226 1.0 242 216 1.0 
     Consumers 228 193 0.97 (0.79, 1.19) 215 215 0.86 (0.71, 1.05) 
       
Baked/broiled fish       
     None 144 124 1.0 185 159 1.0 
     T1 77 67 1.10 (0.81, 1.49) 76 64 0.99 (0.74, 1.34) 
     T2 214 184 0.98 (0.76, 1.26) 180 151 0.86 (0.66, 1.13) 
     T3 48 44 0.81 (0.55, 1.18) 66 57 0.99 (0.72, 1.35) 
   ptrend=0.08   ptrend=0.76 
Shellfish       
     Non-consumers 197 170 1.0 222 191 1.0 
     Consumers 286 249 1.02 (0.83, 1.26) 285 240 0.90 (0.73, 1.11) 
ω-3       
     Q1 111 93 1.0 138 116 1.0 
     Q2 125 115 1.19 (0.89, 1.58) 122 110 1.04 (0.79, 1.37) 
     Q3 118 101 0.99 (0.73, 1.34) 129 113 0.73 (0.54, 0.97) 
     Q4 129 110 1.00 (0.71, 1.39) 118 92 0.78 (0.57, 1.08) 
   ptrend=0.21   ptrend=0.28 







Appendix Table 14 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 














ALA       
     Q1 109 94 1.0 138 116 1.0 
     Q2 122 106 0.98 (0.73, 1.30) 127 114 1.13 (0.86, 1.47) 
     Q3 119 106 0.99 (0.73, 1.34) 126 111 0.73 (0.54, 0.97) 
     Q4 133 113 0.89 (0.64, 1.25) 116 90 0.77 (0.55, 1.06) 
   ptrend=0.24   ptrend=0.23 
EPA       
     Q1 114 100 1.0 133 115 1.0 
     Q2 122 106 0.90 (0.68, 1.19) 127 109 0.99 (0.75, 1.30) 
     Q3 123 106 0.88 (0.66, 1.16) 123 101 0.86 (0.65, 1.13) 
     Q4 124 107 0.76 (0.57, 1.02) 124 106 1.10 (0.83, 1.46) 
   ptrend=0.35   ptrend=0.41 
DHA       
     Q1 120 103 1.0 127 112 1.0 
     Q2 107 93 0.98 (0.73, 1.31) 141 114 0.73 (0.55, 0.95) 
     Q3 130 116 1.18 (0.90, 1.55) 117 100 1.08 (0.81, 1.43) 
     Q4 126 107 0.73 (0.54, 0.97) 122 105 0.97 (0.73, 1.28) 
   ptrend=0.11   ptrend=0.63 
DPA       
     Q1 79 70 1.0 105 87 1.0 
     Q2 90 78 1.26 (0.90, 1.77) 112 101 0.96 (0.72, 1.30) 
     Q3 129 108 0.93 (0.68, 1.29) 117 98 0.88 (0.64, 1.21) 
     Q4 185 163 0.91 (0.67, 1.26) 173 145 1.02 (0.75, 1.38) 
   ptrend=0.58   ptrend=0.93 








Appendix Table 14 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 














ω-6       
     Q1 103 89 1.0 146 121 1.0 
     Q2 130 116 1.14 (0.86, 1.52) 115 104 1.05 (0.80, 1.38) 
     Q3 117 100 0.84 (0.62, 1.15) 132 115 0.88 (0.66, 1.18) 
     Q4 133 114 0.85 (0.60, 1.20) 114 91 0.86 (0.61, 1.20) 
   ptrend=0.15   ptrend=0.91 
LA       
     Q1 105 91 1.0 143 118 1.0 
     Q2 127 112 1.09 (0.82, 1.45) 121 109 1.08 (0.82, 1.41) 
     Q3 119 103 0.86 (0.63, 1.18) 127 111 0.89 (0.67, 1.19) 
     Q4 132 113 0.83 (0.59, 1.17) 116 93 0.88 (0.63, 1.25) 
   ptrend=0.15   ptrend=0.92 
AA       
     Q1 112 99 1.0 137 117 1.0 
     Q2 128 108 1.12 (0.84, 1.50) 118 102 0.89 (0.67, 1.18) 
     Q3 117 99 0.78 (0.58, 1.05) 129 111 0.94 (0.71, 1.25) 
     Q4 126 113 1.07 (0.79, 1.45) 123 101 0.90 (0.67, 1.22) 
   ptrend=1.00   ptrend=0.70 
ω-6:ω-3       
     Q1 130 114 1.0 117 102 1.0 
     Q2 113 95 0.93 (0.70, 1.22) 136 108 0.93 (0.71, 1.23) 
     Q3 108 98 0.88 (0.67, 1.16) 138 117 1.19 (0.91, 1.57) 
     Q4 132 112 0.79 (0.60, 1.03) 116 104 1.22 (0.92, 1.63) 
   ptrend=0.13   ptrend=0.06 







Appendix Table 15. Hazard ratios and 95% confidence intervals for associations between PUFA measures and mortality 
following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up for cases, 















HR* (95%CI) I2 (%) 
phetero 
geneity 
Tuna           
     None 77 66 1.0   124 100 1.0   
     T1 143 126 1.19 (0.87, 1.63)   129 117 1.04 (0.76, 1.38)   
     T2 179 159 1.31 (0.96, 1.78)   174 144 1.03 (0.78, 1.35)   
     T3 100 83 1.06 (0.75, 1.49) 51.1 0.07 101 89 1.01 (0.75, 1.36) 41.5 0.13 
Fried fish           
     Non- 
     consumers 
268 239 1.0   251 224 1.0   
     Consumers 231 195 0.92 (0.75, 1.13) 72.4 0.06 277 226 0.86 (0.70, 1.04) 0 0.57 
Baked/broiled fish         
     None 151 130 1.0   194 168 1.0   
     T1 79 69 1.14 (0.84, 1.54)   79 67 0.92 (0.69, 1.23)   
     T2 221 191 1.05 (0.82, 1.35)   186 155 0.80 (0.60, 1.05)   
     T3 48 44 0.88 (0.60, 1.31) 0 0.75 69 60 0.93 (0.69, 1.26) 0 0.56 
Shellfish           
     Non- 
     consumers 
203 176 1.0   229 197 1.0   
     Consumers 296 258 1.03 (0.84, 1.26) 34.0 0.22 299 253 0.90 (0.74, 1.09) 87.1 0.01 
ω-3           
     Q1 116 99 1.0   141 118 1.0   
     Q2 129 118 1.31 (0.99, 1.73)   127 115 1.11 (0.85, 1.45)   
     Q3 126 108 1.04 (0.77, 1.41)   131 115 0.71 (0.53, 0.96)   
     Q4 128 109 1.10 (0.79, 1.54) 55.0 0.05 129 102 0.73 (0.53, 1.02) 20.0 0.28 








Appendix Table 15 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 















HR* (95%CI) I2 (%) 
phetero 
geneity 
ALA           
     Q1 117 102 1.0   140 117 1.0   
     Q2 126 110 1.06 (0.80, 1.40)   131 118 1.19 (0.91, 1.56)   
     Q3 123 110 1.05 (0.78, 1.43)   132 115 0.70 (0.52, 0.93)   
     Q4 133 112 0.96 (0.69, 1.34) 45.2 0.10 125 100 0.79 (0.56, 1.11) 42.9 0.12 
EPA           
     Q1 119 105 1.0   138 120 1.0   
     Q2 129 113 0.91 (0.70, 1.20)   128 109 0.96 (0.73, 1.26)   
     Q3 127 109 0.90 (0.69, 1.19)   130 107 0.83 (0.63, 1.09)   
     Q4 124 107 0.81 (0.61, 1.09) 42.6 0.12 132 114 1.05 (0.79, 1.38) 29.3 0.22 
DHA           
     Q1 127 110 1.0   129 114 1.0   
     Q2 111 97 0.98 (0.73, 1.30)   146 118 0.73 (0.56, 0.96)   
     Q3 137 121 1.16 (0.88, 1.51)   121 105 0.99 (0.75, 1.30)   
     Q4 124 106 0.78 (0.58, 1.04) 17.4 0.30 132 113 0.90 (0.68, 1.19) 51.5 0.07 
DPA           
     Q1 84 75 1.0   108 90 1.0   
     Q2 97 84 1.23 (0.88, 1.70)   115 103 1.00 (0.74, 1.34)   
     Q3 130 110 0.94 (0.69, 1.30)   122 103 0.92 (0.68, 1.25)   
     Q4 188 165 0.99 (0.71, 1.38) 29.5 0.21 183 154 1.03 (0.76, 1.39) 0 0.72 
ω-6           
     Q1 111 97 1.0   147 122 1.0   
     Q2 134 120 1.21 (0.91, 1.60)   122 110 1.08 (0.82, 1.41)   
     Q3 122 103 0.92 (0.67, 1.27)   135 117 0.86 (0.65, 1.14)   
     Q4 132 114 0.90 (0.64, 1.27) 43.4 0.12 124 101 0.83 (0.58, 1.19) 2.3 0.40 






Appendix Table 15 (cont’d). Hazard ratios and 95% confidence intervals for associations between PUFA measures and 
mortality following a diagnosis of EA/GCA among participants of two US-based case-control studies of EA/GCA with follow-up 















HR* (95%CI) I2 (%) 
phetero 
geneity 
LA           
     Q1 112 99 1.0   145 120 1.0   
     Q2 131 115 1.12 (0.85, 1.49)   125 112 1.09 (0.83, 1.43)   
     Q3 124 106 0.92 (0.68, 1.26)   133 116 0.87 (0.66, 1.16)   
     Q4 132 114 0.87 (0.62, 1.22) 31.1 0.20 125 102 0.86 (0.60, 1.23) 8.0 0.37 
AA           
     Q1 117 104 1.0   139 118 1.0   
     Q2 132 112 1.19 (0.90, 1.58)   125 109 0.92 (0.69, 1.23)   
     Q3 127 109 0.88 (0.66, 1.18)   130 112 0.93 (0.70, 1.23)   
     Q4 123 109 1.07 (0.78, 1.46) 53.6 0.06 134 111 0.86 (0.64, 1.17) 0 0.98 
ω-6:ω-3           
     Q1 135 119 1.0   122 106 1.0   
     Q2 116 99 1.00 (0.76, 1.32)   141 112 0.95 (0.72, 1.24)   
     Q3 114 103 0.90 (0.68, 1.18)   142 122 1.16 (0.89, 1.52)   
     Q4 134 113 0.75 (0.57, 0.98) 29.3 0.22 123 110 1.24 (0.94, 1.63) 33.3 0.19 








Appendix Table 16. Comparison of cutpoints for quantiles between study-specific and 
absolute value based quantiles for assessing associations between PUFAs and 
mortality following a diagnosis of EA and GCA in two US-based case-control studies 
with follow-up for cases  
 
Measure 






Pooled Absolute  
Value-Based 
Quantiles 
Tuna (g/day)    
     None 0 0 0 
     T1 0.01 – <6.89 0.01 – <4.66 0.01 – <5.59 
     T2 6.89 – <14.93 4.66 – <12.12 5.59 – <14.91 
     T3 ≥14.93 ≥12.12 ≥14.91 
Fried fish* (g/day)    
     Non-consumers 0 0 0 
     Consumers 8.09 (10.44) 13.66 (18.82) 10.20 (14.44) 
Baked/broiled fish (g/day)   
     None 0 0 0 
     T1 0.01 – <3.61 0.01 – <7.46 0.01 – <5.83 
     T2 3.61 – <15.63 7.46 – <16.78 5.83 – <15.63 
     T3 ≥15.63 ≥16.78 ≥15.63 
Shellfish* (g/day)    
     Non-consumers 0 0 0 
     Consumers 3.50 (3.73) 11.65 (15.47) 6.43 (10.49) 
ω-3 (g/day)    
     Q1 <1.65 <1.81 <1.70 
     Q2 1.65 – <2.37 1.81 – <2.58 1.70 – <2.46 
     Q3 2.37 – <3.38 2.58 – <3.52 2.46 – <3.45 




     Q1 <1.52 <1.67 <1.59 
     Q2 1.52 – <2.15 1.67 – <2.37 1.59 – <2.27 
     Q3 2.15 – <3.00 2.37 – <3.36 2.27 – <3.16 




     Q1 <0.021 <0.014 <0.017 
     Q2 0.021 – <0.037 0.014 – <0.025 0.017 – <0.032 
     Q3 0.037 – <0.071 0.025 – <0.048 0.032 – <0.057 
     Q4 ≥0.071 ≥0.048 ≥0.057 






Appendix Table 16 (cont’d). Comparison of cutpoints for quantiles between study-
specific and absolute value based quantiles for assessing associations between PUFAs 
and mortality following a diagnosis of EA and GCA in two US-based case-control 
studies with follow-up for cases  
 
Measure 












     Q1 <0.052 <0.041 <0.046 
     Q2 0.052 – <0.098 0.041 – <0.075 0.046 – <0.088 
     Q3 0.098 – <0.178 0.075 – <0.130 0.088 – <0.151 




     Q1 <0.014 <0.011 <0.014 
     Q2 0.014 – <0.023 0.011 – <0.016 0.014 – <0.023 
     Q3 0.023 – <0.058 0.016 – <0.024 0.023 – <0.058 




     Q1 <15.11 <12.22 <13.50 
     Q2 15.11 – <21.11 12.22 – <17.38 13.50 – <19.27 
     Q3 21.11 – <31.39 17.38 – <23.79 19.27 – <28.24 




     Q1 <14.80 <12.16 <13.38 
     Q2 14.80 – <20.80 12.16 – <17.24 13.38 – <18.92 
     Q3 20.80 – <30.11 17.24 – <23.59 18.92 – <27.56 




     Q1 <0.14 <0.092 <0.11 
     Q2 0.14 – <0.37 0.092 – <0.135 0.11 – <0.17 
     Q3 0.37 – <1.03 0.135 – <0.192 0.17 – <0.46 




     Q1 <7.99 <5.91 <6.62 
     Q2 7.99 – <9.16 5.91 – <6.73 6.62 – <7.90 
     Q3 9.16 – <10.52 6.73 – <7.70 7.90 – <9.51 
     Q4 ≥10.52 ≥7.70 ≥9.51 
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